omeprazole has been researched along with Curling Ulcer in 877 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ranitidine in 45 patients admitted as an emergency with an endoscopic diagnosis of bleeding duodenal ulcer." | 10.18 | [Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study]. ( Amadori, L; Arnone, F; Barillari, P; Bolognese, A; Cardi, M; Muttillo, IA; Sammartino, P; Signorelli, C, 1997) |
| "Clinical experience with lansoprazole in the acute treatment of duodenal ulcer patients has been compared with treatment using placebo, H2-antagonists or omeprazole." | 10.17 | Acute treatment of duodenal ulcer: experience with lansoprazole. ( Mignon, M; Vallot, T, 1993) |
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 9.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 9.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| "Patients with at least one endoscopically diagnosed active duodenal ulcer (DU) were enrolled in a multicenter, randomized, double-blind, positive controlled trial and then assigned randomly to the ilaprazole group (10 mg/d) or the omeprazole group (20 mg/d) with a sample allocation ratio 2:1." | 9.16 | Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. ( Hu, H; Lin, S; Wang, L; Xia, J; Zhou, L, 2012) |
| "Ilaprazole is as tolerable, safe, and efficacious as omeprazole in the treatment of duodenal ulcers, especially at a lower dose (10 mg/d ilaprazole vs." | 9.15 | A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. ( Hu, H; Lin, S; Wang, L; Xia, J; Zhou, L, 2011) |
| "Melatonin (MT) and its precursor L-tryptophan (TRP) are implicated in the protection of gastric mucosa against aspirin-induced lesions and in the acceleration of healing of idiopathic gastro-duodenal ulcers, but no information is available whether these agents are also effective in healing of gastroduodenal ulcers accompanied by Helicobacter pylori (H." | 9.15 | Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Slomka, M, 2011) |
| " This study evaluated and compared it with a reference PPI, omeprazole, in the treatment of gastric and duodenal ulcers." | 9.14 | Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. ( Goh, KL; Ho, KY; Kim, DY; Kuan, A; Mahachai, V; Yoon, HM; Zaño, F, 2009) |
| " A total of forty-two patients with duodenal ulcer were randomized into low dose ilaprazole group (5 mg/d), medium dose ilaprazole group (10 mg/d), high dose ilaprazole group (20 mg/d) and omeprazole group (20 mg/d)." | 9.14 | [Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer]. ( Hou, XH; Hu, HT; Lin, SR; Qin, XH; Shi, RH; Xia, JL; Yang, YS; Yuan, YZ; Zhang, ST; Zhou, LY, 2010) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 9.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| "This trial was performed to compare the effects of IV pantoprazole versus omeprazole on 24-hour intragastric acidity in Chinese patients with endoscopically confirmed duodenal ulcer." | 9.12 | Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial. ( Cheng, YC; Lin, HJ; Lo, WC; Perng, CL, 2006) |
| " pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively)." | 9.12 | One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. ( Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E, 2007) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 9.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "To investigate the effect of esomeprazole- and omeprazole-based triple therapy regimens in the treatment of duodenal ulcer with Helicobacter pylori (Hp) infection." | 9.11 | [Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection]. ( Chen, YH; Li, HY; Wang, H; Wang, WM, 2005) |
| "The article discloses the results of the duodenal ulcer treatment with a generic of omeprazole (Omizac) in the in-patient hospital and polyclinic conditions, dynamics of the serum gastrin level against the background of the drug application and after its withdrawal, and assessment of the intensity and duration of acid production inhibition in the stomach." | 9.11 | [Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. ( Belov, DF; Loginov, AF; Maksimova, ID; Ponomarev, AA, 2005) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 9.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "To evaluate the therapeutic effect on duodenal ulcer symptoms and safety of rabeprazol as compared with omeprazole." | 9.10 | [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer]. ( Lin, S, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 9.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 9.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 9.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| "To assess efficiency of esomeprazole in the treatment of duodenal ulcer (DU) associated with H." | 9.10 | [Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy]. ( Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES, 2003) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 9.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| "Duodenal ulcer cure, as a systemic gastroenterologic disease, can be achieved in some patients by the addition of the nootropic drug piracetam to current antisecretory and antihelicobacter therapy." | 9.10 | [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer]. ( Shchetkin, DI; Tsimmerman, IaS, 2002) |
| "To determine which demographic factors may influence serum gastrin and pepsinogen I (PGI) levels in duodenal ulcer patients undergoing omeprazole treatment." | 9.09 | Helicobacter pylori clearance and serum gastrin and pepsinogen I concentrations in omeprazole treatment of duodenal ulcer patients. ( Chang, FY; Chen, CY; Kuo, BI; Lee, CT; Lee, SD, 1999) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 9.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers." | 9.09 | Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 9.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 9.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 9.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 9.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 9.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| "The aim of this randomized, multicenter, double-masked, parallel-group study was to compare the efficacy of lansoprazole with that of omeprazole monotherapy in duodenal ulcer healing and prevention of relapse." | 9.09 | Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. ( Dobrilla, G; Fiocca, R; Piazzi, L, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 9.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| "To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients." | 9.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "In a double-blind, parallel-group clinical trial of 928 patients (from 70 centres in 16 countries) with duodenal ulcers who after a short term study had relief of symptoms and healed ulcers proved endoscopically, 308 were randomly assigned to receive omeprazole 10 mg in the morning, 308 to receive omeprazole 20 mg in the morning and 312 to receive ranitidine 150 mg at bedtime for up to 12 months." | 9.09 | Omeprazole and ranitidine in the prevention of relapse in patients with duodenal ulcer disease. ( Archambault, AP; Bailey, RJ; Bianchi Porro, G; Bolling, E; Brunner, G; Eriksson, S; Frison, L; Galmiche, JP; Gudjónsson, H; Havu, N; Lauritsen, K; Rutgersson, K; Thompson, AB; Walan, A, 1999) |
| "The aim of this study was to compare the effectiveness and tolerance of pantoprazole versus ranitidine in the treatment of duodenal ulcers in the Brazilian population." | 9.09 | Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. ( de Paula Castro, L; Lyra, LG; Malafaia, O; Meneghelli, UG; Zaterka, S, 2000) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 9.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "To investigate the efficacy of a 1-week triple therapy with amoxycillin, clarithromycin, and omeprazole or ranitidine bismuth citrate (RBC) in curing Helicobacter pylori infection and healing duodenal ulcers." | 9.09 | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. ( Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R, 2000) |
| "The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease." | 9.09 | Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. ( Breiter, JR; Humphries, TJ; Riff, D, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 9.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 9.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "Seven-day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with H." | 9.09 | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. ( Abbas, Z; Abid, S; Chang, FY; Chen, PC; Destefano, M; Hamid, SS; Lam, SK; Lin, BR; Schneider, H; Seebaran, A; Simjee, AE; Van Rensburg, C; Wong, BC; Zhang, J, 2000) |
| "Four hundred and forty eight duodenal ulcer patients with Helicobacter pylori infection, confirmed by 13C-urea breath test (UBT), and no current ulcer, were randomised to double-blind treatment with esomeprazole 20 mg twice daily (b." | 9.09 | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. ( Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| " pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3)." | 9.09 | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. ( Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 9.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 9.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| "Pantoprazole (40 mg) was compared with ranitidine (300 mg) in the treatment of acute duodenal ulcer." | 9.08 | Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. ( Classen, M; Schepp, W, 1995) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 9.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 9.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| "The aim of this study was to establish if the discontinuous assumption of omeprazole was effective to reduce the recurrence of duodenal ulcer disease as the cyclic periodical assumptions of the same drug." | 9.08 | [Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer]. ( Bisi, G; Cappellari, L; Caravita, L; Dalla Libera, M; Gullini, S; Massari, M; Matarese, V; Tartari, V; Zibordi, U, 1995) |
| "Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks." | 9.08 | Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995) |
| "We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three omeprazole schedules, i." | 9.08 | Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study. ( , 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 9.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 9.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 9.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| "Five hundred forty five patients with a fibroscopically proven duodenal ulcer were included in a randomized controlled trial and were treated for one month with omeprazole (20 mg) or ranitidine (300 mg)." | 9.08 | [Prognostic factors of the speed of cicatrization in duodenal ulcer. Controlled trial of omeprazole versus ranitidine]. ( Abitbol, V; Barbier, JP; Bergmann, JF; Hamelin, B, 1995) |
| "In this double-blind randomized comparative study patients with active duodenal ulcers were treated with either 30 mg lansoprazole or 20 mg omeprazole in the morning." | 9.08 | Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. ( Anker-Hansen, O; Carling, L; Ekström, P; Sellström, H; Sjöstedt, S; Unge, P, 1995) |
| " Pantoprazole, 40 mg, was compared with the H2-receptor antagonist ranitidine, 300 mg, in the healing of acute duodenal ulcer." | 9.08 | A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. ( Cremer, M; Delle Fave, G; Lambert, R; Lamers, CB; Maier, C, 1995) |
| "In this randomized, double-blind, multicentre study, the proton pump inhibitors pantoprazole and omeprazole were compared in patients with active duodenal ulcers." | 9.08 | Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. ( Rehner, M; Rohner, HG; Schepp, W, 1995) |
| "This study analyzes the effect of short- and long-term omeprazole (OM) on duodenal ulcer healing, recurrence, and H." | 9.08 | Short- and long-term omeprazole for the treatment and prevention of duodenal ulcer, and effect on Helicobacter pylori. ( Biasco, G; Cifani, F; DeFanis, C; Falcucci, M; Ferrini, G; Grossi, L; Iannetti, G; Larcinese, G; Lattanzio, R; Marzio, L, 1995) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 9.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| "Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers." | 9.08 | Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996) |
| "Parenteral omeprazole is better than parenteral ranitidine in keeping the intragastric pH above the proteolytic range for pepsin in patients with bleeding duodenal ulcers." | 9.08 | [Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage]. ( Artal, A; Barrao, ME; Blas, JM; Lanas, A; López, J; Moliner, FJ, 1996) |
| "To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control." | 9.08 | [A clinical trial of lansoprazole in the treatment of duodenal ulcer]. ( Chen, S; Pei, Y; Wang, B, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| " pylori-positive out-patients (n = 231) with duodenal ulcers were treated randomly and double-blind with either omeprazole 20, 40 or 80 mg b." | 9.08 | Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. ( Braden, B; Lembcke, B; Londong, W; Pommerien, W; Schultze, V; Wrangstadh, M, 1996) |
| "Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08." | 9.08 | The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients. ( Celle, G; Mansi, C; Mela, GS; Mele, MR; Savarino, V; Vigneri, S; Zentilin, P, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 9.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| " Our purpose was to evaluate the occurrence of mycotic infection in patients with duodenal ulcer on anti-ulcer therapy and to compare the effects of cimetidine, famotidine, and omeprazole." | 9.08 | Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. ( Chakrabarti, A; Goenka, MK; Gupta, O; Kochhar, R; Kumar, A; Mehta, SK; Talwar, P, 1996) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 9.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 9.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| " Monotherapy of duodenal ulcer with pantoprazole or ranitidine was evaluated in terms of healing rate, tolerance and compliance." | 9.08 | [Treatment of duodenal ulcer with pantoprazole. A multicenter study]. ( Dítĕ, P; Drazná, E; Dufek, V; Dvorák, M; Fric, P; Huslarová, A; Jirásek, V; Kunovská, M; Münzová, H; Pelech, T; Petrtýl, J; Roth, Z; Svoboda, J; Zádorová, Z; Zavoral, M, 1996) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 9.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 9.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 9.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 9.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| "A double-blind, randomized, multicenter, multicountry study (Poland, Chech Republic, Hungary) was carried out in 1995 on patients (n = 326) with endoscopically confirmed duodenal ulcer treated with ranitidine vs." | 9.08 | [Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study]. ( Döbrönte, Z; Juhász, L; Lonovics, J; Papp, J, 1997) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 9.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 9.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 9.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| " Fasting had no influence on the result of duodenal ulcer treatment by lansoprazole which was well tolerated." | 9.08 | [Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study]. ( Ajmi, S; Mehdi, A, 1997) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " Omeprazole was significantly superior to sucralfate in inducing gastric ulcer healing after both 4 (87 vs." | 9.08 | Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. ( Bianchi Porro, G; Lazzaroni, M; Manzionna, G; Petrillo, M, 1998) |
| " ranitidine bismuth citrate plus amoxycillin and clarithromycin in the treatment of Helicobacter pylori-associated duodenal ulcers." | 9.08 | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. ( Bentivegna, C; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Condorelli, G, 1998) |
| "Both treatment regimens, the 1-h topical method and amoxycillin with omeprazole, have low eradication rates in patients with duodenal ulcer." | 9.08 | Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients. ( Butruk, E; Dziurkowska-Marek, A; Hennig, E; Kohut, M; Marek, T; Nowak, A; Ostrowski, J; Przytulski, K; Regula, J, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-infected patients with one or more duodenal ulcer(s) at endoscopy (studies 1, 2) or with a documented duodenal ulcer history and no duodenal ulcer or erosions at endoscopy (study 3) were randomly assigned to 10-day courses of omeprazole 20 mg b." | 9.08 | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. ( Connors, A; Frantz, J; Laine, L; Neil, G; Suchower, L, 1998) |
| "A total of 101 patients with proven duodenal ulcer and a positive urease test were randomized into two groups: one group received the classic triple therapy (bismuth subnitrate 3 x 375 mg for 4 weeks + tetracycline 3 x 500 mg + metronidazole 3 x 250 mg daily, both for 2 weeks ), the other group received dual therapy comprising amoxicillin 2 x 1000 mg + omeprazole 2 x 20 mg daily, both for 2 weeks." | 9.08 | Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin. ( Kashifard, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Siavoshi, F, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 9.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 9.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| "We investigated the relationship between histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine for 4 weeks." | 9.07 | Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine. ( Chen, SH; Liao, CH; Lien, GS; Pan, S, 1994) |
| "This study was carried out to assess the antisecretory effects and their possible changes over time of three different dose regimens of omeprazole that could be proposed for maintenance treatment in duodenal ulcer." | 9.07 | Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. ( Celle, G; Cutela, P; Mansi, C; Mela, GS; Mele, MR; Perilli, D; Savarino, V; Vassallo, A; Zambotti, A; Zentilin, P, 1994) |
| "The purpose of the present study was to investigate the Helicobacter pylori eradication potency of combined amoxicillin-omeprazole treatment in patients with duodenal ulcer disease and to compare the efficacy of two omeprazole and amoxicillin doses concerning H." | 9.07 | Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 9.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "Twenty patients with endoscopically proven duodenal ulcer were studied by means of 24-h gastric pH-metry both in basal conditions and on the 5th day of acute treatment with 40 mg omeprazole in the morning." | 9.07 | A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. ( Badalamenti, S; Di Mario, F; Mela, GS; Muratore, F; Pantalena, M; Savarino, V; Scialabba, A; Termini, R; Vigneri, S; Zentilin, P, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compared in a double-blind randomized multicentre trial." | 9.07 | Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. ( Judmaier, G; Koelz, HR, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime." | 9.07 | Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. ( Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG, 1993) |
| "(i) To study the effect of single oral dose of 20 mg omeprazole on maximal acid output (MAO) and peak acid output (PAO) in duodenal ulcer patients and healthy volunteers." | 9.07 | Alternate-day therapy with omeprazole for duodenal ulcer. ( Amarapurkar, DN; Dhawan, P; Kalro, RH, 1993) |
| "The success of omeprazole in the healing of duodenal ulcer has been attributed to its profound and almost around-the-clock inhibition of acid, but the relevance of reducing meal-stimulated acid secretion exclusively has recently been emphasized in several clinical trials." | 9.07 | Antisecretory effect of three premeal doses of cimetidine 400 mg versus a single morning dose of omeprazole 20 mg: pathophysiological implications for duodenal ulcer treatment. ( Celle, G; Cutela, P; Dallorto, E; Franceschi, M; Mansi, C; Mela, GS; Mela, MR; Savarino, V; Vassallo, A; Zentilin, P, 1993) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 9.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "To assess the comparative efficacy of omeprazole 20 mg in the morning versus ranitidine 150 mg twice a day, in the healing of duodenal ulcer, 43 endoscopically verified cases were randomly allocated to 2 or 4 weeks (if ulcer did not heal at 2 weeks) treatment." | 9.07 | Omeprazole vs ranitidine in the healing of duodenal ulcer. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1993) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " omeprazole on pentagastrin-stimulated acid secretion was studied in 8 patients with duodenal ulcer." | 9.07 | Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. ( Cederberg, C; Lind, T; Olbe, L; Röhss, K, 1992) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 9.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| "The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o." | 9.07 | Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. ( Annibale, B; Cassetta, MR; Delle Fave, G; Franceschi, M; Quatrini, M; Torsoli, A, 1992) |
| "In a double blind, multicenter, parallel group clinical trial in patients with symptomatic duodenal ulcers, 129 patients were randomized to receive either omeprazole 20 mg once daily (n = 65) or famotidine 40 mg once daily (n = 64) for 2 weeks, and if the ulcers were not healed, for a total of 4 weeks." | 9.07 | Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer. ( Babu, S; Chaubal, C; Kumar, TR; Naidu, MU; Prasad, R; Reddy, DN; Shobha, JC; Subhash, S, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 9.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "The present study determined whether the rate of relapse of duodenal ulcer was reduced after ulcer healing with omeprazole compared with ranitidine or placebo." | 9.07 | Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. ( Cagliola, AJ; Colon-Pagan, J; Graham, DY; Johnson, TL; Marks, JW; McCullough, AJ; Morse, RS; Sklar, M; Stone, RC; Walsh, JH, 1992) |
| " Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months' treatment with cimetidine 0." | 9.07 | Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. ( Bardhan, KD; Bianchi Porro, G; Carroll, NJ; Daly, MJ; Hinchliffe, RF; Lazzaroni, M; Morris, P; Naesdal, J; Petrillo, M; Thompson, M, 1991) |
| "The effect of duodenal ulcer healing induced by omeprazole on gastroduodenal generation of eicosanoids, platelet-activating factor (PAF), pepsinogen A, and gastrin was evaluated." | 9.07 | Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients. ( Karmeli, F; Lysy, J; Rachmilewitz, D; Wengrower, D, 1992) |
| "Forty-three patients with active duodenal ulcer and Helicobacter pylori positivity in gastric antrum were randomly assigned to either omeprazole treatment (20 mg once a day) or ranitidine treatment (300 mg once a day) for 28 days." | 9.07 | Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients. ( Ayoubi Khajekini, M; Blasi, A; Brogna, A; Catalano, F; Inserra, G; Mangiameli, A; Monello, S; Rizzo, G; Sofia, M, 1991) |
| "Acid secretory responses and parietal cell sensitivity (PCS) have been studied in 21 duodenal ulcer patients before and after successful treatment with omeprazole (n = 7), sucralfate (n = 7), or Maalox (n = 7)." | 9.07 | Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox. ( Bridger, S; Johnston, DA; Marks, IN; Tigler-Wybrandi, NA; Young, GO; Zak, J, 1991) |
| " This randomized, double-blind multicentre trial studied the dose-response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out-patients with endoscopically assessed, symptomatic duodenal ulcer." | 9.07 | Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. ( Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B, 1991) |
| "The study was a multicenter double-blind parallel-group comparison of omeprazole, a proton-pump inhibitor, with the H2-receptor antagonist, ranitidine, in 206 patients with duodenal ulcer." | 9.07 | A comparison of omeprazole and ranitidine for duodenal ulcer in South African patients. A multiracial study. ( Danilewitz, MD; Garisch, JA; Marks, IN, 1991) |
| "In a double-blind, parallel-group clinical trial of 195 patients with duodenal ulcers who after a short-term study had relief of pain and healed ulcers proved endoscopically, 65 were randomized to receive 20 mg omeprazole 3 days a week (once in the morning from Friday to Sunday), 64 to receive 10 mg omeprazole once daily in the morning, and 66 to receive placebo for up to 6 months." | 9.07 | Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Kjaergaard, J; Lauritsen, K; Laursen, LS; Rask-Madsen, J; Rehfeld, JF, 1991) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 9.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| " To evaluate the effects of 6 months' treatment with omeprazole in humans, the oxyntic endocrine cells were morphometrically investigated at the ultrastructural level in five patients with active duodenal ulcer." | 9.07 | Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients. ( Bianchi-Porro, G; Bordi, C; D'Adda, T; Lazzaroni, M; Pilato, FP; Robutti, F, 1991) |
| "This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer." | 9.07 | Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991) |
| "To assess the comparative efficacy of omeprazole 20 mg, a proton pump inhibitor, versus ranitidine 150 mg twice a day, an H2-receptor antagonist, in healing duodenal ulcers we performed a randomized, double-blind, multicenter trial in 309 patients with endoscopically diagnosed ulcers." | 9.07 | U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group. ( Berlin, RG; Cagliola, A; Colon-Pagan, J; Hirschowitz, BI; Johnson, TL; Morse, RS; Petrozza, J; Snape, WJ; Valenzuela, JE; Van Deventer, GM, 1991) |
| "We studied omeprazole and ranitidine in promoting duodenal ulcer healing in a multicentre trial by comparing the proportion of healed ulcers after two, four, and eight weeks of treatment." | 9.06 | Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. Cooperative study group. ( , 1990) |
| "In a double-blind, parallel-group clinical trial in 248 patients with symptomatic duodenal ulcers [97% greater than 5 mm diameter], 126 were randomized to receive omeprazole 20 mg once daily in the morning and 122 were randomized to receive ranitidine 300 mg once daily at night for 2 wk and if the ulcers were unhealed for a total of 4 wk." | 9.06 | Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. ( Bateson, MC; Burke, GJ; Dickinson, RJ; Dronfield, MW; Green, JR; Keeling, PW; McFarland, RJ; O'Donoghue, DP; Peers, EM; Shreeve, DR, 1990) |
| "To investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique." | 9.06 | Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. ( Branicki, FJ; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM; Poon, GP, 1989) |
| "Thai patients (n = 257) entered a double-blind randomized trial to compare omeprazole, 20 mg once daily, and cimetidine, 800 mg once daily for treatment of duodenal ulcer." | 9.06 | Omeprazole or cimetidine once daily for the treatment of duodenal ulcers? ( Atthapaisalsarudee, C; Kurathong, S; Leethochawalit, M; Saowaros, V; Wilairatana, S, 1989) |
| "A double-blind randomized study in 230 Malaysian patients with duodenal ulcer was conducted to compare the proton-pump inhibitor, omeprazole 20 mg, given once daily in the morning, with ranitidine 300 mg, administered once daily at night." | 9.06 | Omeprazole compared with ranitidine once daily in the treatment of duodenal ulcer. ( Ahmad, H; Chelvam, P; Goh, KL; Jalleh, R; Lee, HB; Leela, MP; Leong, YP; Mahendran, T; Wong, NW; Yin, TP, 1989) |
| "One-hundred and seventy-one patients with endoscopically proven duodenal ulcers were allocated at random to double-blind treatment with 10 or 20 mg of omeprazole in the morning for up to 4 weeks." | 9.06 | Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Jørgensen, T; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1989) |
| "In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o." | 9.06 | Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group. ( Bate, CM; Crowe, JP; Peers, EM; Richardson, PD; Wilkinson, SP; Willoughby, CP, 1989) |
| "The object of this double-blind, multicentre study was to compare duodenal ulcer healing rates after 2 to 4 weeks of treatment with either 20 mg omeprazole o." | 9.06 | Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. ( Cluysenaer, OJ; Gerrits, C; Hazenberg, BP; Meyer, WW; Mulder, CJ; Nicolai, JJ; Stuifbergen, WH; Tijtgat, GN; Vogten, AJ, 1989) |
| "Twenty-seven patients with peptic ulcer (19 with duodenal ulcer (DU) and eight with gastric ulcer (GU] refractory to H2-antagonists were treated with 40 mg of omeprazole once daily for 4-8 weeks, depending on the rate of ulcer healing." | 9.06 | Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists. ( Chelvam, P; Wong, EC, 1989) |
| "The purpose of the present study was to compare omeprazole 20 mg once daily and ranitidine 150 mg twice daily in healing duodenal ulcers unhealed by previous treatment with cimetidine greater than or equal to 0." | 9.06 | Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. ( Delchier, JC; Eriksson, S; Isal, JP; Soule, JC, 1989) |
| "One hundred and twenty-nine patients were studied with regard to healing of duodenal ulcers with 30 mg omeprazole once daily, recurrence rates after 2 and 4 weeks' treatment in patients with ulcers healed after 2 weeks, and recurrences in rapid and slow healers." | 9.06 | Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission? ( Andersen, OK; Bernklev, T; Farup, PG; Halvorsen, L; Rosseland, AR, 1989) |
| "The effect of 7 days of oral dosing with 5 mg day-1 and 20 mg day-1 omeprazole on basal and pentagastrin-stimulated gastric acid output was studied in nine duodenal ulcer patients." | 9.06 | Effect of low-dose omeprazole on gastric acid secretion in duodenal ulcer patients. ( Crean, GP; McColl, KE; McLauchlan, G, 1988) |
| "We conducted a double-blind, randomized, parallel group study in 169 patients with acute duodenal ulcers to compare omeprazole, 20 mg daily, with cimetidine, 600 mg twice daily." | 9.06 | Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. ( Archambault, AP; Bailey, RJ; Baker, SJ; Freeman, HJ; Hunt, RH; Marcon, NE; Navert, H; Pare, P; Sutherland, L; Williams, CN, 1988) |
| "In a double-blind, dose comparison multicenter trial 115 patients with duodenal ulcer were treated with either 20 or 30 mg oral omeprazole once daily for 4 weeks." | 9.06 | 20 versus 30 mg omeprazole once daily: effect on healing rates in 115 duodenal ulcer patients. ( Dammann, HG; duBosque, G; Hebbeln, H; Horstkotte, W; Hüttemann, W; Martens, W; Rehner, M; Rohner, HG, 1986) |
| "The efficacy of and tolerance to omeprazole, 40 mg/day, was studied in an open-label study in 18 patients with endoscopically verified duodenal ulcers." | 9.06 | Effects of omeprazole in duodenal ulcer patients. ( Andrén, K; Helander, HF; Karvonen, AL; Keyriläinen, O; Salaspuro, M; Tarpila, S; Uusitalo, A, 1986) |
| "In an open clinical trial, 16 hospital outpatients with endoscopically proven duodenal ulcer were given 30 mg omeprazole once daily for four weeks." | 9.06 | Effect and tolerability of omeprazole in the treatment of duodenal ulcer disease. ( Jonsson, E; Labó, G; Rinetti, M; Tomassetti, P; Vezzadini, P, 1986) |
| "In a study involving three centers, 105 patients with duodenal ulcer proven by endoscopy were randomly assigned to treatment with either the H+, K+, ATPase inhibitor omeprazole (20 mg or 40 mg taken as a single morning dose), or ranitidine (150 mg morning and night)." | 9.06 | A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. ( Bardhan, KD; Bianchi Porro, G; Bose, K; Daly, M; Hinchliffe, RF; Jonsson, E; Lazzaroni, M; Naesdal, J; Rikner, L; Walan, A, 1986) |
| "The effects of seven days' treatment with omeprazole 5 and 10 mg daily on 24 hours gastric secretion and plasma gastrin concentrations were studied in a randomised double-blinded placebo-controlled study of six male patients with healed duodenal ulcer." | 9.06 | Effects of low dose omeprazole on gastric secretion and plasma gastrin in patients with healed duodenal ulcer. ( Burget, DW; Derodra, JK; Howden, CW; Hunt, RH, 1986) |
| "In a double-blind, dose-comparative trial, 32 patients with duodenal ulcer were assigned to receive either 20 mg/day or 60 mg/day omeprazole for 4 weeks." | 9.05 | Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. ( Adami, HO; Gustavsson, S; Lööf, L; Nyberg, A; Nyrén, O, 1983) |
| "Sixty-one patients with symptomatic endoscopically confirmed duodenal ulcer, 5 mm or more in diameter, were treated with omeprazole 30 mg once daily in the morning for 4 weeks." | 9.05 | [Treatment of duodenal ulcer outbreak with omeprazole. Results of a multicenter non-controlled study]. ( Bader, JP; Bitoun, A; Blanchi, A; Delchier, JC; Modigliani, R; Morin, T; Pariente, EA; Rotenberg, A; Soulé, JC, 1984) |
| "Twenty-seven duodenal ulcer patients were treated with omeprazole, 40 mg daily for 4 weeks." | 9.05 | Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study. ( , 1984) |
| "In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks." | 9.05 | Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study. ( , 1984) |
| "00 h doses of omeprazole or placebo on gastric acid secretion during the following night, 14 to 23 h after administration, in seven male subjects with duodenal ulcer." | 9.05 | Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer. ( Hetzel, DJ; Shearman, DJ, 1984) |
| "In a randomized, endoscopically controlled double-blind trial the effectiveness of a single oral, morning dose of 40 mg omeprazole was compared with a twice daily oral dose of 150 mg ranitidine given to 334 ambulatory patients with duodenal ulcers." | 9.05 | [Short-term therapy of duodenal ulcer with omeprazole and ranitidine. Results of a German multicenter study]. ( Berger, J; Classen, M; Dammann, HG; Domschke, W; Hengels, KJ; Hüttemann, W; Londong, W; Rehner, M; Simon, B; Witzel, L, 1985) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 9.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| "We have studied the rate of healing of duodenal ulcers in 44 patients treated with omeprazole, 40 mg once daily for 4 weeks, with or without an 80-mg loading dose on day 1." | 9.05 | The rate of healing of duodenal ulcers during omeprazole treatment. ( Bergsåker-Aspöy, J; Bernklev, T; Farup, PG; Gillberg, R; Halvorsen, L; Kilander, A; Lind, T; Naesdal, J; Offergaard, S; Walan, A, 1985) |
| "Healing of duodenal ulcers was assessed in 66 patients who received omeprazole either 10 mg or 30 mg daily for four weeks in a double blind study." | 9.05 | Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. ( Dudley, FJ; Jones, DB; Louis, WJ; Prichard, PJ; Rubinstein, D; Smallwood, RA; Yeomans, ND, 1985) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 8.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 8.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| "This paper is a meta-analysis of 30 published, double-blind clinical trials comparing omeprazole with ranitidine or cimetidine for the treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis." | 8.79 | Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. ( Carlsson, R; Eriksson, S; Långström, G; Naesdal, J; Rikner, L, 1995) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 8.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 8.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| "Omeprazole regulates gastric acid secretion and is an effective treatment of acute duodenal ulcer and reflux oesophagitis, achieving more rapid healing and symptomatic relief than histamine H 2-receptor antagonists." | 8.78 | Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. ( Barradell, LB; McTavish, D, 1993) |
| "Ten double-blind randomized studies with omeprazole versus ranitidine in duodenal ulcer healing have been published." | 8.78 | Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials. ( Mulder, CJ; Schipper, DL, 1990) |
| "To evaluate the cost-effectiveness of 10 mg ilaprazole once-daily vs 20 mg omeprazole once-daily to treat newly-diagnosed duodenal ulcer patients in China." | 7.83 | Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China. ( Liu, Z; Lu, WQ; Lu, YJ; Song, RL; Xu, GX; Xuan, JW, 2016) |
| " Cysteamine inhibits the release of somatostatin and induces the formation of duodenal ulcers in rats." | 7.73 | Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. ( Arakawa, M; Fukuhara, S; Hibi, T; Hosoda, H; Ishii, H; Kangawa, K; Kitajima, M; Masaoka, T; Minegishi, Y; Suzuki, H, 2005) |
| "To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer." | 7.73 | Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006) |
| "The focus was on salivary glands in cysteamine-induced duodenal ulcer and the different effects of antiulcer agents on cysteamine-induced duodenal ulcer in sialoadenectomized but not gastrectomized rats." | 7.72 | Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. ( Anic, T; Batelja, L; Bedekovic, V; Boban Blagaic, A; Drvis, P; Gjurasin, M; Kalogjera, L; Kopljar, M; Mise, S; Seiwerth, S; Sikiric, P; Staresinic, M, 2003) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 7.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| "Beta-endorphin plasma levels (pmol/l) were measured during an acute episode of duodenal ulcer, before and after antisecretory therapy with omeprazole." | 7.69 | Beta-endorphin in silent duodenal ulcer. ( Chianelli, M; Delle Fave, G; Mariani, P; Negri, M; Tonnarini, GF, 1995) |
| "The efficacy of omeprazole 20 mg a day was assessed against ranitidine 150 mg twice a day in the healing and relapse of duodenal ulcer." | 7.69 | Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1995) |
| "The clinical outcome and cost-effectiveness of episodic treatment of duodenal ulcer with omeprazole and ranitidine were evaluated over a 5-year period." | 7.69 | Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. ( Eriksson, S; Walan, A, 1994) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 7.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "The study investigated the effect of either nocturnal acid suppression by the H2 antagonist nizatidine 300 mg at night or prolonged acid suppression by the proton- pump inhibitor omeprazole 20 mg in the morning, during four weeks, on intragastric pH profile, occurrence of bacterial growth in gastric fluid and biopsies, and healing rate in 23 patients with an acute duodenal ulcer." | 7.69 | Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. ( Brummer, RJ; Stockbrügger, RW, 1996) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 7.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| "We have previously shown that, in duodenal ulcer patients, pH control by omeprazole is less pronounced after cure of Helicobacter pylori infection." | 7.69 | Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| "To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer." | 7.69 | [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997) |
| "In patients with duodenal ulcer cure of Helicobacter pylori infection resulted in a pronounced decrease in intragastric pH during treatment with omeprazole." | 7.69 | Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 7.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| "The aim of this study is to propose a regimen of omeprazole 20 mg twice weekly for the prevention of duodenal ulcer (DU) relapse." | 7.68 | [Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse]. ( Bei, L; Chen, SP; Wen, SH, 1993) |
| "Thirteen consecutive patients with active duodenal ulcer disease were assigned to a treatment schedule with high-dose omeprazole and amoxycillin." | 7.68 | Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Beattie, S; Collins, R; O'Morain, C; Xia, HX, 1993) |
| "This study compares the efficacy and side effects of omeprazole and regular- and double-dose nizatidine in the treatment of duodenal ulcers." | 7.68 | Comparison of omeprazole and nizatidine in the treatment of duodenal ulcers. ( Chen, CY; Chen, LT; Jan, CM; Perng, DS; Wang, WM, 1992) |
| "Thirty patients with active duodenal ulcer who were Helicobacter pylori positive (HP+) by HLO test and by histology (Giemsa stain) were given omeprazole (OME) 20 mg/d for a two-week period." | 7.68 | Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori? ( Alevizou, V; Archimandritis, A; Davaris, P; Fertakis, A; Kapsalas, D; Kyriaki, D; Tjivras, M, 1992) |
| "Nine patients with duodenal ulcer were on separate occasions given omeprazole, 20 mg orally, 10 mg intravenously (IV), and 40 mg IV once daily for 5 days." | 7.68 | Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. ( Cederberg, C; Fisher, D; Kirdeikis, P; Mahachai, V; Marriage, B; Thomson, AB; Westin, JA; Zuk, L, 1992) |
| "Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o." | 7.68 | Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991) |
| "The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission." | 7.68 | Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. ( Cederberg, C; Lind, T; Olausson, M; Olbe, L, 1991) |
| "The effects of omeprazole, a benzimidazole derivative, have been determined on the secretory responses to modified sham feeding and pentagastrin, and upon serum gastrin and pancreatic polypeptide concentrations in duodenal ulcer patients." | 7.67 | Action of omeprazole (a benzimidazole derivative) on secretory responses to sham feeding and pentagastrin and upon serum gastrin and pancreatic polypeptide in duodenal ulcer patients. ( Konturek, SJ; Kopp, B; Kweicień, N; Obtułowicz, W; Oleksy, J, 1984) |
| "The effect of a single oral dose of omeprazole (90 mg) on gastric emptying was assessed with a dual isotope scintigraphic technique in eight patients with a history of duodenal ulcer disease." | 7.67 | The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. ( Buckle, PJ; Chatterton, BE; Hetzel, DJ; Horowitz, M; Shearman, DJ, 1984) |
| " Acutely induced gastric ulcers or erosions such as Shay ulcers, water-immersion stress-, indomethacin-, aspirin-, or prednisolone-induced erosions were all markedly inhibited by oral or intraduodenal administration of 10-100 mg/kg of omeprazole." | 7.67 | Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. ( Okabe, S; Okada, Y; Yamamoto, O, 1984) |
| " Ten patients with duodenal ulcer disease were studied under fasting conditions and for 3 h after a standard liquid meal on three occasions: day 1, before treatment; day 8, when the proton pump blocker omeprazole had been taken in a daily dose of 30 mg for 7 days consecutively, including the day of the pH study; day 9, 24 h after the last dose of omeprazole." | 7.67 | Effect of omeprazole on intragastric and duodenal bulb acidity in duodenal ulcer patients. ( Bendtsen, F; Ovesen, L; Rosenkilde-Gram, B; Rune, SJ, 1989) |
| "Healing of duodenal ulcers induced by indomethacin + histamine was investigated in rats." | 7.67 | Healing process of duodenal ulcers induced by indomethacin plus histamine in rats. ( Niida, H; Okabe, S; Okada, M; Takeuchi, K, 1989) |
| "The effect of intermittent dosage with omeprazole on basal and pentagastrin stimulated gastric acid secretion and fasting plasma gastrin was assessed in eight duodenal ulcer subjects who were in remission." | 7.67 | Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients. ( Angus, PW; Brook, CW; Hewson, EG; Sewell, RB; Shulkes, A; Smallwood, RA; Yeomans, ND, 1988) |
| "We have studied the effect on serum gastrin concentrations of weekly 3-day courses of 20 mg/day omeprazole followed by a 4-day period without medication (weekend therapy) for 4 weeks in 10 patients with duodenal ulcer." | 7.67 | Effect of intermittent weekend therapy with omeprazole on basal and postprandial serum gastrin concentrations in patients with duodenal ulcer. ( Crobach, LF; Jansen, JB; Lamers, CB, 1988) |
| "Penetrated cysteamine-induced duodenal ulcers in rats have a very prolonged course of healing." | 7.67 | Effect of antisecretory agents and vagotomy on healing of "chronic" cysteamine-induced duodenal ulcers in rats. ( Kirkegaard, P; Poulsen, SS; Raaberg, L; Skov Olsen, P; Therkelsen, K, 1986) |
| "Endoscopic biopsies were taken from the oxyntic mucosa in patients with duodenal ulcer (DU) before and after 4 weeks of treatment with omeprazole." | 7.67 | Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. ( Helander, HF, 1986) |
| "Gastric secretion was measured in nine patients with duodenal ulcer before, and after treatment for four weeks with omeprazole 20 mg or 40 mg daily." | 7.67 | Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. ( Baron, JH; Barr, JA; Bush, A; Collier, N; Cope, L; Gribble, RJ; Spencer, J; Thompson, JN, 1985) |
| "3%) and there were no serious adverse events." | 6.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| "In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89." | 6.69 | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. ( Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY, 1998) |
| "Treatment with omeprazole 20 mg every morning maintained significantly more patients in remission than treatment with ranitidine 150 mg at bedtime." | 6.69 | Omeprazole and ranitidine in long-term treatment of duodenal ulcer: a double-blind comparison of length of time in remission. ( Aran-Suau, R; Berenguer, J; Caswell, C; Clerch, L; Da Silveira, JC; Diaz de Rojas, F; Garcia Aparicio, P; Rodrigo, L, 1998) |
| " There was also a clear dose-dependent pharmacodynamic effect, which augmented on moving from the lowest dosage of 20 mg o." | 6.69 | Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. ( Bisso, G; Celle, G; Fiorucci, S; Malesci, A; Mela, GS; Pivari, M; Savarino, V; Termini, R; Usai, P; Vigneri, S; Zentilin, P, 1998) |
| "Treatment with omeprazole (OME), azithromycin (AZI) and amoxicillin (AMO) resulted in encouraging Helicobacter pylori cure rates in pilot and control studies." | 6.69 | Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. ( Blazanović, A; Dmitrović, B; Ivandić, A; Karner, I; Kovac, D; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A, 1998) |
| " The optimal dosage and duration of treatment need to be specified." | 6.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 6.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies." | 6.68 | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995) |
| "Pirenzepine has been reported to inhibit gastrin secretion." | 6.68 | Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. ( Fukino, Y; Hamada, M; Haruma, K; Inoue, M; Kajiyama, G; Kamiyasu, T; Sumii, K; Sumii, M; Tari, A, 1996) |
| "When lansoprazole alone was administered to the patients, H." | 6.68 | [Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer]. ( Maruyama, M, 1996) |
| " Thus, a true dose-response relationship exists between omeprazole and treatment success." | 6.68 | Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997) |
| "For H." | 6.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 6.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| "Pantoprazole is a newly developed benzimidazole derivative with strong inhibitory actions on gastric acid secretion by blocking H(+)-K(+)-ATPase." | 6.67 | Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. ( Khalil, H; Leucht, U; Lühmann, R; Müller, P; Schneider, A; Simon, B, 1992) |
| "Omeprazole was given once daily." | 6.67 | An open trial on short-term omeprazole therapy for gastric and duodenal ulcers. ( Alvarez, SZ; Espiritu, AC; Perez, JY; Sollano, JD, 1991) |
| " Both drugs were generally well tolerated, and the number of adverse events in the two treatment groups were similar." | 6.67 | The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients. ( Backman, L; Granström, L; Kager, L; Kollberg, B; Lindberg, G; Moberg, S; Nilsson, LH; Seensalu, R; Sidenvall, L; Sörstad, J, 1991) |
| "Omeprazole was well tolerated; fewer patients had clinical and laboratory adverse experiences in the omeprazole group than in the placebo group." | 6.67 | Omeprazole versus placebo in duodenal ulcer healing. The United States experience. ( Berman, RS; Bishop, RH; Cagliola, AJ; Gitlin, N; Graham, DY; McCullough, A; Roufail, WM; Sklar, M; Sontag, SJ; Stone, RC, 1990) |
| "Omeprazole was superior to cimetidine in ulcer-healing rate after 2, 4 and 6 weeks." | 6.66 | The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms. ( Brunkwall, J; Dahlgren, S; Domellöf, L; Gasslander, T; Hradsky, M; Karlsson, J; Knutson, U; Norryd, C; Svensson, G; Svensson, JO, 1988) |
| "in short-term treatment of acute duodenal ulcer." | 6.66 | Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study. ( Abbiati, R; Barbara, L; Blasi, A; Cheli, R; Corinaldesi, R; Dobrilla, G; Francavilla, A; Gradnik, R; Rinetti, M; Vezzaldini, P, 1987) |
| "Omeprazole is a proton pump inhibitor which induces a dose-dependent reduction of gastric acid secretion." | 6.66 | [Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage. A French multicenter, controlled therapeutic trial]. ( Bader, JP; Bigard, MA; Ebrard, F; Galmiche, JP; Isal, JP, 1987) |
| "Omeprazole is a very potent and long-acting inhibitor of gastric acid secretion." | 6.38 | Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. ( Jansen, JB; Lamers, CB; Meijer, JL, 1989) |
| " ranitidine in 45 patients admitted as an emergency with an endoscopic diagnosis of bleeding duodenal ulcer." | 6.18 | [Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study]. ( Amadori, L; Arnone, F; Barillari, P; Bolognese, A; Cardi, M; Muttillo, IA; Sammartino, P; Signorelli, C, 1997) |
| "Clinical experience with lansoprazole in the acute treatment of duodenal ulcer patients has been compared with treatment using placebo, H2-antagonists or omeprazole." | 6.17 | Acute treatment of duodenal ulcer: experience with lansoprazole. ( Mignon, M; Vallot, T, 1993) |
| "More than 13,000 individuals with duodenal ulcer, gastric ulcer or reflux oesophagitis have now taken part in controlled clinical studies with omeprazole." | 6.16 | The clinical utility and safety of omeprazole. ( Walan, A, 1989) |
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 5.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 5.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| "Omeprazole is a proton pump inhibitor widely used for the treatment of peptic ulcer disease." | 5.30 | Omeprazole-induced acute interstitial nephritis. ( d'Adamo, G; Forte, F; Gangeri, F; Spinelli, C, 1997) |
| "Duodenal ulcer is a chronic disease with a high risk of relapse--if left untreated, the relapse rate is 50-80% per year (1)." | 5.29 | Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. ( Festen, HP, 1994) |
| "It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome." | 5.29 | [The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993) |
| " From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages." | 5.29 | [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer]. ( Battaglia, G; Chiozzini, G; De Bona, M; De Boni, M; Di Mario, F; Grasso, GA; Pasquino, M; Saggioro, A; Vianello, F, 1993) |
| "Fewer duodenal ulcers were found in animals receiving drug treatments than in the oral vehicle group." | 5.28 | Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model. ( Baron, JH; Gompertz, RH; Li, SK; Man, WK; Michalowski, AS; Spencer, J, 1991) |
| " This study investigated the mechanism of the increase in oral bioavailability of omeprazole during repeated oral dosing." | 5.28 | Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. ( Angus, PW; Ching, MS; Devenish-Meares, S; Mihaly, GW; Morgan, DJ; Smallwood, RA; Yeomans, ND, 1991) |
| " Omeprazole, a substituted benzimidazole inhibitor of the gastric H+/K(+)-APT-ase, was administered orally at a dose of 20 mg in the morning of 3 consecutive days, followed by a period of 4 days without medication, and this intermittent dosage regimen was continued for 4 weeks." | 5.28 | Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers. ( Biemond, I; Crobach, LF; Jansen, JB; Lamers, CB, 1990) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 5.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| "This study was aimed to identify an intravenous dosage regime of omeprazole which would sufficiently suppress acid secretion to maintain intragastric pH greater than 4 continuously." | 5.27 | Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients. ( Lind, T; Moore, M; Olbe, L, 1986) |
| "Patients with at least one endoscopically diagnosed active duodenal ulcer (DU) were enrolled in a multicenter, randomized, double-blind, positive controlled trial and then assigned randomly to the ilaprazole group (10 mg/d) or the omeprazole group (20 mg/d) with a sample allocation ratio 2:1." | 5.16 | Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. ( Hu, H; Lin, S; Wang, L; Xia, J; Zhou, L, 2012) |
| "Ilaprazole is as tolerable, safe, and efficacious as omeprazole in the treatment of duodenal ulcers, especially at a lower dose (10 mg/d ilaprazole vs." | 5.15 | A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. ( Hu, H; Lin, S; Wang, L; Xia, J; Zhou, L, 2011) |
| " pylori infection was statistically significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H." | 5.15 | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. ( Chern, HD; Lin, BR; Lin, CJ; Shun, CT; Wang, HL; Wang, TH; Yang, JC, 2011) |
| "Melatonin (MT) and its precursor L-tryptophan (TRP) are implicated in the protection of gastric mucosa against aspirin-induced lesions and in the acceleration of healing of idiopathic gastro-duodenal ulcers, but no information is available whether these agents are also effective in healing of gastroduodenal ulcers accompanied by Helicobacter pylori (H." | 5.15 | Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Slomka, M, 2011) |
| " This study evaluated and compared it with a reference PPI, omeprazole, in the treatment of gastric and duodenal ulcers." | 5.14 | Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. ( Goh, KL; Ho, KY; Kim, DY; Kuan, A; Mahachai, V; Yoon, HM; Zaño, F, 2009) |
| " A total of forty-two patients with duodenal ulcer were randomized into low dose ilaprazole group (5 mg/d), medium dose ilaprazole group (10 mg/d), high dose ilaprazole group (20 mg/d) and omeprazole group (20 mg/d)." | 5.14 | [Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer]. ( Hou, XH; Hu, HT; Lin, SR; Qin, XH; Shi, RH; Xia, JL; Yang, YS; Yuan, YZ; Zhang, ST; Zhou, LY, 2010) |
| " The aim of this study was to compare therapeutic effects of oral omeprazole and intravenous cimetidine on reducing rebleeding rates, duration of hospitalization, and the need for blood transfusion in duodenal ulcer patients." | 5.12 | A comparison of oral omeprazole and intravenous cimetidine in reducing complications of duodenal peptic ulcer. ( Fattahi, E; Khaleghian, F; Khoshbaten, M; Naderi, N; Rezailashkajani, M, 2006) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 5.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| "A total of 909 H pylori-positive patients with duodenal ulcer, enrolled in 81 endoscopy units in Italy, were randomised to receive omeprazole, amoxicillin and clarithromycin for either 1 week (OAC1W) or 2 weeks (OAC2W) or omeprazole and amoxicillin for 2 weeks." | 5.12 | Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. ( Bazzoli, F; Bianchi-Porro, G; Fiocca, R; Gasbarrini, G; Roda, E; Zagari, RM, 2007) |
| "This trial was performed to compare the effects of IV pantoprazole versus omeprazole on 24-hour intragastric acidity in Chinese patients with endoscopically confirmed duodenal ulcer." | 5.12 | Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial. ( Cheng, YC; Lin, HJ; Lo, WC; Perng, CL, 2006) |
| " pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively)." | 5.12 | One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. ( Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E, 2007) |
| "248 patients with Hp-associated active duodenal ulcer confirmed by endoscopy, 193 males and 55 females, were randomized to receive OAC(250): omeprazole (0." | 5.11 | [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. ( , 2004) |
| "This analysis compared the efficacy of misoprostol, lansoprazole, and placebo in reducing the risk of gastric or duodenal ulcer recurrence in patients taking NSAIDs and low-dose aspirin." | 5.11 | Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. ( Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 5.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "To investigate the effect of esomeprazole- and omeprazole-based triple therapy regimens in the treatment of duodenal ulcer with Helicobacter pylori (Hp) infection." | 5.11 | [Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection]. ( Chen, YH; Li, HY; Wang, H; Wang, WM, 2005) |
| "Four-hundred and fifty duodenal ulcer patients were randomized to receive: (1) esomeprazole (20 mg b." | 5.11 | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? ( Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S, 2005) |
| "The article discloses the results of the duodenal ulcer treatment with a generic of omeprazole (Omizac) in the in-patient hospital and polyclinic conditions, dynamics of the serum gastrin level against the background of the drug application and after its withdrawal, and assessment of the intensity and duration of acid production inhibition in the stomach." | 5.11 | [Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. ( Belov, DF; Loginov, AF; Maksimova, ID; Ponomarev, AA, 2005) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 5.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "To assess and compare the efficacy and safety of two triple regimes: A) metronidazole, amoxicillin and omeprazole, which is still widely used in Russia, and B) azithromycin, amoxicillin and omeprazole in healing active duodenal ulcer and H." | 5.10 | Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer. ( Bondarenko, OY; Fedchenko, VI; Grigoriev, PY; Gulyaev, PV; Ivashkin, VT; Lapina, TL; Sklanskaya, OA; Vasiliev, YV; Yakovenko, EP, 2002) |
| "To evaluate the therapeutic effect on duodenal ulcer symptoms and safety of rabeprazol as compared with omeprazole." | 5.10 | [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer]. ( Lin, S, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 5.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 5.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 5.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| "To assess efficiency of esomeprazole in the treatment of duodenal ulcer (DU) associated with H." | 5.10 | [Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy]. ( Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES, 2003) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 5.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| "To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
| " Medical treatment included omeprazole, clarithromycin, and amoxicillin for 7 days followed by omeprazole for 3 weeks for duodenal ulcer and 5 weeks for gastric ulcer." | 5.10 | [Treatment of perforated gastroduodenal ulcer by simple suture followed by Helicobacter pylori eradication]. ( Quandalle, P; Tran, TT, 2002) |
| "Duodenal ulcer cure, as a systemic gastroenterologic disease, can be achieved in some patients by the addition of the nootropic drug piracetam to current antisecretory and antihelicobacter therapy." | 5.10 | [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer]. ( Shchetkin, DI; Tsimmerman, IaS, 2002) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| "To determine which demographic factors may influence serum gastrin and pepsinogen I (PGI) levels in duodenal ulcer patients undergoing omeprazole treatment." | 5.09 | Helicobacter pylori clearance and serum gastrin and pepsinogen I concentrations in omeprazole treatment of duodenal ulcer patients. ( Chang, FY; Chen, CY; Kuo, BI; Lee, CT; Lee, SD, 1999) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 5.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers." | 5.09 | Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 5.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| "Bleeding due to duodenal ulcer was not observed in any patients who received clarithromycin plus omeprazole, whereas five patients in the omeprazole treatment group and six patients in the ranitidine treatment group experienced an episode of ulcer-related hemorrhage during follow-up." | 5.09 | The effect of antibiotic therapy on bleeding from duodenal ulcer. ( Olson, CA; Sonnenberg, A; Zhang, J, 1999) |
| " pylori-positive patients with endoscopically defined peptic ulcer [DU (n = 65), GU (n = 12)] or non-ulcer dyspepsia (NUD, n = 43) were randomized to receive a 1-week course of twice daily omeprazole 20 mg, clarithromycin 250 mg and either metronidazole 400 mg (OCM) or tinidazole 500 mg (OCT) in a double-blind fashion." | 5.09 | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. ( Goddard, AF; Lawes, S; Logan, RP; Spiller, RC, 1999) |
| "Adult patients with active duodenal ulcer and confirmed H pylori infection were randomized to receive treatment with clarithromycin plus omeprazole, omeprazole alone, or ranitidine alone." | 5.09 | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. ( Levenson, SD; Pauly, MP; Schwartz, JS; Sonnenberg, A, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 5.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| "To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly." | 5.09 | Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999) |
| "Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms." | 5.09 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 5.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| "The aim of this randomized, multicenter, double-masked, parallel-group study was to compare the efficacy of lansoprazole with that of omeprazole monotherapy in duodenal ulcer healing and prevention of relapse." | 5.09 | Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. ( Dobrilla, G; Fiocca, R; Piazzi, L, 1999) |
| "A health economic evaluation of triple therapy with lansoprazole, amoxicillin and clarithromycin versus 2 dual therapies (lansoprazole or omeprazole, each with amoxicillin) in the eradication of Helicobacter pylori in patients with duodenal ulcers was performed in parallel with a randomised clinical trial." | 5.09 | Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives. ( Norinder, A; Ohlin, B; Tennvall, GR, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 5.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| "To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients." | 5.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "In this open, randomized, monocenter, parallel group comparison, 107 patients with duodenal ulcer or functional dyspepsia were assigned to receive one of the following treatment regimens: a 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid, which was either preceded or followed by a 7-day therapy with pantoprazole, 40 mg (P-PCM or PCM-P)." | 5.09 | Pantoprazole suppresses Helicobacter pylori without affecting cure. ( Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999) |
| "In a double-blind, parallel-group clinical trial of 928 patients (from 70 centres in 16 countries) with duodenal ulcers who after a short term study had relief of symptoms and healed ulcers proved endoscopically, 308 were randomly assigned to receive omeprazole 10 mg in the morning, 308 to receive omeprazole 20 mg in the morning and 312 to receive ranitidine 150 mg at bedtime for up to 12 months." | 5.09 | Omeprazole and ranitidine in the prevention of relapse in patients with duodenal ulcer disease. ( Archambault, AP; Bailey, RJ; Bianchi Porro, G; Bolling, E; Brunner, G; Eriksson, S; Frison, L; Galmiche, JP; Gudjónsson, H; Havu, N; Lauritsen, K; Rutgersson, K; Thompson, AB; Walan, A, 1999) |
| " Treating duodenal ulcer with simultaneous administration of omeprazole achieves ulcer pain relief more rapidly." | 5.09 | Does eradication of Helicobacter pylori alone heal duodenal ulcers? ( Chen, Y; Ge, ZZ; Hu, YB; Xiao, SD; Zhang, DZ, 2000) |
| "The aim of this study was to compare the effectiveness and tolerance of pantoprazole versus ranitidine in the treatment of duodenal ulcers in the Brazilian population." | 5.09 | Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. ( de Paula Castro, L; Lyra, LG; Malafaia, O; Meneghelli, UG; Zaterka, S, 2000) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 5.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "To compare the eradication rates of Helicobacter pylori, ulcer healing rates and side-effects of three regimens of omeprazole triple therapy in patients with duodenal ulcer from South-East Asia and to study the impact of metronidazole resistance." | 5.09 | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. ( Chelvam, P; Fock, KM; Lim, SG, 2000) |
| " In a prospective clinical trial, primed infusions of different dosages of omeprazole (8 or 4 mg/h) after a bolus (40 mg) produced consistently high intragastric pH values in patients with bleeding duodenal ulcer." | 5.09 | Effect of intragastric pH on control of peptic ulcer bleeding. ( Dai, S; Jia, L; Li, Y; Nie, Y; Sha, W; She, Q; Wu, H; Yu, W, 2000) |
| "To investigate the efficacy of a 1-week triple therapy with amoxycillin, clarithromycin, and omeprazole or ranitidine bismuth citrate (RBC) in curing Helicobacter pylori infection and healing duodenal ulcers." | 5.09 | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. ( Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R, 2000) |
| "The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease." | 5.09 | Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. ( Breiter, JR; Humphries, TJ; Riff, D, 2000) |
| "To compare the efficacy of either omeprazole or ranitidine in a second-line quadruple regimen in patients with duodenal ulcer or erosive duodenitis." | 5.09 | Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. ( Balta, A; Bouzakis, H; Broutet, N; Kralios, N; Michopoulos, S; Tsibouris, P; Vougadiotis, J, 2000) |
| " pylori eradication and duodenal ulcer healing in this region despite the high metronidazole resistance rate." | 5.09 | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. ( Adamthwaite, D; Davidson, G; Katelaris, PH; Lambert, J; Midolo, P; Yeomans, ND, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 5.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b." | 5.09 | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000) |
| "5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks." | 5.09 | Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 5.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "Seven-day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with H." | 5.09 | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. ( Abbas, Z; Abid, S; Chang, FY; Chen, PC; Destefano, M; Hamid, SS; Lam, SK; Lin, BR; Schneider, H; Seebaran, A; Simjee, AE; Van Rensburg, C; Wong, BC; Zhang, J, 2000) |
| " Patients with gastric ulcer (GU) or duodenal ulcer (DU) were enrolled in this study; 583 eligible patients (GU, 325; DU, 258) were administered lansoprazole (30 mg/day for 8 weeks for GU, and the same dosage for 6 weeks for DU) as first-line therapy, and a half dose of H2RA as maintenance therapy for 12 months." | 5.09 | Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000) |
| "Patients with active duodenal ulcer were randomized either to omeprazole, 20 mg twice daily until healing, followed by omeprazole, 20 mg/ day for 1 year, or to eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year." | 5.09 | Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. ( Aalykke, C; Bekker, C; Bonnevie, O; Bytzer, P; Eriksen, J; Gjørup, T; Hansen, J; Justesen, T; Kjaergaard, J; Kromann-Andersen, H; Rask-Madsen, J; Rune, S; Teglbjaerg, PS; Vilien, M; Vyberg, M; Weywadt, L, 2000) |
| "Four hundred and forty eight duodenal ulcer patients with Helicobacter pylori infection, confirmed by 13C-urea breath test (UBT), and no current ulcer, were randomised to double-blind treatment with esomeprazole 20 mg twice daily (b." | 5.09 | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. ( Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| " pylori was cultured and clarithromycin susceptibility was determined before and after treatment, from duodenal ulcer patients receiving RBC and clarithromycin or omeprazole and clarithromycin for 2 weeks in a multicenter randomized clinical trial." | 5.09 | Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. ( Mégraud, F; Roberts, P; Williamson, R, 2000) |
| " pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3)." | 5.09 | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. ( Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg." | 5.09 | Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. ( Bateson, MC, 2001) |
| "To compare the efficacy of one-week versus two-week treatment with lansoprazole, amoxycillin and clarithromycin in inducing healing of Helicobacter pylori-positive duodenal ulcers as well as to investigate the role of several factors, determinant in the ulcer healing process." | 5.09 | Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? ( Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A, 2000) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 5.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 5.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| "Pantoprazole (40 mg) was compared with ranitidine (300 mg) in the treatment of acute duodenal ulcer." | 5.08 | Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. ( Classen, M; Schepp, W, 1995) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 5.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 5.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| "The aim of this study was to establish if the discontinuous assumption of omeprazole was effective to reduce the recurrence of duodenal ulcer disease as the cyclic periodical assumptions of the same drug." | 5.08 | [Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer]. ( Bisi, G; Cappellari, L; Caravita, L; Dalla Libera, M; Gullini, S; Massari, M; Matarese, V; Tartari, V; Zibordi, U, 1995) |
| "Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks." | 5.08 | Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995) |
| "We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three omeprazole schedules, i." | 5.08 | Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study. ( , 1995) |
| "A trial was carried out to compare the efficacy and safety of ranitidine 300 mg die, famotidine 40 mg die and omeprazole 20 mg die in short-term treatment of bleeding duodenal ulcer in 3 groups of 15 patients." | 5.08 | [Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer]. ( Maculotti, L; Pradella, P, 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To evaluate whether eradication with omeprazole and amoxicillin results in a reduction of ulcer recurrence and rebleeding in patients with Helicobacter pylori-associated duodenal ulcer hemorrhage, patients with upper gastrointestinal hemorrhage from duodenal ulcers with stigmata of recent hemorrhage, a drop in hemoglobin level of more than 2 g/dL, and documented H." | 5.08 | Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Koerner, T; Raschka, C; Schorr, W, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 5.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 5.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| "Five hundred forty five patients with a fibroscopically proven duodenal ulcer were included in a randomized controlled trial and were treated for one month with omeprazole (20 mg) or ranitidine (300 mg)." | 5.08 | [Prognostic factors of the speed of cicatrization in duodenal ulcer. Controlled trial of omeprazole versus ranitidine]. ( Abitbol, V; Barbier, JP; Bergmann, JF; Hamelin, B, 1995) |
| "In this double-blind randomized comparative study patients with active duodenal ulcers were treated with either 30 mg lansoprazole or 20 mg omeprazole in the morning." | 5.08 | Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. ( Anker-Hansen, O; Carling, L; Ekström, P; Sellström, H; Sjöstedt, S; Unge, P, 1995) |
| " Pantoprazole, 40 mg, was compared with the H2-receptor antagonist ranitidine, 300 mg, in the healing of acute duodenal ulcer." | 5.08 | A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group. ( Cremer, M; Delle Fave, G; Lambert, R; Lamers, CB; Maier, C, 1995) |
| ") in eradicating Helicobacter pylori in patients with duodenal ulcer successfully healed with omeprazole or ranitidine; second, to examine the influence of the eradication on duodenal ulcer recurrence rate after 12 months." | 5.08 | Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. ( Archimandritis, A; Balatsos, V; Delis, V; Kastanas, K; Mentis, A; Scandalis, N, 1995) |
| "In this randomized, double-blind, multicentre study, the proton pump inhibitors pantoprazole and omeprazole were compared in patients with active duodenal ulcers." | 5.08 | Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. ( Rehner, M; Rohner, HG; Schepp, W, 1995) |
| "This study analyzes the effect of short- and long-term omeprazole (OM) on duodenal ulcer healing, recurrence, and H." | 5.08 | Short- and long-term omeprazole for the treatment and prevention of duodenal ulcer, and effect on Helicobacter pylori. ( Biasco, G; Cifani, F; DeFanis, C; Falcucci, M; Ferrini, G; Grossi, L; Iannetti, G; Larcinese, G; Lattanzio, R; Marzio, L, 1995) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 5.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| "In this double-blind trial, conducted in 19 hospitals, 119 patients with symptomatic duodenal ulcer disease were randomized to receive either 14 days treatment with omeprazole 40 mg daily, amoxycillin 500 mg t." | 5.08 | Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. ( Axon, AT; Bate, CM; Bell, GD; Emmas, CE; Green, JR; Kerr, GD; Taylor, MD; Tildesley, G, 1995) |
| "Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers." | 5.08 | Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996) |
| "Parenteral omeprazole is better than parenteral ranitidine in keeping the intragastric pH above the proteolytic range for pepsin in patients with bleeding duodenal ulcers." | 5.08 | [Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage]. ( Artal, A; Barrao, ME; Blas, JM; Lanas, A; López, J; Moliner, FJ, 1996) |
| "The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence." | 5.08 | Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996) |
| "To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control." | 5.08 | [A clinical trial of lansoprazole in the treatment of duodenal ulcer]. ( Chen, S; Pei, Y; Wang, B, 1995) |
| "Changes in Helicobacter pylori-associated gastritis of the antrum and corpus were investigated in a large number of patients treated with omeprazole, with or without the addition of amoxycillin." | 5.08 | Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. ( Carlsson, J; Fiocca, R; Rudbäck, A; Solcia, E; Villani, L; Zeijlon, L, 1996) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| " Those patients with active duodenal ulcers present at endoscopy were given omeprazole 20 mg nocte for a further 21 days." | 5.08 | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. ( Broadbent, A; Chambers, S; Gould, SR; Mistry, R; Ranganath, L; Weldon, MJ, 1996) |
| " pylori-positive out-patients (n = 231) with duodenal ulcers were treated randomly and double-blind with either omeprazole 20, 40 or 80 mg b." | 5.08 | Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. ( Braden, B; Lembcke, B; Londong, W; Pommerien, W; Schultze, V; Wrangstadh, M, 1996) |
| "Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08." | 5.08 | The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients. ( Celle, G; Mansi, C; Mela, GS; Mele, MR; Savarino, V; Vigneri, S; Zentilin, P, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 5.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| " Sixty duodenal ulcer patients were randomised to receive either standard triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds), quadruple therapy A (triple therapy+omeprazole 20 mg od) or quadruple therapy B (triple therapy+omeprazole 40 mg od), for 7 days." | 5.08 | One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. ( Griffiths, AE; Halliday, D; Jacyna, MR; Phull, PS, 1995) |
| " Our purpose was to evaluate the occurrence of mycotic infection in patients with duodenal ulcer on anti-ulcer therapy and to compare the effects of cimetidine, famotidine, and omeprazole." | 5.08 | Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. ( Chakrabarti, A; Goenka, MK; Gupta, O; Kochhar, R; Kumar, A; Mehta, SK; Talwar, P, 1996) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 5.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 5.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| " pylori infection in patients with chronic gastritis (CG), duodenal ulcer (DU), and gastric ulcer (GU) after two dual therapies (omeprazole with either amoxycillin or clarithromycin)." | 5.08 | Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. ( Carpintero, P; García Grávalos, R; Hermida, C; Lara, S; Moreno, JA; Pajares, JM; Santander, C, 1996) |
| " Monotherapy of duodenal ulcer with pantoprazole or ranitidine was evaluated in terms of healing rate, tolerance and compliance." | 5.08 | [Treatment of duodenal ulcer with pantoprazole. A multicenter study]. ( Dítĕ, P; Drazná, E; Dufek, V; Dvorák, M; Fric, P; Huslarová, A; Jirásek, V; Kunovská, M; Münzová, H; Pelech, T; Petrtýl, J; Roth, Z; Svoboda, J; Zádorová, Z; Zavoral, M, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| " After 2 weeks duodenal ulcer healing was confirmed in 91% (95% CI = 80-100%) of patients treated with omeprazole and in 76% (95% CI = 60-91%) in the placebo group (P = 0." | 5.08 | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. ( Adamek, RJ; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Tillenburg, B, 1997) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 5.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 5.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "In two parallel studies, 20 patients with bleeding duodenal ulcers and 20 patients with bleeding gastric ulcers were randomly assigned to receive either ranitidine (0." | 5.08 | Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. ( Blum, AL; Börsch, G; Labenz, J; Leusing, C; Peitz, U; Tillenburg, B, 1997) |
| "Fifty-four patients with active duodenal ulcers were treated with amoxycillin tablets, 750 mg three times daily, and omeprazole, either 40 mg twice daily (group 1) or 40 mg three times daily (group 2), for 14 days in a prospective randomized trial." | 5.08 | Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial. ( Barnert, J; Busch, R; Demharter, R; Fleischmann, R; Füger, K; Wienbeck, M, 1997) |
| "The purpose of the present study was to examine the association between interleukin-8 (IL-8) in the gastric body due to Helicobacter pylori infection and histological gastritis, as well as elucidating the effect of acid secretion inhibitors on H." | 5.08 | Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Oomoto, Y; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 5.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 5.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| " Patients (n = 787) with proved duodenal ulcer disease were randomized to treatment twice daily for 1 week with omeprazole, 20 mg (O), plus either placebo (P) or combinations of two of the following antimicrobials: amoxicillin, 1 gm (A), clarithromycin, 250 or 500 mg (C250, C500), or metronidazole, 400 mg (M)." | 5.08 | Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. ( Bardhan, KD; Bayerdörffer, E; Bradette, M; Cederberg, C; Chiba, N; Idström, JP; Lind, T; O'Morain, C; Spiller, R; Unge, P; Veldhuyzen van Zanten, S; Wrangstadh, M, 1996) |
| " pylori-positive peptic ulcer received omeprazole 20 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily for seven days." | 5.08 | One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? ( Bhutta, AS; Bindel, H; Cunnane, K; Loane, J; O'Connor, HJ, 1997) |
| "A double-blind, randomized, multicenter, multicountry study (Poland, Chech Republic, Hungary) was carried out in 1995 on patients (n = 326) with endoscopically confirmed duodenal ulcer treated with ranitidine vs." | 5.08 | [Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study]. ( Döbrönte, Z; Juhász, L; Lonovics, J; Papp, J, 1997) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 5.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| " The aim of the present study was to assess efficacy and tolerability of the proton pump inhibitors lansoprazole given at bedtime as compared to ranitidine, both in acute and maintenance treatment of duodenal ulcer." | 5.08 | Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 5.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| "To compare the efficacy of two "new" one-week triple therapies (with omeprazole, metronidazole and clarithromycin or amoxycillin) for the eradication of Helicobacter pylori and healing duodenal ulcer." | 5.08 | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. ( Abraira, V; Boixeda, D; García Plaza, A; Gisbert, JP; Martín de Argila, C; Moreno, L; Redondo, C, 1998) |
| "In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H." | 5.08 | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998) |
| " Fasting had no influence on the result of duodenal ulcer treatment by lansoprazole which was well tolerated." | 5.08 | [Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study]. ( Ajmi, S; Mehdi, A, 1997) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| " Patients with duodenal ulcer were treated with lansoprazole alone (n = 11) or lansoprazole and amoxycillin (n = 12)." | 5.08 | Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment. ( Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M, 1998) |
| " pylori infection and duodenal ulcer bleeding were treated with omeprazole (40 mg/day for 4 wk), colloidal bismuth (480 mg/day for 2 wk), amoxicillin (2 g/day for 1 wk), and metronidazole (750 mg/day for 1 wk), and followed up for 48 months." | 5.08 | Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. ( Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E, 1998) |
| " pylori-positive patients with active duodenal ulcer or gastritis, with confirmed history of duodenal ulcer, were randomized to treatment with ranitidine bismuth citrate 400 mg b." | 5.08 | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. ( Crobach, LF; Geraedts, AA; Kolkman, JJ; Nicolai, JJ; Oudkerk Pool, M; Tan, TG; Timmerman, RJ; Van Der Laan, J; Van Kleef, WA; Wolff, AA, 1997) |
| " Omeprazole was significantly superior to sucralfate in inducing gastric ulcer healing after both 4 (87 vs." | 5.08 | Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. ( Bianchi Porro, G; Lazzaroni, M; Manzionna, G; Petrillo, M, 1998) |
| " ranitidine bismuth citrate plus amoxycillin and clarithromycin in the treatment of Helicobacter pylori-associated duodenal ulcers." | 5.08 | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. ( Bentivegna, C; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Condorelli, G, 1998) |
| "Both treatment regimens, the 1-h topical method and amoxycillin with omeprazole, have low eradication rates in patients with duodenal ulcer." | 5.08 | Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients. ( Butruk, E; Dziurkowska-Marek, A; Hennig, E; Kohut, M; Marek, T; Nowak, A; Ostrowski, J; Przytulski, K; Regula, J, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| "Ninety patients with active duodenal ulcer disease and H pylori infection, proven with the 13C-urea breath test and CLO test (Campylobacter-like organism test) were treated randomly in three therapeutic groups: Group A, DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days; Group B, omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days; Group C, omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days." | 5.08 | New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. ( Ho, AS; Hsu, CT; Huang, WH; Lee, MM; Lee, SC; Shyu, RY, 1998) |
| " pylori-infected patients with one or more duodenal ulcer(s) at endoscopy (studies 1, 2) or with a documented duodenal ulcer history and no duodenal ulcer or erosions at endoscopy (study 3) were randomly assigned to 10-day courses of omeprazole 20 mg b." | 5.08 | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. ( Connors, A; Frantz, J; Laine, L; Neil, G; Suchower, L, 1998) |
| "A total of 101 patients with proven duodenal ulcer and a positive urease test were randomized into two groups: one group received the classic triple therapy (bismuth subnitrate 3 x 375 mg for 4 weeks + tetracycline 3 x 500 mg + metronidazole 3 x 250 mg daily, both for 2 weeks ), the other group received dual therapy comprising amoxicillin 2 x 1000 mg + omeprazole 2 x 20 mg daily, both for 2 weeks." | 5.08 | Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin. ( Kashifard, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Siavoshi, F, 1998) |
| "Sixty patients with active duodenal ulcers who tested positive for the rapid urease test had a C-14 UBT at 0 weeks (at enrollment) and at 6 and 12 weeks using 5 microCi (185 KBq) of C-14 urea." | 5.08 | Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? ( Ahuja, V; Bal, CS; Sharma, MP, 1998) |
| "In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate." | 5.08 | Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. ( Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 5.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " pylori-positive gastroduodenal ulcer bleeding, which could be commenced intravenously after endoscopic diagnosis, and to assess the effect of omeprazole pretreatment on bacterial eradication." | 5.07 | Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study. ( Adamek, RJ; Freitag, M; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 5.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| "We investigated the relationship between histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine for 4 weeks." | 5.07 | Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine. ( Chen, SH; Liao, CH; Lien, GS; Pan, S, 1994) |
| "Serum gastrin levels in 44 peptic ulcer patients (26 gastric ulcer patients and 18 duodenal ulcer patients) were determined after they had been treated with omeprazole (OPZ) (20 mg/day) alone or in combination with pirenzepine (PZP) (100 mg/day)." | 5.07 | Serum gastrin levels following administration of omeprazole alone or in combination with pirenzepine. ( Arakawa, Y; Ito, K; Iwasaki, A; Kawamura, Y; Matsuo, Y; Miyazawa, K; Sakai, Y; Tashiro, Y, 1994) |
| "This study was carried out to assess the antisecretory effects and their possible changes over time of three different dose regimens of omeprazole that could be proposed for maintenance treatment in duodenal ulcer." | 5.07 | Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. ( Celle, G; Cutela, P; Mansi, C; Mela, GS; Mele, MR; Perilli, D; Savarino, V; Vassallo, A; Zambotti, A; Zentilin, P, 1994) |
| "The purpose of the present study was to investigate the Helicobacter pylori eradication potency of combined amoxicillin-omeprazole treatment in patients with duodenal ulcer disease and to compare the efficacy of two omeprazole and amoxicillin doses concerning H." | 5.07 | Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 5.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "Twenty patients with endoscopically proven duodenal ulcer were studied by means of 24-h gastric pH-metry both in basal conditions and on the 5th day of acute treatment with 40 mg omeprazole in the morning." | 5.07 | A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. ( Badalamenti, S; Di Mario, F; Mela, GS; Muratore, F; Pantalena, M; Savarino, V; Scialabba, A; Termini, R; Vigneri, S; Zentilin, P, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compared in a double-blind randomized multicentre trial." | 5.07 | Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group. ( Judmaier, G; Koelz, HR, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime." | 5.07 | Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. ( Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG, 1993) |
| "(i) To study the effect of single oral dose of 20 mg omeprazole on maximal acid output (MAO) and peak acid output (PAO) in duodenal ulcer patients and healthy volunteers." | 5.07 | Alternate-day therapy with omeprazole for duodenal ulcer. ( Amarapurkar, DN; Dhawan, P; Kalro, RH, 1993) |
| " pylori-positive gastroduodenal ulcer disease were treated with a 14-day course of 20 mg omeprazole bid orally, combined with either 1 g amoxicillin tid intravenously (n = 15) or 500 mg amoxicillin six times daily orally (n = 16)." | 5.07 | Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. ( Adamek, RJ; Freitag, M; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| "This study was carried out in order to perform a combined prospective assessment of the individual pharmacodynamic response and of duodenal ulcer healing in patients treated with three different doses of omeprazole." | 5.07 | Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. ( Celle, G; Cutela, P; Mela, GS; Mele, MR; Savarino, V; Vigneri, S; Zentilin, P, 1994) |
| " pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77)." | 5.07 | One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "The success of omeprazole in the healing of duodenal ulcer has been attributed to its profound and almost around-the-clock inhibition of acid, but the relevance of reducing meal-stimulated acid secretion exclusively has recently been emphasized in several clinical trials." | 5.07 | Antisecretory effect of three premeal doses of cimetidine 400 mg versus a single morning dose of omeprazole 20 mg: pathophysiological implications for duodenal ulcer treatment. ( Celle, G; Cutela, P; Dallorto, E; Franceschi, M; Mansi, C; Mela, GS; Mela, MR; Savarino, V; Vassallo, A; Zentilin, P, 1993) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 5.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "To assess the comparative efficacy of omeprazole 20 mg in the morning versus ranitidine 150 mg twice a day, in the healing of duodenal ulcer, 43 endoscopically verified cases were randomly allocated to 2 or 4 weeks (if ulcer did not heal at 2 weeks) treatment." | 5.07 | Omeprazole vs ranitidine in the healing of duodenal ulcer. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1993) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " omeprazole on pentagastrin-stimulated acid secretion was studied in 8 patients with duodenal ulcer." | 5.07 | Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. ( Cederberg, C; Lind, T; Olbe, L; Röhss, K, 1992) |
| " Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted." | 5.07 | [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. ( Ogawa, N, 1992) |
| "A one week regimen of bismuth, tetracycline, and metronidazole is safe and effective in eradicating H pylori and reduces the number of duodenal ulcers four weeks after completing treatment." | 5.07 | Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. ( Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY, 1992) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 5.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| "The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o." | 5.07 | Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. ( Annibale, B; Cassetta, MR; Delle Fave, G; Franceschi, M; Quatrini, M; Torsoli, A, 1992) |
| "In a double blind, multicenter, parallel group clinical trial in patients with symptomatic duodenal ulcers, 129 patients were randomized to receive either omeprazole 20 mg once daily (n = 65) or famotidine 40 mg once daily (n = 64) for 2 weeks, and if the ulcers were not healed, for a total of 4 weeks." | 5.07 | Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer. ( Babu, S; Chaubal, C; Kumar, TR; Naidu, MU; Prasad, R; Reddy, DN; Shobha, JC; Subhash, S, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 5.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "The present study determined whether the rate of relapse of duodenal ulcer was reduced after ulcer healing with omeprazole compared with ranitidine or placebo." | 5.07 | Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. ( Cagliola, AJ; Colon-Pagan, J; Graham, DY; Johnson, TL; Marks, JW; McCullough, AJ; Morse, RS; Sklar, M; Stone, RC; Walsh, JH, 1992) |
| " Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months' treatment with cimetidine 0." | 5.07 | Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. ( Bardhan, KD; Bianchi Porro, G; Carroll, NJ; Daly, MJ; Hinchliffe, RF; Lazzaroni, M; Morris, P; Naesdal, J; Petrillo, M; Thompson, M, 1991) |
| "The effect of duodenal ulcer healing induced by omeprazole on gastroduodenal generation of eicosanoids, platelet-activating factor (PAF), pepsinogen A, and gastrin was evaluated." | 5.07 | Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients. ( Karmeli, F; Lysy, J; Rachmilewitz, D; Wengrower, D, 1992) |
| "Forty-three patients with active duodenal ulcer and Helicobacter pylori positivity in gastric antrum were randomly assigned to either omeprazole treatment (20 mg once a day) or ranitidine treatment (300 mg once a day) for 28 days." | 5.07 | Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients. ( Ayoubi Khajekini, M; Blasi, A; Brogna, A; Catalano, F; Inserra, G; Mangiameli, A; Monello, S; Rizzo, G; Sofia, M, 1991) |
| "To study the effect of intravenously given omeprazole on the 24-hour gastric secretion, 9 male patients with previously endoscopic proven duodenal ulcer disease were studied." | 5.07 | Effect of intravenous omeprazole on twenty-four-hour intragastric pH in patients with a history of peptic ulcer. Comparison of two four-dosage regimens. ( Elsborg, L; Kiilerich, S, 1991) |
| "Acid secretory responses and parietal cell sensitivity (PCS) have been studied in 21 duodenal ulcer patients before and after successful treatment with omeprazole (n = 7), sucralfate (n = 7), or Maalox (n = 7)." | 5.07 | Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox. ( Bridger, S; Johnston, DA; Marks, IN; Tigler-Wybrandi, NA; Young, GO; Zak, J, 1991) |
| " This randomized, double-blind multicentre trial studied the dose-response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out-patients with endoscopically assessed, symptomatic duodenal ulcer." | 5.07 | Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. ( Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B, 1991) |
| "The study was a multicenter double-blind parallel-group comparison of omeprazole, a proton-pump inhibitor, with the H2-receptor antagonist, ranitidine, in 206 patients with duodenal ulcer." | 5.07 | A comparison of omeprazole and ranitidine for duodenal ulcer in South African patients. A multiracial study. ( Danilewitz, MD; Garisch, JA; Marks, IN, 1991) |
| "In a double-blind, parallel-group clinical trial of 195 patients with duodenal ulcers who after a short-term study had relief of pain and healed ulcers proved endoscopically, 65 were randomized to receive 20 mg omeprazole 3 days a week (once in the morning from Friday to Sunday), 64 to receive 10 mg omeprazole once daily in the morning, and 66 to receive placebo for up to 6 months." | 5.07 | Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Kjaergaard, J; Lauritsen, K; Laursen, LS; Rask-Madsen, J; Rehfeld, JF, 1991) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 5.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| " To evaluate the effects of 6 months' treatment with omeprazole in humans, the oxyntic endocrine cells were morphometrically investigated at the ultrastructural level in five patients with active duodenal ulcer." | 5.07 | Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients. ( Bianchi-Porro, G; Bordi, C; D'Adda, T; Lazzaroni, M; Pilato, FP; Robutti, F, 1991) |
| "This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer." | 5.07 | Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991) |
| "To assess the comparative efficacy of omeprazole 20 mg, a proton pump inhibitor, versus ranitidine 150 mg twice a day, an H2-receptor antagonist, in healing duodenal ulcers we performed a randomized, double-blind, multicenter trial in 309 patients with endoscopically diagnosed ulcers." | 5.07 | U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group. ( Berlin, RG; Cagliola, A; Colon-Pagan, J; Hirschowitz, BI; Johnson, TL; Morse, RS; Petrozza, J; Snape, WJ; Valenzuela, JE; Van Deventer, GM, 1991) |
| "This paper compares cost-effectiveness of drug regimens based on omeprazole, ranitidine and sucralfate in the treatment of duodenal ulcers." | 5.06 | Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. ( Alander, V; Sintonen, H, 1990) |
| "We studied omeprazole and ranitidine in promoting duodenal ulcer healing in a multicentre trial by comparing the proportion of healed ulcers after two, four, and eight weeks of treatment." | 5.06 | Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. Cooperative study group. ( , 1990) |
| "In a double-blind, parallel-group clinical trial in 248 patients with symptomatic duodenal ulcers [97% greater than 5 mm diameter], 126 were randomized to receive omeprazole 20 mg once daily in the morning and 122 were randomized to receive ranitidine 300 mg once daily at night for 2 wk and if the ulcers were unhealed for a total of 4 wk." | 5.06 | Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. ( Bateson, MC; Burke, GJ; Dickinson, RJ; Dronfield, MW; Green, JR; Keeling, PW; McFarland, RJ; O'Donoghue, DP; Peers, EM; Shreeve, DR, 1990) |
| "To investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique." | 5.06 | Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. ( Branicki, FJ; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM; Poon, GP, 1989) |
| "Thai patients (n = 257) entered a double-blind randomized trial to compare omeprazole, 20 mg once daily, and cimetidine, 800 mg once daily for treatment of duodenal ulcer." | 5.06 | Omeprazole or cimetidine once daily for the treatment of duodenal ulcers? ( Atthapaisalsarudee, C; Kurathong, S; Leethochawalit, M; Saowaros, V; Wilairatana, S, 1989) |
| "A double-blind randomized study in 230 Malaysian patients with duodenal ulcer was conducted to compare the proton-pump inhibitor, omeprazole 20 mg, given once daily in the morning, with ranitidine 300 mg, administered once daily at night." | 5.06 | Omeprazole compared with ranitidine once daily in the treatment of duodenal ulcer. ( Ahmad, H; Chelvam, P; Goh, KL; Jalleh, R; Lee, HB; Leela, MP; Leong, YP; Mahendran, T; Wong, NW; Yin, TP, 1989) |
| "One-hundred and seventy-one patients with endoscopically proven duodenal ulcers were allocated at random to double-blind treatment with 10 or 20 mg of omeprazole in the morning for up to 4 weeks." | 5.06 | Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Jørgensen, T; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1989) |
| "In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o." | 5.06 | Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group. ( Bate, CM; Crowe, JP; Peers, EM; Richardson, PD; Wilkinson, SP; Willoughby, CP, 1989) |
| "The object of this double-blind, multicentre study was to compare duodenal ulcer healing rates after 2 to 4 weeks of treatment with either 20 mg omeprazole o." | 5.06 | Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. ( Cluysenaer, OJ; Gerrits, C; Hazenberg, BP; Meyer, WW; Mulder, CJ; Nicolai, JJ; Stuifbergen, WH; Tijtgat, GN; Vogten, AJ, 1989) |
| "Twenty-seven patients with peptic ulcer (19 with duodenal ulcer (DU) and eight with gastric ulcer (GU] refractory to H2-antagonists were treated with 40 mg of omeprazole once daily for 4-8 weeks, depending on the rate of ulcer healing." | 5.06 | Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists. ( Chelvam, P; Wong, EC, 1989) |
| "The purpose of the present study was to compare omeprazole 20 mg once daily and ranitidine 150 mg twice daily in healing duodenal ulcers unhealed by previous treatment with cimetidine greater than or equal to 0." | 5.06 | Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. ( Delchier, JC; Eriksson, S; Isal, JP; Soule, JC, 1989) |
| "One hundred and twenty-nine patients were studied with regard to healing of duodenal ulcers with 30 mg omeprazole once daily, recurrence rates after 2 and 4 weeks' treatment in patients with ulcers healed after 2 weeks, and recurrences in rapid and slow healers." | 5.06 | Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission? ( Andersen, OK; Bernklev, T; Farup, PG; Halvorsen, L; Rosseland, AR, 1989) |
| "The effect of 7 days of oral dosing with 5 mg day-1 and 20 mg day-1 omeprazole on basal and pentagastrin-stimulated gastric acid output was studied in nine duodenal ulcer patients." | 5.06 | Effect of low-dose omeprazole on gastric acid secretion in duodenal ulcer patients. ( Crean, GP; McColl, KE; McLauchlan, G, 1988) |
| " Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome." | 5.06 | Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. ( Gardner, JD; Jensen, RT; McArthur, KE, 1986) |
| "We conducted a double-blind, randomized, parallel group study in 169 patients with acute duodenal ulcers to compare omeprazole, 20 mg daily, with cimetidine, 600 mg twice daily." | 5.06 | Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. ( Archambault, AP; Bailey, RJ; Baker, SJ; Freeman, HJ; Hunt, RH; Marcon, NE; Navert, H; Pare, P; Sutherland, L; Williams, CN, 1988) |
| "In a double-blind, dose comparison multicenter trial 115 patients with duodenal ulcer were treated with either 20 or 30 mg oral omeprazole once daily for 4 weeks." | 5.06 | 20 versus 30 mg omeprazole once daily: effect on healing rates in 115 duodenal ulcer patients. ( Dammann, HG; duBosque, G; Hebbeln, H; Horstkotte, W; Hüttemann, W; Martens, W; Rehner, M; Rohner, HG, 1986) |
| "The efficacy of and tolerance to omeprazole, 40 mg/day, was studied in an open-label study in 18 patients with endoscopically verified duodenal ulcers." | 5.06 | Effects of omeprazole in duodenal ulcer patients. ( Andrén, K; Helander, HF; Karvonen, AL; Keyriläinen, O; Salaspuro, M; Tarpila, S; Uusitalo, A, 1986) |
| "In an open clinical trial, 16 hospital outpatients with endoscopically proven duodenal ulcer were given 30 mg omeprazole once daily for four weeks." | 5.06 | Effect and tolerability of omeprazole in the treatment of duodenal ulcer disease. ( Jonsson, E; Labó, G; Rinetti, M; Tomassetti, P; Vezzadini, P, 1986) |
| "In a study involving three centers, 105 patients with duodenal ulcer proven by endoscopy were randomly assigned to treatment with either the H+, K+, ATPase inhibitor omeprazole (20 mg or 40 mg taken as a single morning dose), or ranitidine (150 mg morning and night)." | 5.06 | A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. ( Bardhan, KD; Bianchi Porro, G; Bose, K; Daly, M; Hinchliffe, RF; Jonsson, E; Lazzaroni, M; Naesdal, J; Rikner, L; Walan, A, 1986) |
| "The effects of seven days' treatment with omeprazole 5 and 10 mg daily on 24 hours gastric secretion and plasma gastrin concentrations were studied in a randomised double-blinded placebo-controlled study of six male patients with healed duodenal ulcer." | 5.06 | Effects of low dose omeprazole on gastric secretion and plasma gastrin in patients with healed duodenal ulcer. ( Burget, DW; Derodra, JK; Howden, CW; Hunt, RH, 1986) |
| "In a double-blind, dose-comparative trial, 32 patients with duodenal ulcer were assigned to receive either 20 mg/day or 60 mg/day omeprazole for 4 weeks." | 5.05 | Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. ( Adami, HO; Gustavsson, S; Lööf, L; Nyberg, A; Nyrén, O, 1983) |
| "Sixty-one patients with symptomatic endoscopically confirmed duodenal ulcer, 5 mm or more in diameter, were treated with omeprazole 30 mg once daily in the morning for 4 weeks." | 5.05 | [Treatment of duodenal ulcer outbreak with omeprazole. Results of a multicenter non-controlled study]. ( Bader, JP; Bitoun, A; Blanchi, A; Delchier, JC; Modigliani, R; Morin, T; Pariente, EA; Rotenberg, A; Soulé, JC, 1984) |
| "Twenty-seven duodenal ulcer patients were treated with omeprazole, 40 mg daily for 4 weeks." | 5.05 | Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study. ( , 1984) |
| "In a preliminary study to compare the effects of different doses of omeprazole 44 patients with endoscopically diagnosed duodenal ulceration randomly received omeprazole 20 mg, 30 mg, 40 mg, or 60 mg daily for four weeks." | 5.05 | Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study. ( , 1984) |
| "00 h doses of omeprazole or placebo on gastric acid secretion during the following night, 14 to 23 h after administration, in seven male subjects with duodenal ulcer." | 5.05 | Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer. ( Hetzel, DJ; Shearman, DJ, 1984) |
| "In a randomized, endoscopically controlled double-blind trial the effectiveness of a single oral, morning dose of 40 mg omeprazole was compared with a twice daily oral dose of 150 mg ranitidine given to 334 ambulatory patients with duodenal ulcers." | 5.05 | [Short-term therapy of duodenal ulcer with omeprazole and ranitidine. Results of a German multicenter study]. ( Berger, J; Classen, M; Dammann, HG; Domschke, W; Hengels, KJ; Hüttemann, W; Londong, W; Rehner, M; Simon, B; Witzel, L, 1985) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 5.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| "We have studied the rate of healing of duodenal ulcers in 44 patients treated with omeprazole, 40 mg once daily for 4 weeks, with or without an 80-mg loading dose on day 1." | 5.05 | The rate of healing of duodenal ulcers during omeprazole treatment. ( Bergsåker-Aspöy, J; Bernklev, T; Farup, PG; Gillberg, R; Halvorsen, L; Kilander, A; Lind, T; Naesdal, J; Offergaard, S; Walan, A, 1985) |
| "Healing of duodenal ulcers was assessed in 66 patients who received omeprazole either 10 mg or 30 mg daily for four weeks in a double blind study." | 5.05 | Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. ( Dudley, FJ; Jones, DB; Louis, WJ; Prichard, PJ; Rubinstein, D; Smallwood, RA; Yeomans, ND, 1985) |
| "The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis." | 4.89 | Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. ( Satoh, H, 2013) |
| "Esomeprazole (Nexium); S-omeprazole) is a single optical isomer proton-pump inhibitor (PPI) approved for the management of reflux oesophagitis, the symptomatic treatment of gastro-oesophageal reflux disease (GORD), the prevention and healing of NSAID-associated gastric ulcer disease (and the prevention of NSAID-associated duodenal ulcers in the UK), the treatment of Helicobacter pylori infection and associated duodenal ulcer disease (and prevention of relapse of H." | 4.84 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K, 2008) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 4.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "An 11-year-old boy with Helicobacter pylori-associated duodenal ulcer was successfully treated with a combination of lansoprazole, amoxicillin, and clarithromycin." | 4.82 | Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature. ( Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T, 2005) |
| " To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide-three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing)." | 4.81 | Efficacy of rabeprazole once daily for acid-related disorders. ( Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C, 2001) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs." | 4.80 | Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. ( Armstrong, D; Lad, R, 1999) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| " Previous studies have shown that misoprostol is effective in reducing the incidence of gastric and duodenal ulcers as well as serious gastrointestinal complications." | 4.80 | [Present position in the prevention and therapy of NSAID-induced ulcers]. ( Beglinger, C; Lehmann, FS, 1999) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 4.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| " Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine." | 4.80 | The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| "This paper is a meta-analysis of 30 published, double-blind clinical trials comparing omeprazole with ranitidine or cimetidine for the treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis." | 4.79 | Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. ( Carlsson, R; Eriksson, S; Långström, G; Naesdal, J; Rikner, L, 1995) |
| "The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease." | 4.79 | Clinical efficacy of pantoprazole compared with ranitidine. ( Bader, JP; Delchier, JC, 1994) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 4.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 4.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| " The results of the randomized, double-blind, controlled trials show that misoprostol is the only antiulcer drug proven to be effective in the prevention of NSAID-induced gastric and duodenal ulcers as well as for reducing serious upper gastrointestinal complications (perforation and/or haemorrhage)." | 4.79 | Prevention of NSAID-gastropathy. ( Ardizzone, S; Bianchi Porro, G, 1996) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| "Omeprazole regulates gastric acid secretion and is an effective treatment of acute duodenal ulcer and reflux oesophagitis, achieving more rapid healing and symptomatic relief than histamine H 2-receptor antagonists." | 4.78 | Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. ( Barradell, LB; McTavish, D, 1993) |
| "Ten double-blind randomized studies with omeprazole versus ranitidine in duodenal ulcer healing have been published." | 4.78 | Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials. ( Mulder, CJ; Schipper, DL, 1990) |
| "In duodenal ulcer studies comprising more than 2,000 patients the efficacy of omeprazole in doses of 20-40 mg once daily has been compared with the recommended doses of the H2-receptor antagonists cimetidine and ranitidine." | 4.77 | Efficacy of the H+/K+-adenosine triphosphatase inhibitor omeprazole in peptic ulcer. ( de Bruijne, JW; Lamers, CB; Snel, P, 1989) |
| "Arguments in favour of the use of omeprazole outweight the arguments against its use in the treatment of all peptic disorders--duodenal ulcer, gastric ulcer and reflux oesophagitis." | 4.77 | Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis. ( Bium, AL, 1989) |
| "Due to its potent and long-lasting antisecretory properties is omeprazole, the first clinically used H+/K+-adenosine triphosphatase inhibitor, highly effective in healing of duodenal and gastric ulcers and reflux oesophagitis." | 4.77 | H+/K+-adenosine triphosphatase inhibitors. A new approach to the treatment of acid-peptic diseases. ( Lamers, CB, 1989) |
| "To evaluate the cost-effectiveness of 10 mg ilaprazole once-daily vs 20 mg omeprazole once-daily to treat newly-diagnosed duodenal ulcer patients in China." | 3.83 | Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China. ( Liu, Z; Lu, WQ; Lu, YJ; Song, RL; Xu, GX; Xuan, JW, 2016) |
| " Anti-ulcer activity was evaluated against cold restraint (CRU), pyloric ligation (PL), aspirin (ASP), alcohol (AL) induced gastric ulcer and histamine (HA) induced duodenal ulcer model and further confirmed through in vitro assay of H(+) K(+)-ATPase activity and plasma gastrin level." | 3.77 | Anti-ulcer constituents of Annona squamosa twigs. ( Dev, K; Maurya, R; Palit, G; Sahai, M; Sharma, R; Singh, N; Yadav, DK, 2011) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| "Omeprazole has given healing rates of 58-83% after treatment for 2 weeks and 84-100% after 4 weeks." | 3.76 | Clinical experience with omeprazole: assessment of efficacy and safety. ( Walan, A, 1989) |
| "The authors made an attempt to find a new approach to Helicobacter pylori (HP) eradication in patients with chronic gastritis and peptic ulcer without application of antibiotics, but using melatonin properties instead." | 3.74 | [Antihelicobacter effects of melatonin]. ( Malinovskaia, NK; Parkhomenko, IE; Postnikova, LI; Rapoport, SI; Rybnikova, SN; Zhernakova, NI, 2007) |
| " Cysteamine inhibits the release of somatostatin and induces the formation of duodenal ulcers in rats." | 3.73 | Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. ( Arakawa, M; Fukuhara, S; Hibi, T; Hosoda, H; Ishii, H; Kangawa, K; Kitajima, M; Masaoka, T; Minegishi, Y; Suzuki, H, 2005) |
| "The present study was designed to investigate anti-ulcerogenic property of ethanolic extract of Desmodium gangeticum (DG) against cold restraint (CRU, 2 hr cold restraint stress), aspirin (ASP, 150 mg/kg orally), alcohol (AL, absolute alcohol 1 ml/200gm) and pyloric ligation (PL, 4 hr pylorus ligation) induced gastric ulcer models in Sprague Dawley rats, and histamine (HST, 0." | 3.73 | Desmodium gangeticum: a potent anti-ulcer agent. ( Chauhan, VS; Dharmani, P; Maurya, R; Mishra, PK; Palit, G, 2005) |
| "To evaluate the omeprazole maintenance therapy in patients with recurrent ulcer bleeding after surgery for duodenal ulcer." | 3.73 | Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer. ( Demertzis, K; Emmanuel, T; Ladas, SD; Polymeros, D; Tassios, P; Triantafyllou, K, 2006) |
| "46 patients having exacerbation of duodenal ulcer in the presence of Helicobacter pylori (HP) were studied for efficacy of HP eradication treatment which comprised omeprazole (40 mg/day), colloid bismuth subcitrate (480 mg/day) and metronidazole (1000 mg/day) for 2 weeks." | 3.72 | [Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens]. ( Nurbaev, FE; Orziev, ZM; Rakhimova, GSh, 2003) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| "The focus was on salivary glands in cysteamine-induced duodenal ulcer and the different effects of antiulcer agents on cysteamine-induced duodenal ulcer in sialoadenectomized but not gastrectomized rats." | 3.72 | Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. ( Anic, T; Batelja, L; Bedekovic, V; Boban Blagaic, A; Drvis, P; Gjurasin, M; Kalogjera, L; Kopljar, M; Mise, S; Seiwerth, S; Sikiric, P; Staresinic, M, 2003) |
| " pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b." | 3.72 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. ( Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK, 2003) |
| "The results of treatment of duodenal ulcers and gastroesophageal reflux disease with using of modern proton pump inhibitor controloc (pantoprazole) are presented in this article." | 3.72 | [Efficacy of controloc in the treatment of acid-dependent diseases]. ( Agibalov, AN; Chubenko, SS; Gaĭdukov, VO; Onishenko, AV, 2003) |
| " H pylori infection does not affect duodenal ulcer healing and enhances gastric ulcer healing by ranitidine and possibly other acid suppressing treatments." | 3.71 | Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. ( Hawkey, CJ; Långström, G; Naesdal, J; Swannell, AJ; Wilson, I; Yeomans, ND, 2002) |
| "To study the long-term curative effects of suture plus proximal gastric vagotomy (PGV) and suture plus triad-therapy (omeprazole, amoxycillin and flagyl taken orally) for the treatment of duodenal ulcer with acute perforation." | 3.71 | [Long-term curative effects of suture plus proximal gastric vagotomy or triad-therapy for duodenal ulcer with acute perforation]. ( Fang, L; Huang, S; Jiang, K; Jiang, X; Lin, N; Pan, W; Wan, Y; Xu, R, 2002) |
| " Nineteen Helicobacter pylori-positive nonduodenal ulcer subjects, 15 omeprazole chronically treated subjects, and 19 duodenal ulcer patients were studied against 19 controls." | 3.71 | Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications. ( Amorosi, A; Bacci, S; Bechi, P; Cianchi, F; Dei, R; Nesi, G; Romagnoli, P, 2001) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| "We describe a 54-year-old man with Helicobacter pylori (+) duodenal ulcer who developed Clostridium difficile associated colitis, 5 days after commencing a 'triple' regimen consisting of omeprazole 20 mg b." | 3.70 | Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. ( Archimandritis, A; Katsorida, M; Souyioultzis, S; Tzivras, M, 1998) |
| " Likewise, pantoprazole showed the healing promoting action on chronic duodenal ulcers induced by acetic acid, and this effect was also more potent when compared to omeprazole or lansoprazole." | 3.70 | Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. ( Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T, 1999) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| "Ulcer-healing drugs should be continued after a 2-week course of omeprazole-containing anti-Helicobacter therapy for gastric ulcers and large peptic ulcers that have bled, but can be omitted in most patients with a bleeding duodenal ulcer." | 3.70 | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. ( Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC, 2000) |
| "To evaluate endogenous and exogenous factors affecting the quality of ulcer healing produced by proton pump inhibitors, gastric acid pH, serum gastrin, and serum pepsinogen (PG) I and II were measured in peptic ulcer patients before and after treatment with lansoprazole 30 mg once daily." | 3.69 | Factors affecting quality of ulcer healing after lansoprazole treatment. ( Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F, 1995) |
| "Beta-endorphin plasma levels (pmol/l) were measured during an acute episode of duodenal ulcer, before and after antisecretory therapy with omeprazole." | 3.69 | Beta-endorphin in silent duodenal ulcer. ( Chianelli, M; Delle Fave, G; Mariani, P; Negri, M; Tonnarini, GF, 1995) |
| "The efficacy of omeprazole 20 mg a day was assessed against ranitidine 150 mg twice a day in the healing and relapse of duodenal ulcer." | 3.69 | Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1995) |
| ") inhibited mepirizole-induced duodenal ulcers." | 3.69 | YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. ( Akuzawa, S; Ito, H; Kamato, T; Kobayashi, A; Miyata, K; Nagakura, Y; Nishida, A; Takinami, Y; Yamano, M; Yuki, H, 1994) |
| "The clinical outcome and cost-effectiveness of episodic treatment of duodenal ulcer with omeprazole and ranitidine were evaluated over a 5-year period." | 3.69 | Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. ( Eriksson, S; Walan, A, 1994) |
| "A 51-year-old obese woman with a duodenal ulcer developed symptomatic, famotidine-induced hepatitis." | 3.69 | Hepatitis following treatments with famotidine and then cimetidine. ( Davis, RL; Egli, D; Hashimoto, F, 1994) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 3.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To evaluate the efficiency of omeprazole (20 mg/12 h) plus amoxycillin (1 gr/12 h) in eradicating Helicobacter pylori in duodenal ulcer patients studied in four hospitals in our country." | 3.69 | [Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?]. ( Boixeda, D; Ceña, G; Gisbert, JP; Martín, C; Monés, J; Mur, M; Sainz, R; Sainz, S, 1996) |
| "We investigated the effects of cimetidine, omeprazole and atropine, antisecretory anti-ulcer agents, on the healing of gastric and duodenal ulcers simultaneously induced in the same rats." | 3.69 | Simultaneous evaluation of gastric and duodenal ulcers-healing activities of anti-ulcer agents in rats. ( Ito, M; Segami, T; Suzuki, Y, 1996) |
| "The study investigated the effect of either nocturnal acid suppression by the H2 antagonist nizatidine 300 mg at night or prolonged acid suppression by the proton- pump inhibitor omeprazole 20 mg in the morning, during four weeks, on intragastric pH profile, occurrence of bacterial growth in gastric fluid and biopsies, and healing rate in 23 patients with an acute duodenal ulcer." | 3.69 | Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. ( Brummer, RJ; Stockbrügger, RW, 1996) |
| "To study a possible correlation between the urea breath test values prior to treatment and the response to Helicobacter pylori eradication therapy in patients with duodenal ulcer." | 3.69 | [Is there a correlation between the values of breath tests and the response to the treatment for the eradication of Helicobacter pylori?]. ( Bermejo, F; Boixeda, D; Gisbert, JP; Jiménez, I; Martín de Argila, C; Pérez, T, 1996) |
| "Two patients who developed gastric giardiasis after 2 weeks of treatment with omeprazole 20 mg b." | 3.69 | Proton-pump inhibition and gastric giardiasis: a causal or casual association? ( Bourgain, C; Devis, G; Fernandes, E; Reynaert, H; Smekens, L, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 3.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| "We have previously shown that, in duodenal ulcer patients, pH control by omeprazole is less pronounced after cure of Helicobacter pylori infection." | 3.69 | Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| " In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 microg or 10 ng/kg intraperitoneally) were further challenged." | 3.69 | Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. ( Buljat, G; Gjurasin, M; Grabarević, Z; Hanzevacki, M; Jadrijević, S; Jagić, V; Jelovac, N; Jurina, L; Konjevoda, P; Marović, A; Miklić, P; Mikus, D; Mise, S; Perić, J; Perović, D; Petek, M; Rotkvić, I; Rucman, R; Seiwerth, S; Separović, J; Sikirić, P; Turković, B; Zoricić, I, 1997) |
| "To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer." | 3.69 | [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997) |
| "In patients with duodenal ulcer cure of Helicobacter pylori infection resulted in a pronounced decrease in intragastric pH during treatment with omeprazole." | 3.69 | Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| " and omeprazole 20 mg daily for one week, followed by 20 mg omeprazole daily for further 3 weeks) in a prospective study of 36 patients with Helicobacter pylori-associated ulcers (10 gastric ulcers, 26 duodenal ulcers)." | 3.69 | [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. ( Kobler, E; Reinhart, WH; Werth, B; Wüst, W, 1997) |
| "The in-vitro activities of omeprazole and three antimicrobial agents against 89 clinical isolates of Helicobacter pylori from a population with duodenal ulcer disease were determined by an agar dilution method." | 3.69 | In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. ( Barkun, AN; De Souza, E; Fallone, CA; Lavallée, J; Loo, VG, 1997) |
| "In patients with duodenal ulcer, omeprazole plus clarithromycin (OC) has achieved Helicobacter pylori eradication rates of about 80%, compared with 50% for omeprazole plus amoxicillin (OA)." | 3.69 | Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. ( Craig, AM; Davey, P; Malek, M; Murray, F, 1996) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 3.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| " Hyperpepsinogenaemia A has been shown in patients with duodenal ulcer disease, Zollinger-Ellison syndrome, hypertrophic gastropathy, chronic renal failure, and during omeprazole treatment." | 3.68 | Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A. ( Biemond, I; Jansen, JB; Kreuning, J; Lamers, CB, 1993) |
| "The aim of this study is to propose a regimen of omeprazole 20 mg twice weekly for the prevention of duodenal ulcer (DU) relapse." | 3.68 | [Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse]. ( Bei, L; Chen, SP; Wen, SH, 1993) |
| "Thirteen consecutive patients with active duodenal ulcer disease were assigned to a treatment schedule with high-dose omeprazole and amoxycillin." | 3.68 | Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Beattie, S; Collins, R; O'Morain, C; Xia, HX, 1993) |
| "Thirty-six patients with nonhealing or recurrent duodenal ulcers (DU) were treated with omeprazole; 20 mg/day for one month followed by triple therapies (metronidazole, 400 mg three times a day, tetracycline, 500 mg four times a day with either colloidal bismuth, 120 mg four times a day or sucralfate 1 g four times a day." | 3.68 | Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori. ( Jaskiewicz, K; Louw, JA; Marks, IN, 1993) |
| " Included were 82 normal subjects, 126 patients with active duodenal ulcer, 272 ulcer patients in clinical remission treated with a single bedtime dose (at 10 PM) of various H2 antagonists and 125 patients with active ulcer treated with a single morning dose (8 AM) of omeprazole." | 3.68 | Optimizing the information obtained from continuous 24-hour gastric pH monitoring. ( Mela, GS; Savarino, V; Vigneri, S, 1992) |
| "This study compares the efficacy and side effects of omeprazole and regular- and double-dose nizatidine in the treatment of duodenal ulcers." | 3.68 | Comparison of omeprazole and nizatidine in the treatment of duodenal ulcers. ( Chen, CY; Chen, LT; Jan, CM; Perng, DS; Wang, WM, 1992) |
| "Thirty patients with active duodenal ulcer who were Helicobacter pylori positive (HP+) by HLO test and by histology (Giemsa stain) were given omeprazole (OME) 20 mg/d for a two-week period." | 3.68 | Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori? ( Alevizou, V; Archimandritis, A; Davaris, P; Fertakis, A; Kapsalas, D; Kyriaki, D; Tjivras, M, 1992) |
| "Nine patients with duodenal ulcer were on separate occasions given omeprazole, 20 mg orally, 10 mg intravenously (IV), and 40 mg IV once daily for 5 days." | 3.68 | Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. ( Cederberg, C; Fisher, D; Kirdeikis, P; Mahachai, V; Marriage, B; Thomson, AB; Westin, JA; Zuk, L, 1992) |
| "The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated." | 3.68 | Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. ( Dorrian, CA; Fullarton, GM; Harwood, J; Macdonald, AM; McColl, KE; Nujumi, AM, 1992) |
| "Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o." | 3.68 | Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991) |
| "The effect of omeprazole on acid secretion and gastrin levels has been investigated in 10 elderly duodenal ulcer patients in remission." | 3.68 | Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. ( Cederberg, C; Lind, T; Olausson, M; Olbe, L, 1991) |
| "The effects of omeprazole, a benzimidazole derivative, have been determined on the secretory responses to modified sham feeding and pentagastrin, and upon serum gastrin and pancreatic polypeptide concentrations in duodenal ulcer patients." | 3.67 | Action of omeprazole (a benzimidazole derivative) on secretory responses to sham feeding and pentagastrin and upon serum gastrin and pancreatic polypeptide in duodenal ulcer patients. ( Konturek, SJ; Kopp, B; Kweicień, N; Obtułowicz, W; Oleksy, J, 1984) |
| "In a series of 59 experiments in nine duodenal ulcer patients, 24 hour intragastric acidity was measured before, during, and after treatment with daily oral omeprazole." | 3.67 | Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. ( Gomes, MD; Logan, LH; Pounder, RE; Sharma, BK; Walt, RP; Wood, EC, 1984) |
| "The effect of a single oral dose of omeprazole (90 mg) on gastric emptying was assessed with a dual isotope scintigraphic technique in eight patients with a history of duodenal ulcer disease." | 3.67 | The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. ( Buckle, PJ; Chatterton, BE; Hetzel, DJ; Horowitz, M; Shearman, DJ, 1984) |
| " Acutely induced gastric ulcers or erosions such as Shay ulcers, water-immersion stress-, indomethacin-, aspirin-, or prednisolone-induced erosions were all markedly inhibited by oral or intraduodenal administration of 10-100 mg/kg of omeprazole." | 3.67 | Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. ( Okabe, S; Okada, Y; Yamamoto, O, 1984) |
| " Ten patients with duodenal ulcer disease were studied under fasting conditions and for 3 h after a standard liquid meal on three occasions: day 1, before treatment; day 8, when the proton pump blocker omeprazole had been taken in a daily dose of 30 mg for 7 days consecutively, including the day of the pH study; day 9, 24 h after the last dose of omeprazole." | 3.67 | Effect of omeprazole on intragastric and duodenal bulb acidity in duodenal ulcer patients. ( Bendtsen, F; Ovesen, L; Rosenkilde-Gram, B; Rune, SJ, 1989) |
| "Basal and pentagastrin stimulated gastric acid secretions were measured in 20 patients with duodenal ulcer before and after one week of treatment with oral omeprazole 20 mg daily." | 3.67 | [Omeprazole in peptic ulceration: acid inhibition and endoscopic healing]. ( Chen, SP; Ke, MY; Mai, CR, 1989) |
| "Healing of duodenal ulcers induced by indomethacin + histamine was investigated in rats." | 3.67 | Healing process of duodenal ulcers induced by indomethacin plus histamine in rats. ( Niida, H; Okabe, S; Okada, M; Takeuchi, K, 1989) |
| "Simultaneous 24-hour intragastric acidity and plasma gastrin concentrations were measured in 12 duodenal ulcer patients before and on the twenty-eighth day of treatment with either ranitidine 150 mg b." | 3.67 | Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. ( Ball, S; Cederberg, C; Chronos, NA; Hamilton, MR; Lanzon-Miller, S; Olausson, M; Pounder, RE; Raymond, F, 1987) |
| "The effect of intermittent dosage with omeprazole on basal and pentagastrin stimulated gastric acid secretion and fasting plasma gastrin was assessed in eight duodenal ulcer subjects who were in remission." | 3.67 | Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients. ( Angus, PW; Brook, CW; Hewson, EG; Sewell, RB; Shulkes, A; Smallwood, RA; Yeomans, ND, 1988) |
| " On a molar basis and with regard to inhibition of cysteamine-induced acid secretion, telenzepine ranked first, followed by omeprazole, cimetidine, and pirenzepine; cysteamine-induced duodenal ulcers were best inhibited by telenzepine, with pirenzepine, omeprazole and cimetidine ranking 2nd, 3rd and 4th." | 3.67 | An acid-independent antiulcer effect of M1 antimuscarinics in the rat. ( Gönne, S; Kromer, W, 1988) |
| "We have studied the effect on serum gastrin concentrations of weekly 3-day courses of 20 mg/day omeprazole followed by a 4-day period without medication (weekend therapy) for 4 weeks in 10 patients with duodenal ulcer." | 3.67 | Effect of intermittent weekend therapy with omeprazole on basal and postprandial serum gastrin concentrations in patients with duodenal ulcer. ( Crobach, LF; Jansen, JB; Lamers, CB, 1988) |
| "In a series of 59 experiments on nine duodenal ulcer patients, 24-hour intragastric acidity was measured before, during and after treatment with daily oral omeprazole." | 3.67 | Twenty-four hour intragastric acidity during treatment with oral omeprazole. ( Pounder, RE; Sharma, BK; Walt, RP, 1986) |
| "Penetrated cysteamine-induced duodenal ulcers in rats have a very prolonged course of healing." | 3.67 | Effect of antisecretory agents and vagotomy on healing of "chronic" cysteamine-induced duodenal ulcers in rats. ( Kirkegaard, P; Poulsen, SS; Raaberg, L; Skov Olsen, P; Therkelsen, K, 1986) |
| "Endoscopic biopsies were taken from the oxyntic mucosa in patients with duodenal ulcer (DU) before and after 4 weeks of treatment with omeprazole." | 3.67 | Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. ( Helander, HF, 1986) |
| "Gastric secretion was measured in nine patients with duodenal ulcer before, and after treatment for four weeks with omeprazole 20 mg or 40 mg daily." | 3.67 | Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. ( Baron, JH; Barr, JA; Bush, A; Collier, N; Cope, L; Gribble, RJ; Spencer, J; Thompson, JN, 1985) |
| "Twenty four hour intragastric acidity was measured in nine patients with duodenal ulcer before and after one week of treatment with oral omeprazole 30 mg daily, a drug that inhibits gastric secretion by inhibition of parietal cell H+K+ adenosinetriphosphatase (ATPase)." | 3.66 | Effect of daily oral omeprazole on 24 hour intragastric acidity. ( Gomes, MD; Logan, LH; Pounder, RE; Walt, RP; Wood, EC, 1983) |
| "omeprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "There were authentic distinctions between the groups of healthy volunteers and patients with a peptic ulcer disease in Cmax, Tmax, AUC(0-t), AUC(0-infinity), CIt, Vd of omeprazole and Cmax of esomeprazole (Nexium, AstraZeneca)." | 2.74 | [Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer]. ( Dobrovol'skiĭ, OV; Kondratenko, SN; Pisarev, VV; Serebrova, SIu; Starodubtsev, AK; Vasilenko, GF, 2009) |
| "3%) and there were no serious adverse events." | 2.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| "Duodenal ulcers were healed in nine of 10 (90%) patients in the BTF group and in all patients (12/12) (100%) in the OBTM group (P = N." | 2.70 | Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. ( Domareva, I; Ganskaya, Z; Isakov, V; Koudryavtseva, L; Maev, I, 2002) |
| "Omeprazole was given (40 mg/day) for 2 or 4 weeks." | 2.70 | Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease. ( Abdel-Baset, EZ; Atta, MM; Kabil, SM; Murray, JA; Nassar, AK; Shahin, WA, 2001) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Active duodenal ulcer recurrence was identified in seven of 23 H." | 2.70 | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. ( Choi, IJ; Jung, HC; Kim, BG; Kim, JS; Kim, SG; Park, MJ; Song, IS, 2002) |
| "Omeprazole was better tolerated than misoprostol." | 2.69 | Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. ( Barkun, A; Hawkey, CJ; Karrasch, JA; Swannell, AJ; Szczepañski, L; Walker, DG; Yeomans, ND, 1998) |
| "We hypothesized that treatment of duodenal ulcer disease with antibiotic therapy directed toward Helicobacter pylori infection is more cost-effective than therapy with antisecretory agents." | 2.69 | Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. ( Bloom, BS; Cutler, AF; Schwartz, JS; Sonnenberg, A; Vakil, N, 1998) |
| "Omeprazole is an effective agent for gastroduodenal prophylaxis in patients taking NSAIDs." | 2.69 | Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. ( Bardhan, KD; Cullen, D; Eisner, M; Hawkey, CJ; Kogut, DG; Peacock, RA; Thomson, JM, 1998) |
| "In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89." | 2.69 | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. ( Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY, 1998) |
| " Sixty patients received 40 mg of omeprazole twice a day, 1500 mg of amoxicillin three times a day, and 300 mg of rebamipide three times a day (group OAR); the other 60 patients received the same dosage of omeprazole and amoxicillin but no rebamipide for two weeks (group OA)." | 2.69 | Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. ( Ando, K; Arakawa, T; Harihara, S; Higuchi, K; Ito, H; Kobayashi, K; Kuroki, T; Nebiki, H; Uchida, T, 1998) |
| "Treatment with omeprazole 20 mg every morning maintained significantly more patients in remission than treatment with ranitidine 150 mg at bedtime." | 2.69 | Omeprazole and ranitidine in long-term treatment of duodenal ulcer: a double-blind comparison of length of time in remission. ( Aran-Suau, R; Berenguer, J; Caswell, C; Clerch, L; Da Silveira, JC; Diaz de Rojas, F; Garcia Aparicio, P; Rodrigo, L, 1998) |
| "The 1-week triple therapy was safe and effective for eradicating H." | 2.69 | Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998) |
| " There was also a clear dose-dependent pharmacodynamic effect, which augmented on moving from the lowest dosage of 20 mg o." | 2.69 | Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. ( Bisso, G; Celle, G; Fiorucci, S; Malesci, A; Mela, GS; Pivari, M; Savarino, V; Termini, R; Usai, P; Vigneri, S; Zentilin, P, 1998) |
| "Treatment with omeprazole (OME), azithromycin (AZI) and amoxicillin (AMO) resulted in encouraging Helicobacter pylori cure rates in pilot and control studies." | 2.69 | Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. ( Blazanović, A; Dmitrović, B; Ivandić, A; Karner, I; Kovac, D; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A, 1998) |
| "pylori eradication rate and ulcer recurrence rate were compared." | 2.69 | Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study. ( Chen, J; Chen, SY; Wang, JY; Zhang, SS; Zhang, XD, 1999) |
| "The ulcer recurrences appeared in patients with H." | 2.69 | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. ( Mach, T; Zahradnik-Bilska, J, 1999) |
| "Eradication of H." | 2.69 | Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. ( Chan, AC; Chung, SC; Lam, YH; Lau, JY; Lau, WY; Law, BK; Lee, DW; Ling, TK; Ng, EK; Sung, JJ; To, KF; Yung, MY, 2000) |
| "We present data on development of GERD from a controlled study of H." | 2.69 | Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. ( Befrits, R; Lindberg, G; Odman, B; Sjöstedt, S; Sörngård, H, 2000) |
| " This study is designed to determine the efficacy of omeprazole 20 mg bd in combination with amoxycillin 500 mg tid (Group A), amoxycillin 750 mg tds (Group B) and clarithromycin 500 mg tid (Group C) in Singapore." | 2.69 | A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore. ( Fock, KM; Law, NM; Lim, CC; Ng, HS; Ng, TM, 2000) |
| " The optimal dosage and duration of treatment need to be specified." | 2.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 2.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies." | 2.68 | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995) |
| "Duodenal ulcers were healed in 44 of 49 (89." | 2.68 | Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. ( Cheng, AF; Chung, SC; Lau, JY; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ, 1996) |
| "91%)." | 2.68 | Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. ( Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J, 1996) |
| "Pirenzepine has been reported to inhibit gastrin secretion." | 2.68 | Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. ( Fukino, Y; Hamada, M; Haruma, K; Inoue, M; Kajiyama, G; Kamiyasu, T; Sumii, K; Sumii, M; Tari, A, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | 2.68 | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "Omeprazole has been shown to have a suppressive effect on Helicobacter pylori." | 2.68 | Prolonged treatment with omeprazole does not improve the eradication rate of Helicobacter pylori infection--a short report [corrected]. ( Anderson, PE; Goh, KL; Parasakthi, N; Peh, SC; Tan, KK, 1995) |
| "The results indicate that conventional treatment for duodenal ulcers with a proton pump inhibitor significantly increases bacterial colonization of the duodenum and the speed of intestinal transit." | 2.68 | Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. ( Franco, S; Lewis, SJ; O'Keefe, SJ; Young, G, 1996) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "When lansoprazole alone was administered to the patients, H." | 2.68 | [Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer]. ( Maruyama, M, 1996) |
| "Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H." | 2.68 | Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. ( Goh, KL; Navaratnam, P; Peh, SC, 1996) |
| "Clarithromycin is a new macrolide antibiotic which is known to be highly effective in eradicating Helicobacter pylori (H." | 2.68 | Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. ( Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K, 1997) |
| " Thus, a true dose-response relationship exists between omeprazole and treatment success." | 2.68 | Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997) |
| "For H." | 2.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "Time to ulcer recurrence was significantly longer (P < 0." | 2.68 | Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997) |
| " Group II (n = 47) treated with the same drug and dosage for 2 weeks." | 2.68 | [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. ( Bei, L; Chen, S; Chen, Z, 1996) |
| " Amoxycillin dosing was randomised to either 1 h before or 10 min after food." | 2.67 | Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. ( Atherton, JC; Hawkey, CK; Hudson, N; Kirk, GE; Spiller, RC, 1994) |
| ", in the dosage used and in a selected group of patients with gastrointestinal bleeding, is similar." | 2.67 | [The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole]. ( Blasco Colmenarejo, MM; Cabot Lozano, A; Caneiro Alcubilla, E; García Molinero, MJ; García-Rayo Somoza, M; Herrero Quirós, C; Pérez Flores, R, 1994) |
| "pylori-positive after treatment, and duodenal ulcer relapsed in 16 out of 25 (64%) patients within the median follow-up of 18 months." | 2.67 | Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Ruckdeschel, G; Sommer, A; Stolte, M; Weingart, J, 1993) |
| "Those without recurrence during this treatment were followed up for another 6 months." | 2.67 | Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial. ( Bonnevie, O; Bremmelgaard, A; Eriksen, J; Hansen, JM; Jensen, TG; Justesen, T; Rune, SJ; Scheibel, J; Thomsen, OO; Vilien, M, 1993) |
| "Pantoprazole is a newly developed benzimidazole derivative with strong inhibitory actions on gastric acid secretion by blocking H(+)-K(+)-ATPase." | 2.67 | Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. ( Khalil, H; Leucht, U; Lühmann, R; Müller, P; Schneider, A; Simon, B, 1992) |
| "Omeprazole was given once daily." | 2.67 | An open trial on short-term omeprazole therapy for gastric and duodenal ulcers. ( Alvarez, SZ; Espiritu, AC; Perez, JY; Sollano, JD, 1991) |
| " Both drugs were generally well tolerated, and the number of adverse events in the two treatment groups were similar." | 2.67 | The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients. ( Backman, L; Granström, L; Kager, L; Kollberg, B; Lindberg, G; Moberg, S; Nilsson, LH; Seensalu, R; Sidenvall, L; Sörstad, J, 1991) |
| "Omeprazole was well tolerated; fewer patients had clinical and laboratory adverse experiences in the omeprazole group than in the placebo group." | 2.67 | Omeprazole versus placebo in duodenal ulcer healing. The United States experience. ( Berman, RS; Bishop, RH; Cagliola, AJ; Gitlin, N; Graham, DY; McCullough, A; Roufail, WM; Sklar, M; Sontag, SJ; Stone, RC, 1990) |
| "Omeprazole is a substituted benzimidazole which inhibits profoundly and long-lasting human acid secretion." | 2.66 | [Omeprazole in the therapy of acid-induced diseases]. ( Dammann, HG; Müller, P; Simon, B, 1987) |
| "Omeprazole was superior to cimetidine in ulcer-healing rate after 2, 4 and 6 weeks." | 2.66 | The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms. ( Brunkwall, J; Dahlgren, S; Domellöf, L; Gasslander, T; Hradsky, M; Karlsson, J; Knutson, U; Norryd, C; Svensson, G; Svensson, JO, 1988) |
| "in short-term treatment of acute duodenal ulcer." | 2.66 | Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study. ( Abbiati, R; Barbara, L; Blasi, A; Cheli, R; Corinaldesi, R; Dobrilla, G; Francavilla, A; Gradnik, R; Rinetti, M; Vezzaldini, P, 1987) |
| "Omeprazole is a proton pump inhibitor which induces a dose-dependent reduction of gastric acid secretion." | 2.66 | [Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage. A French multicenter, controlled therapeutic trial]. ( Bader, JP; Bigard, MA; Ebrard, F; Galmiche, JP; Isal, JP, 1987) |
| " The effects of different dosage regimens of intravenous omeprazole was compared with placebo." | 2.66 | Intravenous omeprazole rapidly raises intragastric pH. ( Hawkey, CJ; Kitchingman, G; Langman, MJ; Reynolds, JR; Smart, HL; Somerville, KW; Walt, RP, 1985) |
| " Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal." | 2.41 | The clinical importance of proton pump inhibitor pharmacokinetics. ( Thomson, AB; Yacyshyn, BR, 2002) |
| "Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "When lansoprazole was used as monotherapy, the mean Hp eradication was 6% in four studies." | 2.39 | Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. ( Lamouliatte, H, 1995) |
| "In gastroesophageal reflux disease in particular, although the optimal degree of acid suppression is not yet defined, the consistently superior performance of proton pump inhibitors demonstrates that increased suppression of acidity is clinically beneficial." | 2.39 | Optimizing acid suppression for treatment of acid-related diseases. ( Cederberg, C; Dent, J; Halter, F; Howden, C; Hunt, RH; Marks, IN; Rune, S; Walt, RP, 1995) |
| " Pantoprazole formulated in an enteric-coated tablet displays high bioavailability and linear pharmacokinetics whether on single or multiple dose regimens." | 2.39 | Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. ( Huber, R; Kohl, B; Sachs, G; Senn-Bilfinger, J; Simon, WA; Sturm, E, 1995) |
| "This review provides an updated overview on Helicobacter pylori (HP) trials, focusing on drug dosage and cost:benefit ratio." | 2.39 | The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. ( Treiber, G, 1996) |
| "Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion." | 2.39 | Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. ( Fitton, A; Wiseman, L, 1996) |
| " Tests of gastric acidity, in particular 24-h acidity studies, have provided considerable insight into normal and abnormal gastric physiology, and have largely determined the dosing regimens for the management of acid-peptic diseases." | 2.38 | Gastric acid secretion and intragastric acidity: measurement in health and disease. ( Fraser, AG; Pounder, RE, 1993) |
| "Omeprazole is a powerful inhibitor of gastric acid secretion." | 2.38 | Omeprazole. Overview and opinion. ( Holt, S; Howden, CW, 1991) |
| "Omeprazole is a very potent and long-acting inhibitor of gastric acid secretion." | 2.38 | Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. ( Jansen, JB; Lamers, CB; Meijer, JL, 1989) |
| "Omeprazole has been shown to give significantly higher healing rates than ranitidine or cimetidine in patients with duodenal ulcer and gastric ulcer." | 2.38 | Clinical utility and safety of omeprazole. ( Walan, A, 1989) |
| "Omeprazole has a marked effect on the duration and the degree of inhibition of intragastric acidity which is dose-dependent." | 2.38 | Relationship between inhibition of acid secretion and healing of peptic ulcers. ( Chiverton, SG; Hunt, RH, 1989) |
| " Common causes were discarded and the hypomagnesaemia was attributed to chronic use of the proton pump inhibitor, omeprazole." | 1.40 | From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. ( Braun, E; Eyal, A; Naffaa, ME; Sueissa, A, 2014) |
| "Primary lymph node gastrinomas are relatively rare in children and, to the best of our knowledge, have not previously been reported at this location." | 1.37 | Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. ( Nazir, Z, 2011) |
| "Studying role of duodenogastric reflux (DGR) in pathogenesis and sanogenesis of duodenal ulcer (DU)." | 1.37 | [Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication]. ( Kolesnikova, IIu; Liubskaia, LA; Volkov, VS, 2011) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 1.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| " Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36." | 1.36 | Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. ( Dimassi, HI; Nasser, SC; Nassif, JG, 2010) |
| "Pre-existing nonerosive gastroesophageal reflux disease, smoking, and older age are important predictors of de novo development of erosive esophagitis." | 1.36 | De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupčinskas, J; Kupčinskas, L, 2010) |
| "Especially patients with severe sepsis or septic shock are prone to develop lesions of the upper gastrointestinal tract with consecutive bleeding." | 1.35 | [Stress ulcer prophylaxis in septic patients. Evidence-based overview]. ( Elke, G; Schädler, D; Scholz, J; Weiler, N; Zick, G, 2008) |
| "Duodenal ulcer (DU) and gastroesophageal reflux disease (GERD) are often combined." | 1.34 | [Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. ( Tsimmerman, IaS; Vologzhanina, LG, 2007) |
| "Chronic gastritis was evaluated according to sydney system." | 1.33 | [Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori]. ( Ben Ayed, M; Ben Khelifa, H; Chedly-Debbiche, A; Gargouri, D; Ghorbel, AJ; Kharrat, J; Khayat, O; Kilani, A; Souissi, A; Zeddini, A, 2006) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Exploration found volvulus and a gangrenous segment of the distal ileum." | 1.32 | Massive gastrointestinal bleeding in infants with ascariasis. ( Chedphaopan, J; Mitamun, W; Patrapinyokul, S; Sangkhathat, S; Wudhisuthimethawee, P, 2003) |
| "Treatment with omeprazole, amoxicillin, and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 (80%) of 19 patients who had a follow-up examination." | 1.31 | Helicobacter pylori infection in recurrent abdominal pain. ( Braegger, CP; Frank, F; Stallmach, T; Stricker, T, 2000) |
| "It was concluded that the recurrence of HP infection is low at the end of one year after successful eradication therapy in this urban East Asian population." | 1.31 | Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population. ( Fock, KM; Khor, CJ; Ng, A; Ng, TM; Sim, CS; Tan, AL; Teo, EK, 2000) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "Rabeprazole has also been shown to have a more consistent suppression of acid, including at night." | 1.31 | Optimizing acid-suppression therapy. ( Barnett, JL; Robinson, M, 2001) |
| "Omeprazole is a potent proton pump inhibitor and usually is well tolerated." | 1.31 | Cutaneous leucocytoclastic vasculitis associated with omeprazole. ( Lurie, M; Odeh, M; Oliven, A, 2002) |
| "Rabeprazole has a favourable profile with rapid action and good safety." | 1.31 | [Pharma-clinics medication of the month. Rabeprazole (Pariet)]. ( Louis, E, 2002) |
| "Omeprazole is a proton pump inhibitor widely used for the treatment of peptic ulcer disease." | 1.30 | Omeprazole-induced acute interstitial nephritis. ( d'Adamo, G; Forte, F; Gangeri, F; Spinelli, C, 1997) |
| "Of the 83 smokers, 3 (3." | 1.30 | Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? ( Chan, FK; Chan, LY; Chung, SC; Lee, YT; Leung, WK; Sung, JJ; Yung, MY, 1997) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| "Omeprazole does increase intragastric pH in bleeding peptic ulcer patients with H." | 1.30 | Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy? ( Chang, FY; Hsieh, YH; Lee, FY; Lee, SD; Lin, HJ; Perng, CL; Tseng, GY, 1999) |
| "After 1 year, no patient had H." | 1.30 | Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study. ( Annibale, B; D'Ambra, G; Delle Fave, G; Marcheggiano, A; Martino, G; Paoletti, M, 1999) |
| "pylori)with an increased risk of gastric cancer has been well documented, the exact mechanisms of this association have not been fully elucidated." | 1.30 | Proliferating cell nuclear antigen (PCNA) immunostaining in Helicobacter pylori infection: impact of eradication. ( Antoniades, D; Kalafatis, E; Karameris, A; Lazaris, A; Liatsos, C; Petridou, E; Rokkas, T, 1999) |
| "Duodenal ulcers were healed with omeprazole, 20 mg/day." | 1.29 | Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. ( Jaskiewicz, K; Lastovica, AJ; Louw, JA; Lucke, W; Marks, IN; Winter, TA, 1995) |
| "Omeprazole is a powerful inhibitor of gastric acid and may suppress Helicobacter pylori by effecting the pKa of H pylori urease, by altering the pattern of infection, or by promoting overgrowth of other bacteria." | 1.29 | Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. ( Baron, JH; Gummett, PA; Karim, QN; Logan, RP; Misiewicz, JJ; Walker, MM, 1995) |
| " Moreover, if omeprazole is administered at a pharmacologically effective dosage for a short period of time, it may not have serious effects on the ultrastructure of human parietal cells." | 1.29 | The effects of omeprazole on the ultrastructure of gastric parietal cells. ( Fujii, T; Kato, S; Naganuma, H; Nakagawa, H; Nakano, K, 1994) |
| "Duodenal ulcer is a chronic disease with a high risk of relapse--if left untreated, the relapse rate is 50-80% per year (1)." | 1.29 | Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. ( Festen, HP, 1994) |
| "It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome." | 1.29 | [The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993) |
| " No differences in cell cycle distribution of the antrum, body, and fundus were found in the two different dosage groups after 1 month of therapy, considering the synthetic phase (S-phase) of the cell cycle." | 1.29 | Effect of short- and long-term treatment with omeprazole on cell cycle distribution in the gastric mucosa. Results of a flow cytometric study. ( Bertolissi, E; Bortoluzzi, F; Cannizzaro, R; Cernigoi, C; Fornasarig, M; Sozzi, M; Toffoli, G; Valentini, M, 1993) |
| " From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages." | 1.29 | [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer]. ( Battaglia, G; Chiozzini, G; De Bona, M; De Boni, M; Di Mario, F; Grasso, GA; Pasquino, M; Saggioro, A; Vianello, F, 1993) |
| "To verify the effectiveness and side-effect profile of an eradicating regimen consisting of omeprazole 20 mg daily for 4 weeks and, during the first week, combination antimicrobial treatment with tinidazole 500 mg b." | 1.29 | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. ( Carli, G; Dalla Libera, M; Gamberini, S; Gullini, S; Merighi, A; Pazzi, P; Scagliarini, R, 1996) |
| "Omeprazole has a potent antisecretory effect and is a suitable alternative for short-term treatment of refractory acid-related diseases; a relatively low dose (0." | 1.29 | Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. ( Chiba, H; Ebina, K; Fujii, K; Kato, S; Nakagawa, H, 1996) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| "3%) had received previous therapy with H2-receptor antagonists and in 33% of these patients it was at an inadequate dose or for an inadequate period of dosing or both." | 1.28 | A drug usage review of omeprazole. ( Kay, EA; McManus, PV; Norris, CM; Petty, D, 1992) |
| "Fewer duodenal ulcers were found in animals receiving drug treatments than in the oral vehicle group." | 1.28 | Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model. ( Baron, JH; Gompertz, RH; Li, SK; Man, WK; Michalowski, AS; Spencer, J, 1991) |
| "Omeprazole was well tolerated, and the incidence of clinical and laboratory adverse experiences was similar in patients receiving omeprazole, placebo, cimetidine, or ranitidine." | 1.28 | Comparative tolerability profile of omeprazole in clinical trials. ( Bradstreet, DC; Simon, TJ, 1991) |
| " This study investigated the mechanism of the increase in oral bioavailability of omeprazole during repeated oral dosing." | 1.28 | Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. ( Angus, PW; Ching, MS; Devenish-Meares, S; Mihaly, GW; Morgan, DJ; Smallwood, RA; Yeomans, ND, 1991) |
| "2." | 1.28 | [Current perspectives in ulcer disease]. ( Beglinger, C, 1990) |
| " Omeprazole, a substituted benzimidazole inhibitor of the gastric H+/K(+)-APT-ase, was administered orally at a dose of 20 mg in the morning of 3 consecutive days, followed by a period of 4 days without medication, and this intermittent dosage regimen was continued for 4 weeks." | 1.28 | Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers. ( Biemond, I; Crobach, LF; Jansen, JB; Lamers, CB, 1990) |
| " An oral daily dose of 15 mg omeprazole in humans produced about 80% acid inhibition just after dosage and about 40% 24 hours later." | 1.27 | [Acid secretion inhibition with new mechanisms of action: substituted benzimidazole]. ( Carlsson, E; Cederberg, C; Helander, H; Lind, T; Olbe, L; Wallmark, B, 1984) |
| "Treatment with omeprazole also gave faster and more pronounced pain relief." | 1.27 | Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors. ( Walan, A, 1986) |
| "This study was aimed to identify an intravenous dosage regime of omeprazole which would sufficiently suppress acid secretion to maintain intragastric pH greater than 4 continuously." | 1.27 | Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients. ( Lind, T; Moore, M; Olbe, L, 1986) |
| " The expected antisecretory effect of a particular dosage regimen in patients with duodenal ulcer can be predicted mathematically from data derived from studies in normal volunteers." | 1.27 | Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer. ( Burget, DW; Howden, CW; Hunt, RH; Jones, DB, 1986) |
| "Omeprazole was not recoverable from dialysis fluid." | 1.27 | Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. ( Forrest, JA; Howden, CW; Hughes, DM; Macdougall, AI; Meredith, PA; Payton, CD; Reid, JL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 102 (11.63) | 18.7374 |
| 1990's | 518 (59.06) | 18.2507 |
| 2000's | 223 (25.43) | 29.6817 |
| 2010's | 33 (3.76) | 24.3611 |
| 2020's | 1 (0.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Pan, X | 2 |
| Zhang, L | 1 |
| Sun, H | 1 |
| Fan, H | 1 |
| Pan, Z | 1 |
| Huang, C | 1 |
| Shi, Z | 1 |
| Ding, J | 1 |
| Wang, Q | 1 |
| Du, Y | 2 |
| Lyu, N | 1 |
| Li, Z | 1 |
| Li, CY | 1 |
| Wu, C | 1 |
| Takata, K | 1 |
| Fukuda, H | 1 |
| Umeda, K | 1 |
| Yamauchi, R | 1 |
| Fukuda, S | 1 |
| Kunimoto, H | 1 |
| Tanaka, T | 1 |
| Yokoyama, K | 1 |
| Morihara, D | 1 |
| Takeyama, Y | 1 |
| Irie, M | 1 |
| Shakado, S | 1 |
| Sakisaka, S | 1 |
| Xie, Y | 1 |
| Li, Y | 3 |
| Wang, H | 4 |
| Xu, J | 1 |
| Wang, J | 1 |
| Zeng, Z | 1 |
| Chen, Y | 2 |
| Zhang, G | 1 |
| Wu, K | 1 |
| Liu, D | 1 |
| Lv, N | 1 |
| Salmanroghani, H | 1 |
| Mirvakili, M | 1 |
| Baghbanian, M | 1 |
| Salmanroghani, R | 1 |
| Sanati, G | 1 |
| Yazdian, P | 1 |
| Konorev, MR | 2 |
| Kubyshkin, VA | 1 |
| Petrov, DIu | 1 |
| Smirnov, AV | 1 |
| Ono, K | 1 |
| Takeda, M | 1 |
| Makihata, E | 1 |
| Okazaki, J | 1 |
| Nagai, A | 1 |
| Khamraev, AA | 1 |
| Rustamova, MT | 1 |
| Khaĭrullaeva, SS | 1 |
| Tanaka, K | 1 |
| Nakada, TA | 1 |
| Abe, R | 1 |
| Itoga, S | 1 |
| Nomura, F | 1 |
| Oda, S | 1 |
| Eyal, A | 1 |
| Sueissa, A | 1 |
| Braun, E | 1 |
| Naffaa, ME | 1 |
| Goldstein, JL | 2 |
| Scheiman, JM | 1 |
| Fort, JG | 1 |
| Whellan, DJ | 1 |
| Xuan, JW | 1 |
| Song, RL | 1 |
| Xu, GX | 1 |
| Lu, WQ | 1 |
| Lu, YJ | 1 |
| Liu, Z | 1 |
| Chwiesko, A | 1 |
| Charkiewicz, R | 1 |
| Niklinski, J | 1 |
| Luczaj, W | 1 |
| Skrzydlewska, E | 1 |
| Milewski, R | 1 |
| Baniukiewicz, A | 2 |
| Wroblewski, E | 1 |
| Rosolowski, M | 1 |
| Dabrowski, A | 1 |
| Silva, FM | 2 |
| Eisig, JN | 3 |
| Teixeira, AC | 1 |
| Barbuti, RC | 2 |
| Navarro-Rodriguez, T | 2 |
| Mattar, R | 1 |
| McKeage, K | 1 |
| Blick, SK | 1 |
| Croxtall, JD | 1 |
| Lyseng-Williamson, KA | 1 |
| Keating, GM | 1 |
| El-Nakeeb, A | 1 |
| Fikry, A | 1 |
| Abd El-Hamed, TM | 1 |
| Fouda, el Y | 1 |
| El Awady, S | 1 |
| Youssef, T | 1 |
| Sherief, D | 1 |
| Farid, M | 1 |
| Pellicano, R | 1 |
| Ho, KY | 1 |
| Kuan, A | 1 |
| Zaño, F | 1 |
| Goh, KL | 7 |
| Mahachai, V | 2 |
| Kim, DY | 1 |
| Yoon, HM | 1 |
| Cheng, HC | 1 |
| Chang, WL | 1 |
| Yeh, YC | 1 |
| Chen, WY | 1 |
| Tsai, YC | 1 |
| Sheu, BS | 1 |
| Osadchuk, AM | 2 |
| Milova-Filippova, LA | 1 |
| Kvetnoĭ, IM | 4 |
| Tan, VP | 1 |
| Wong, BC | 8 |
| Javid, G | 3 |
| Zargar, SA | 2 |
| U-Saif, R | 1 |
| Khan, BA | 3 |
| Yatoo, GN | 2 |
| Shah, AH | 2 |
| Gulzar, GM | 3 |
| Sodhi, JS | 2 |
| Khan, MA | 1 |
| Esedov, EM | 1 |
| Magomedéminova, AS | 1 |
| Serebrova, SIu | 1 |
| Starodubtsev, AK | 1 |
| Pisarev, VV | 1 |
| Kondratenko, SN | 1 |
| Vasilenko, GF | 1 |
| Dobrovol'skiĭ, OV | 1 |
| Nasser, SC | 1 |
| Nassif, JG | 1 |
| Dimassi, HI | 1 |
| Zhou, LY | 1 |
| Lin, SR | 1 |
| Yang, YS | 1 |
| Zhang, ST | 1 |
| Yuan, YZ | 1 |
| Shi, RH | 1 |
| Hou, XH | 1 |
| Xia, JL | 1 |
| Hu, HT | 1 |
| Qin, XH | 1 |
| Wang, L | 2 |
| Zhou, L | 2 |
| Lin, S | 3 |
| Hu, H | 2 |
| Xia, J | 2 |
| Jonaitis, L | 1 |
| Kupčinskas, J | 1 |
| Kiudelis, G | 1 |
| Kupčinskas, L | 1 |
| Komarov, FI | 1 |
| Osadchuk, MA | 2 |
| Islamova, EA | 1 |
| Felga, G | 1 |
| Zaterka, S | 3 |
| Yakoob, J | 1 |
| Abid, S | 2 |
| Abbas, Z | 2 |
| Jafri, SN | 1 |
| Yadav, DK | 1 |
| Singh, N | 1 |
| Dev, K | 1 |
| Sharma, R | 1 |
| Sahai, M | 1 |
| Palit, G | 2 |
| Maurya, R | 2 |
| Yang, JC | 2 |
| Wang, HL | 1 |
| Chern, HD | 1 |
| Shun, CT | 1 |
| Lin, BR | 2 |
| Lin, CJ | 1 |
| Wang, TH | 3 |
| Nazir, Z | 1 |
| Valooran, GJ | 1 |
| Kate, V | 1 |
| Jagdish, S | 1 |
| Basu, D | 1 |
| Kim, JY | 1 |
| Kim, N | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Lee, DH | 1 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Lee, JH | 1 |
| Jung, HC | 3 |
| Song, IS | 2 |
| Kolesnikova, IIu | 2 |
| Volkov, VS | 1 |
| Liubskaia, LA | 1 |
| Veres, G | 1 |
| Korponay-Szabó, I | 1 |
| Maka, E | 1 |
| Glasz, T | 1 |
| Mamula, P | 1 |
| Schuster, V | 2 |
| Tefs, K | 2 |
| Papp, M | 1 |
| Dezsöfi, A | 1 |
| Arató, A | 1 |
| Celinski, K | 1 |
| Konturek, PC | 2 |
| Konturek, SJ | 3 |
| Slomka, M | 1 |
| Cichoz-Lach, H | 1 |
| Brzozowski, T | 1 |
| Bielanski, W | 3 |
| Saha, SK | 2 |
| Masud, H | 1 |
| Islam, N | 1 |
| Raihan, AS | 1 |
| Roy, PK | 1 |
| Hasan, M | 1 |
| Niero, R | 1 |
| Dal Molin, MM | 1 |
| Silva, S | 1 |
| Damian, NS | 1 |
| Maia, LO | 1 |
| Delle Monache, F | 1 |
| Cechinel Filho, V | 1 |
| de Andrade, SF | 1 |
| Satoh, H | 2 |
| Wee, EW | 1 |
| Varghese, NM | 1 |
| Tung, ML | 1 |
| Low, HC | 1 |
| Isakov, V | 1 |
| Domareva, I | 1 |
| Koudryavtseva, L | 1 |
| Maev, I | 1 |
| Ganskaya, Z | 1 |
| Ishibashi, S | 1 |
| Iwakiri, R | 1 |
| Shimoda, R | 1 |
| Ootani, H | 1 |
| Kawasaki, S | 1 |
| Tadano, J | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Oda, K | 1 |
| Fujise, T | 1 |
| Yoshida, T | 1 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Hawkey, CJ | 7 |
| Naesdal, J | 8 |
| Wilson, I | 2 |
| Långström, G | 3 |
| Swannell, AJ | 4 |
| Peacock, RA | 2 |
| Yeomans, ND | 9 |
| Wu, XP | 1 |
| He, JR | 1 |
| Wang, CL | 1 |
| Ling, QH | 1 |
| Vasil'ev, IuV | 3 |
| Zvenigorodskaia, LA | 2 |
| Kolomiets, EV | 2 |
| Firsanova, VIu | 1 |
| Ivashkin, VT | 1 |
| Lapina, TL | 2 |
| Bondarenko, OY | 1 |
| Sklanskaya, OA | 1 |
| Grigoriev, PY | 1 |
| Vasiliev, YV | 1 |
| Yakovenko, EP | 1 |
| Gulyaev, PV | 1 |
| Fedchenko, VI | 1 |
| Murakami, K | 2 |
| Sato, R | 2 |
| Okimoto, T | 2 |
| Nasu, M | 2 |
| Fujioka, T | 2 |
| Kodama, M | 2 |
| Kagawa, J | 2 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Xu, R | 1 |
| Fang, L | 1 |
| Jiang, X | 1 |
| Wan, Y | 1 |
| Huang, S | 1 |
| Jiang, K | 1 |
| Lin, N | 1 |
| Pan, W | 1 |
| Cherniakevich, SA | 1 |
| Babkova, IV | 1 |
| Mikhalev, AI | 1 |
| Gorshkov, VA | 1 |
| Yacyshyn, BR | 1 |
| Thomson, AB | 5 |
| Taeron, C | 1 |
| Mantzaris, GJ | 1 |
| Petraki, K | 1 |
| Archavlis, E | 1 |
| Amberiadis, P | 1 |
| Christoforidis, P | 1 |
| Kourtessas, D | 1 |
| Chiotakakou, E | 1 |
| Triantafyllou, G | 1 |
| Louis, E | 2 |
| Catalano, F | 6 |
| Terminella, C | 1 |
| Branciforte, G | 4 |
| Bentivegna, C | 5 |
| Brogna, A | 6 |
| Scalia, A | 1 |
| Chan, FK | 3 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wu, JC | 1 |
| Lee, KC | 1 |
| Leung, VK | 3 |
| Hui, AJ | 1 |
| To, KF | 2 |
| Leung, WK | 3 |
| Wong, VW | 1 |
| Chung, SC | 9 |
| Sung, JJ | 9 |
| Grinevich, VB | 1 |
| Sablin, OA | 1 |
| Uspenskiĭ, IuL | 1 |
| Kaviani, MJ | 1 |
| Hashemi, MR | 1 |
| Kazemifar, AR | 1 |
| Roozitalab, S | 1 |
| Mostaghni, AA | 1 |
| Merat, S | 2 |
| Alizadeh-Naini, M | 1 |
| Yarmohammadi, H | 1 |
| Chaudhuri, S | 1 |
| Chowdhury, A | 1 |
| Datta, S | 1 |
| Mukhopadhyay, AK | 1 |
| Chattopadhya, S | 1 |
| Saha, DR | 1 |
| Dhali, G | 1 |
| Santra, A | 1 |
| Nair, GB | 1 |
| Bhattacharya, S | 1 |
| Berg, DE | 1 |
| Urakami, Y | 2 |
| Sano, T | 1 |
| Tsimmerman, IaS | 4 |
| Mikhaleva, EN | 1 |
| Kirika, NV | 1 |
| Bodrug, NI | 1 |
| Butorov, SI | 1 |
| Verbitskiĭ, ON | 1 |
| Ridlovskiĭ, AIu | 1 |
| Butorov, IV | 1 |
| Lagutkin, DI | 1 |
| Martyniuk, LI | 1 |
| Laine, L | 5 |
| Hunt, R | 1 |
| El-Zimaity, H | 1 |
| Nguyen, B | 1 |
| Osato, M | 1 |
| Spénard, J | 1 |
| Baskhaeva, RG | 1 |
| Maev, IV | 4 |
| Kurilo, AE | 1 |
| V'iuchnova, ES | 2 |
| Shchekina, MI | 2 |
| Hiramoto, JS | 1 |
| Terdiman, JP | 1 |
| Norton, JA | 1 |
| Marzio, L | 3 |
| Cellini, L | 3 |
| Angelucci, D | 1 |
| Kaise, M | 1 |
| Miwa, J | 1 |
| Iihara, K | 1 |
| Suzuki, N | 1 |
| Oda, Y | 1 |
| Ohta, Y | 1 |
| Fedele, E | 1 |
| Boixeda, D | 13 |
| Martín De Argila, C | 12 |
| Bermejo, F | 5 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 2 |
| García Plaza, A | 7 |
| Lai, YC | 1 |
| Huang, SH | 1 |
| Yang, SS | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Lee, CL | 1 |
| Osipenko, MF | 1 |
| Pankova, LIu | 1 |
| Bikbulatova, EA | 1 |
| Orziev, ZM | 2 |
| Nurbaev, FE | 2 |
| Rakhimova, GSh | 2 |
| Kamiya, T | 1 |
| Kobayashi, Y | 1 |
| Misu, N | 1 |
| Hirako, M | 1 |
| Adachi, H | 1 |
| Nagao, T | 1 |
| Shikano, M | 1 |
| Matsuhisa, E | 1 |
| Ando, T | 1 |
| Kimura, G | 1 |
| Rukhliada, NV | 1 |
| Nazarov, VE | 1 |
| Ermolaev, IA | 1 |
| Uthaisaengsook, W | 1 |
| Hassan, C | 1 |
| De Francesco, V | 3 |
| Zullo, A | 2 |
| Scaccianoce, G | 1 |
| Piglionica, D | 1 |
| Ierardi, E | 1 |
| Panella, C | 1 |
| Morini, S | 1 |
| Sjölund, M | 1 |
| Wreiber, K | 1 |
| Andersson, DI | 1 |
| Blaser, MJ | 1 |
| Engstrand, L | 1 |
| Bedekovic, V | 1 |
| Mise, S | 2 |
| Anic, T | 1 |
| Staresinic, M | 1 |
| Gjurasin, M | 2 |
| Kopljar, M | 1 |
| Kalogjera, L | 1 |
| Drvis, P | 1 |
| Boban Blagaic, A | 1 |
| Batelja, L | 1 |
| Seiwerth, S | 2 |
| Sikiric, P | 2 |
| Chang, FY | 5 |
| Lu, CL | 2 |
| Chen, CY | 4 |
| Luo, JC | 2 |
| Jium, KL | 1 |
| Lee, SD | 5 |
| Sangkhathat, S | 1 |
| Patrapinyokul, S | 1 |
| Wudhisuthimethawee, P | 1 |
| Chedphaopan, J | 1 |
| Mitamun, W | 1 |
| Romero-Gómez, M | 1 |
| Martínez-Delgado, C | 1 |
| Hergueta, P | 1 |
| Navarro, JM | 1 |
| Garrido-Serrano, A | 1 |
| Santos, O | 1 |
| Montojo, C | 1 |
| Keelan, M | 2 |
| Lastiwka, R | 1 |
| Appelman-Eszczuk, S | 1 |
| Zuk, L | 2 |
| Drozdowski, L | 1 |
| Prentice, A | 1 |
| Sinclair, P | 4 |
| Nie, YQ | 1 |
| Dai, SJ | 1 |
| She, QZ | 1 |
| Li, YY | 2 |
| Lee, SB | 1 |
| Park, SJ | 1 |
| Ryu, JK | 1 |
| Lee, JK | 1 |
| Kim, HJ | 2 |
| Bae, JS | 1 |
| Jung, HS | 1 |
| Park, SM | 1 |
| Isakov, VA | 3 |
| Simanenkov, VI | 1 |
| Kononov, AV | 1 |
| Abdulkhakov, RA | 1 |
| Zakharova, NV | 1 |
| Livzan, MA | 1 |
| Predvechnaia, IK | 1 |
| Combe, B | 1 |
| Flipo, RM | 1 |
| Chubenko, SS | 1 |
| Gaĭdukov, VO | 1 |
| Agibalov, AN | 1 |
| Onishenko, AV | 1 |
| Ganskaia, ZhIu | 1 |
| Podgrobunskikh, EI | 1 |
| Gumurdulu, Y | 1 |
| Serin, E | 1 |
| Ozer, B | 1 |
| Kayaselcuk, F | 1 |
| Ozsahin, K | 1 |
| Cosar, AM | 1 |
| Gursoy, M | 1 |
| Gur, G | 1 |
| Yilmaz, U | 1 |
| Boyacioglu, S | 1 |
| Kornienko, EA | 2 |
| Klochko, OG | 1 |
| Chaudhary, A | 1 |
| Ahuja, V | 3 |
| Bal, CS | 2 |
| Das, B | 1 |
| Pandey, RM | 1 |
| Sharma, MP | 5 |
| Namiot, Z | 2 |
| Namiot, DB | 2 |
| Kemona, A | 2 |
| Stasiewicz, J | 2 |
| Tiesmeier, J | 1 |
| Hinner, H | 1 |
| Kraus, J | 1 |
| Schuppert, F | 1 |
| Yukselen, V | 1 |
| Yasa, MH | 1 |
| Karaoglu, AO | 1 |
| Ghazzawi, IM | 1 |
| Obeidat, WA | 1 |
| Zuriekat, FA | 1 |
| Sivri, B | 1 |
| Simsek, I | 1 |
| Hulagu, S | 1 |
| Kadayifci, A | 3 |
| Tozun, N | 2 |
| Akarsu, M | 1 |
| Uraz, S | 1 |
| Savas, MC | 1 |
| Koruk, M | 1 |
| Bozbas, A | 1 |
| Vasil'ev, IuB | 1 |
| Huang, B | 1 |
| Amer, F | 1 |
| Christopoulos, NG | 1 |
| Markowski, AR | 1 |
| Jaroszewicz, W | 1 |
| Górski, J | 1 |
| Wong, WM | 3 |
| Xiao, SD | 4 |
| Hu, PJ | 2 |
| Wang, WH | 2 |
| Gu, Q | 1 |
| Huang, JQ | 1 |
| Xia, HH | 1 |
| Wu, SM | 2 |
| Li, CJ | 1 |
| Chen, MH | 1 |
| Cui, Y | 1 |
| Lai, KC | 5 |
| Hu, WH | 5 |
| Chan, CK | 3 |
| Lam, SK | 9 |
| Hirschowitz, BI | 3 |
| Simmons, J | 1 |
| Mohnen, J | 2 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 2 |
| Mäkinen, J | 1 |
| Rautelin, H | 1 |
| Färkkilä, M | 1 |
| Kato, S | 6 |
| Ozawa, K | 1 |
| Sekine, H | 1 |
| Ohyauchi, M | 1 |
| Shimosegawa, T | 1 |
| Minoura, T | 1 |
| Iinuma, K | 2 |
| Lu, RH | 1 |
| Fukuhara, S | 1 |
| Suzuki, H | 4 |
| Masaoka, T | 1 |
| Arakawa, M | 1 |
| Hosoda, H | 1 |
| Minegishi, Y | 1 |
| Kangawa, K | 1 |
| Ishii, H | 4 |
| Kitajima, M | 1 |
| Hibi, T | 3 |
| García-Altés, A | 1 |
| Rota, R | 1 |
| Barenys, M | 1 |
| Abad, A | 1 |
| Moreno, V | 1 |
| Pons, JM | 1 |
| Piqué, JM | 1 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Dharmani, P | 1 |
| Mishra, PK | 1 |
| Chauhan, VS | 1 |
| Chen, YH | 1 |
| Wang, WM | 2 |
| Li, HY | 1 |
| Gisbert, JP | 14 |
| Domínguez-Muñoz, A | 1 |
| Domínguez-Martín, A | 1 |
| Gisbert, JL | 2 |
| Marcos, S | 2 |
| Solomon, LK | 1 |
| Vogiatzis, I | 1 |
| Craig, E | 1 |
| Campbell, FC | 1 |
| Güliter, S | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Kataoka, H | 1 |
| Jho, T | 1 |
| Itoh, M | 1 |
| Khoshbaten, M | 1 |
| Fattahi, E | 1 |
| Naderi, N | 1 |
| Khaleghian, F | 1 |
| Rezailashkajani, M | 1 |
| Shiwani, MH | 1 |
| Malinovskaia, NK | 2 |
| Komarova, FI | 1 |
| Rapoport, SI | 2 |
| Raĭkhlin, NT | 1 |
| Lakshin, AA | 1 |
| Voznesenskaia, LA | 1 |
| Rasulov, MI | 1 |
| Demertzis, K | 1 |
| Polymeros, D | 1 |
| Emmanuel, T | 1 |
| Triantafyllou, K | 1 |
| Tassios, P | 1 |
| Ladas, SD | 1 |
| Aladağ, M | 1 |
| Kantarçeken, B | 1 |
| Karincaoğlu, M | 1 |
| Sertkaya, A | 1 |
| Cikim, K | 1 |
| Harputluoğlu, MM | 1 |
| Demirel, U | 1 |
| Alan, H | 1 |
| Ateş, F | 1 |
| Yildirim, B | 1 |
| Hilmioğlu, F | 1 |
| Vakhrushev, IaM | 2 |
| Muravtseva, OV | 2 |
| Hizawa, K | 1 |
| Miura, N | 1 |
| Hasegawa, H | 1 |
| Kitamura, M | 1 |
| Nakamori, M | 1 |
| Matsumoto, T | 1 |
| Iida, M | 1 |
| Kochurova, IA | 1 |
| Vladimirskiĭ, EV | 1 |
| Jensen, DM | 1 |
| Pace, SC | 1 |
| Soffer, E | 1 |
| Comer, GM | 1 |
| Kawakami, E | 1 |
| Machado, RS | 1 |
| Ogata, SK | 1 |
| Langner, M | 1 |
| Fukushima, E | 1 |
| Carelli, AP | 1 |
| Bonucci, VC | 1 |
| Patricio, FR | 1 |
| Zagari, RM | 1 |
| Bianchi-Porro, G | 2 |
| Fiocca, R | 6 |
| Gasbarrini, G | 2 |
| Roda, E | 1 |
| Bazzoli, F | 3 |
| Khayat, O | 1 |
| Kilani, A | 1 |
| Chedly-Debbiche, A | 1 |
| Zeddini, A | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Souissi, A | 1 |
| Ghorbel, AJ | 1 |
| Ben Ayed, M | 1 |
| Ben Khelifa, H | 1 |
| Lin, HJ | 3 |
| Lo, WC | 2 |
| Cheng, YC | 1 |
| Perng, CL | 3 |
| Yilmaz, S | 1 |
| Bayan, K | 1 |
| Dursun, M | 1 |
| Canoruç, F | 1 |
| Kilinç, N | 1 |
| Tüzün, Y | 1 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Tsai, SH | 1 |
| Chang, WC | 1 |
| Chu, SJ | 1 |
| Wu, CP | 1 |
| Belov, DF | 1 |
| Maksimova, ID | 1 |
| Ponomarev, AA | 1 |
| Loginov, AF | 1 |
| Minushkin, ON | 1 |
| Volodin, DV | 1 |
| Zverkov, IV | 1 |
| Ivanova, OI | 1 |
| Shuleshova, AG | 1 |
| Burdina, EG | 1 |
| Subei, IM | 1 |
| Cardona, HJ | 1 |
| Bachelet, E | 1 |
| Useche, E | 1 |
| Arigbabu, A | 1 |
| Hammour, AA | 1 |
| Miller, T | 1 |
| Zhernakova, NI | 1 |
| Rybnikova, SN | 1 |
| Postnikova, LI | 1 |
| Parkhomenko, IE | 1 |
| Vologzhanina, LG | 1 |
| Koussoulas, V | 1 |
| Vassiliou, S | 1 |
| Spyridaki, E | 1 |
| Demonakou, M | 1 |
| Vaki, I | 1 |
| Barbatzas, C | 1 |
| Giamarellou, H | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Roblin, X | 1 |
| Dam, C | 1 |
| Bygum, A | 1 |
| Desai, JC | 1 |
| Sanyal, SM | 1 |
| Goo, T | 1 |
| Benson, AA | 1 |
| Bodian, CA | 1 |
| Miller, KM | 1 |
| Cohen, LB | 1 |
| Aisenberg, J | 1 |
| Ganesh, R | 1 |
| Suresh, N | 1 |
| Prahalad, N | 1 |
| Vijayakumar, M | 1 |
| Nammalwar, BR | 1 |
| Sathiyasekaran, M | 1 |
| Elke, G | 1 |
| Schädler, D | 1 |
| Zick, G | 1 |
| Scholz, J | 1 |
| Weiler, N | 1 |
| Misiewicz, JJ | 6 |
| Gustavsson, S | 2 |
| Adami, HO | 2 |
| Lööf, L | 2 |
| Nyberg, A | 2 |
| Nyrén, O | 2 |
| Sharma, BK | 3 |
| Santana, IA | 1 |
| Walt, RP | 8 |
| Pounder, RE | 8 |
| Demling, L | 1 |
| Lundborg, P | 1 |
| Levine, JB | 1 |
| Müller, P | 6 |
| Dammann, HG | 8 |
| Seitz, H | 1 |
| Simon, B | 8 |
| Becker, HD | 1 |
| Blanchi, A | 1 |
| Rotenberg, A | 1 |
| Soulé, JC | 2 |
| Delchier, JC | 4 |
| Morin, T | 1 |
| Pariente, EA | 2 |
| Bitoun, A | 1 |
| Modigliani, R | 1 |
| Bader, JP | 3 |
| Gomes, MD | 2 |
| Wood, EC | 2 |
| Logan, LH | 2 |
| Kweicień, N | 1 |
| Obtułowicz, W | 1 |
| Kopp, B | 1 |
| Oleksy, J | 1 |
| Hetzel, DJ | 2 |
| Shearman, DJ | 3 |
| Horowitz, M | 1 |
| Buckle, PJ | 1 |
| Chatterton, BE | 1 |
| Bodemar, G | 2 |
| Walan, A | 13 |
| Yamamoto, O | 1 |
| Okada, Y | 1 |
| Okabe, S | 4 |
| Olbe, L | 5 |
| Lind, T | 10 |
| Carlsson, E | 1 |
| Cederberg, C | 8 |
| Helander, H | 1 |
| Wallmark, B | 1 |
| Labenz, J | 17 |
| Stolte, M | 15 |
| Peitz, U | 7 |
| Tillenburg, B | 8 |
| Köhl, H | 2 |
| Becker, T | 2 |
| Börsch, G | 13 |
| Schepp, W | 4 |
| Villanueva, C | 1 |
| Balanzó, J | 1 |
| Torras, X | 1 |
| Sáinz, S | 2 |
| Soriano, G | 1 |
| González, D | 1 |
| Vilardell, F | 2 |
| Swain, P | 1 |
| Ahmed, W | 4 |
| Ali, A | 1 |
| Qureshi, H | 3 |
| Zuberi, SJ | 3 |
| Shamsi, ZU | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Classen, M | 3 |
| Jhala, NC | 1 |
| McFarland, MM | 1 |
| Brightman, SA | 1 |
| Morale, B | 1 |
| Rubin, W | 2 |
| Atkinson, BF | 1 |
| Sugiyama, T | 3 |
| Hisano, K | 1 |
| Ochiai, T | 1 |
| Fujita, N | 1 |
| Kobayashi, T | 1 |
| Yabana, T | 1 |
| Kurokawa, I | 1 |
| Yachi, A | 1 |
| Katoh, M | 1 |
| Asaka, M | 5 |
| Kudoh, M | 1 |
| Kagaya, H | 2 |
| Katagiri, M | 2 |
| Takeda, H | 2 |
| Furuta, T | 6 |
| Futami, H | 4 |
| Arai, H | 4 |
| Hanai, H | 7 |
| Kaneko, E | 8 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 1 |
| Saifuku, K | 1 |
| Kihira, K | 2 |
| Yoshida, Y | 1 |
| Kimura, K | 1 |
| Nakata, H | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Shirai, T | 1 |
| Takagi, A | 1 |
| Kurumada, T | 1 |
| Ohta, U | 1 |
| Kobayashi, H | 1 |
| Harasawa, S | 2 |
| Miwa, T | 2 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 3 |
| Ueda, F | 1 |
| Suzuki, Y | 2 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 1 |
| Asaki, S | 2 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Ashida, K | 2 |
| Sakaguchi, M | 1 |
| Tanaka, M | 1 |
| Takiuchi, H | 1 |
| Egashira, Y | 1 |
| Katsu, K | 1 |
| Ito, G | 1 |
| Nakagawara, M | 1 |
| Watanabe, F | 1 |
| Ooi, S | 1 |
| Nawano, M | 1 |
| Hoshino, E | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 2 |
| Miyashita, H | 1 |
| Mine, T | 3 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Ogoshi, K | 1 |
| Kato, T | 2 |
| Sakagawa, T | 1 |
| Tonnarini, GF | 1 |
| Delle Fave, G | 6 |
| Chianelli, M | 1 |
| Mariani, P | 1 |
| Negri, M | 1 |
| Beker, JA | 3 |
| Bianchi Porro, G | 18 |
| Bigard, MA | 3 |
| Devis, G | 2 |
| Gouerou, H | 1 |
| Maier, C | 2 |
| Eriksson, S | 7 |
| Rikner, L | 2 |
| Carlsson, R | 1 |
| Bisi, G | 1 |
| Dalla Libera, M | 2 |
| Gullini, S | 3 |
| Tartari, V | 1 |
| Caravita, L | 1 |
| Massari, M | 1 |
| Cappellari, L | 1 |
| Zibordi, U | 1 |
| Matarese, V | 2 |
| Ponce, J | 3 |
| Nos, P | 1 |
| Alam, SE | 2 |
| Jaspersen, D | 2 |
| Körner, T | 1 |
| Schorr, W | 2 |
| Brennenstuhl, M | 2 |
| Hammar, CH | 2 |
| Miehlke, S | 3 |
| Bayerdörffer, E | 7 |
| Lehn, N | 3 |
| Mannes, GA | 4 |
| Sommer, A | 3 |
| Höchter, W | 3 |
| Weingart, J | 3 |
| Hatz, R | 2 |
| Ruckdeschel, G | 2 |
| Dirschedl, P | 2 |
| Maculotti, L | 1 |
| Pradella, P | 1 |
| Saberi-Firoozi, M | 1 |
| Massarrat, S | 4 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Dehbashi, N | 1 |
| Ling, TK | 7 |
| Suen, R | 2 |
| Cheng, AF | 5 |
| Li, AK | 5 |
| Blum, AL | 6 |
| Jorias, I | 1 |
| Leverkus, F | 2 |
| Sollböhmer, M | 1 |
| Bertrams, J | 3 |
| Lamouliatte, H | 3 |
| Kohli, Y | 1 |
| Azuma, T | 1 |
| Ito, S | 1 |
| Hirai, M | 1 |
| Koerner, T | 1 |
| Raschka, C | 1 |
| Lazzaroni, M | 12 |
| Maconi, G | 5 |
| Bargiggia, S | 4 |
| Minguzzi, M | 1 |
| Andersson, T | 1 |
| Hässle, A | 1 |
| Heldwein, W | 1 |
| Klann, H | 1 |
| Simon, T | 1 |
| Schmitt, W | 1 |
| Forné, M | 2 |
| Viver, JM | 2 |
| Espinós, JC | 2 |
| Coll, I | 1 |
| Tresserra, F | 1 |
| Garau, J | 2 |
| Park, KN | 1 |
| Hahm, JS | 1 |
| Louw, JA | 4 |
| Lucke, W | 3 |
| Jaskiewicz, K | 3 |
| Lastovica, AJ | 1 |
| Winter, TA | 2 |
| Marks, IN | 9 |
| Michel, P | 1 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 2 |
| Colin, R | 2 |
| Bergmann, JF | 1 |
| Barbier, JP | 1 |
| Abitbol, V | 1 |
| Hamelin, B | 2 |
| Ekström, P | 1 |
| Carling, L | 2 |
| Unge, P | 5 |
| Anker-Hansen, O | 1 |
| Sjöstedt, S | 2 |
| Sellström, H | 1 |
| Agrawal, NM | 1 |
| Cremer, M | 1 |
| Lambert, R | 1 |
| Lamers, CB | 9 |
| Alvarez Baleriola, I | 6 |
| Redondo, C | 4 |
| De Rafael, L | 3 |
| Kountouras, J | 1 |
| Boura, P | 1 |
| Apostolides, G | 1 |
| Zaharioudaki, E | 1 |
| Tsapas, G | 1 |
| Schneider, S | 1 |
| Hébuterne, X | 1 |
| Chichmanian, RM | 1 |
| Rampal, P | 1 |
| Wagner, S | 1 |
| Beil, W | 1 |
| Mai, UE | 1 |
| Bokemeyer, C | 1 |
| Meyer, HJ | 1 |
| Manns, MP | 1 |
| Adamek, RJ | 6 |
| Freitag, M | 2 |
| Opferkuch, W | 3 |
| Rühl, GH | 4 |
| Wegener, M | 3 |
| Kraus, A | 1 |
| Flores-Suárez, LF | 1 |
| Rantala, A | 1 |
| Ovaska, J | 1 |
| Hunt, RH | 11 |
| Dent, J | 2 |
| Halter, F | 1 |
| Howden, C | 1 |
| Rune, S | 2 |
| Rune, SJ | 5 |
| Russo, A | 3 |
| Lanzafame, S | 1 |
| Magnano, A | 1 |
| Giannone, N | 1 |
| Cosentino, S | 1 |
| Atherton, JC | 1 |
| Hudson, N | 1 |
| Kirk, GE | 1 |
| Hawkey, CK | 1 |
| Spiller, RC | 3 |
| Corinaldesi, R | 3 |
| Barbara, L | 3 |
| Capurso, L | 2 |
| Paoluzi, P | 1 |
| Mangiameli, A | 2 |
| Sabbatini, F | 1 |
| Franceschi, M | 5 |
| Bolling, E | 2 |
| Dominguez, HL | 1 |
| Freston, JW | 1 |
| Vetvik, K | 1 |
| Schrumpf, E | 1 |
| Mowinckel, P | 1 |
| Aase, S | 1 |
| Andersen, KJ | 1 |
| Simsek, H | 1 |
| Arslan, M | 1 |
| Tatar, G | 1 |
| Pan, S | 1 |
| Liao, CH | 1 |
| Lien, GS | 1 |
| Chen, SH | 1 |
| Archimandritis, A | 6 |
| Balatsos, V | 3 |
| Delis, V | 3 |
| Mentis, A | 1 |
| Kastanas, K | 1 |
| Scandalis, N | 1 |
| Arizón Deza, P | 1 |
| García Tenorio, A | 1 |
| Gonzalo Til, A | 1 |
| Manero Ruiz, I | 1 |
| Mur Lalueza, MJ | 1 |
| Pascual Parrilla, MS | 1 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| Ricken, D | 1 |
| Logan, RP | 5 |
| Walker, MM | 2 |
| Gummett, PA | 2 |
| Karim, QN | 1 |
| Baron, JH | 7 |
| Domian, C | 1 |
| Kiilerich, S | 2 |
| Rannem, T | 1 |
| Elsborg, L | 2 |
| Degtiareva, II | 1 |
| Semeunovich, S | 1 |
| Kharchenko, NV | 1 |
| Petrovich, S | 1 |
| Gaĭsenko, AV | 1 |
| Egorova, IT | 1 |
| Hosking, SW | 3 |
| Yung, MY | 6 |
| Savarino, V | 13 |
| Vigneri, S | 8 |
| Mela, GS | 12 |
| Termini, R | 4 |
| Celle, G | 11 |
| Sheptulin, AA | 1 |
| Florent, C | 1 |
| Nishida, A | 1 |
| Takinami, Y | 1 |
| Yuki, H | 1 |
| Kobayashi, A | 1 |
| Akuzawa, S | 1 |
| Kamato, T | 1 |
| Ito, H | 2 |
| Yamano, M | 1 |
| Nagakura, Y | 1 |
| Miyata, K | 1 |
| Iwasaki, A | 1 |
| Miyazawa, K | 1 |
| Kawamura, Y | 1 |
| Sakai, Y | 1 |
| Tashiro, Y | 1 |
| Ito, K | 1 |
| Arakawa, Y | 1 |
| Matsuo, Y | 1 |
| Arber, N | 1 |
| Avni, Y | 1 |
| Eliakim, R | 1 |
| Swissa, A | 1 |
| Melzer, E | 1 |
| Rachmilewitz, D | 2 |
| Konikoff, F | 1 |
| Bardan, E | 1 |
| Bar-Meir, S | 1 |
| Fujii, T | 1 |
| Nakano, K | 1 |
| Naganuma, H | 1 |
| Nakagawa, H | 3 |
| Kayser, L | 1 |
| Møller, B | 1 |
| Harting, K | 1 |
| Pérez Flores, R | 1 |
| García Molinero, MJ | 1 |
| Herrero Quirós, C | 1 |
| Blasco Colmenarejo, MM | 1 |
| Caneiro Alcubilla, E | 1 |
| García-Rayo Somoza, M | 1 |
| Cabot Lozano, A | 1 |
| Zentilin, P | 8 |
| Cutela, P | 3 |
| Mele, MR | 3 |
| Perilli, D | 1 |
| Vassallo, A | 2 |
| Zambotti, A | 1 |
| Mansi, C | 3 |
| al-Assi, MT | 1 |
| Genta, RM | 1 |
| Graham, DY | 7 |
| Festen, HP | 2 |
| Solcia, E | 3 |
| Villani, L | 3 |
| Luinetti, O | 2 |
| Boldorini, R | 1 |
| Trespi, E | 2 |
| Perego, M | 2 |
| Alvisi, C | 2 |
| Howden, CW | 6 |
| Burget, DW | 4 |
| Lanza, F | 4 |
| Goff, J | 2 |
| Scowcroft, C | 1 |
| Jennings, D | 2 |
| Greski-Rose, P | 2 |
| Di Mario, F | 4 |
| Pantalena, M | 1 |
| Muratore, F | 1 |
| Scialabba, A | 2 |
| Badalamenti, S | 1 |
| Netchvolodoff, CV | 1 |
| Fraser, AG | 2 |
| Arens, MJ | 1 |
| Mazumder, DN | 2 |
| Hashimoto, F | 1 |
| Davis, RL | 1 |
| Egli, D | 1 |
| Schaufelberger, HD | 1 |
| Greaves, RR | 1 |
| Mendelson, GM | 1 |
| Thomas, PH | 1 |
| Rehner, M | 5 |
| Witzel, L | 3 |
| Brunner, G | 6 |
| Harke, U | 2 |
| Judmaier, G | 1 |
| Koelz, HR | 1 |
| Seifert, E | 1 |
| Maniatis, AG | 1 |
| Brazer, SR | 1 |
| Pallone, F | 2 |
| Luzza, F | 2 |
| Annibale, B | 4 |
| Marcheggiano, A | 2 |
| Biancone, L | 1 |
| Torsoli, A | 2 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| McCarthy, CJ | 1 |
| Collins, R | 2 |
| Beattie, S | 2 |
| Hamilton, H | 1 |
| O'Morain, C | 9 |
| Yamaguchi, T | 1 |
| Aihara, K | 1 |
| Yamada, S | 1 |
| Narita, S | 1 |
| Kogi, K | 1 |
| Biemond, I | 2 |
| Kreuning, J | 1 |
| Jansen, JB | 4 |
| Long, RG | 1 |
| Bardhan, KD | 13 |
| Wormsley, KG | 1 |
| Cochran, KM | 1 |
| Christian, J | 1 |
| Moules, IK | 1 |
| Shi, GY | 1 |
| Chen, SP | 2 |
| Bei, L | 2 |
| Wen, SH | 1 |
| Dhawan, P | 1 |
| Amarapurkar, DN | 1 |
| Kalro, RH | 1 |
| Castellote, E | 1 |
| Bonet, J | 1 |
| Lauzurica, R | 1 |
| Pastor, C | 1 |
| Cofan, F | 1 |
| Caralps, A | 1 |
| Mela, MR | 1 |
| Dallorto, E | 1 |
| Bour, B | 1 |
| Garcia, E | 1 |
| Petite, JP | 1 |
| Slama, JL | 1 |
| Licht, H | 1 |
| Lemerez, M | 1 |
| Coste, T | 1 |
| Andrieu, J | 1 |
| Grimaud, JC | 1 |
| Julien, H | 1 |
| Dupuis, J | 1 |
| Zelenková, J | 1 |
| Soucková, A | 1 |
| Drábek, J | 1 |
| Hanika, J | 1 |
| Vejvalka, J | 1 |
| Zeman, V | 1 |
| Valentini, M | 1 |
| Bortoluzzi, F | 1 |
| Cernigoi, C | 1 |
| Toffoli, G | 1 |
| Bertolissi, E | 1 |
| Cannizzaro, R | 1 |
| Sozzi, M | 1 |
| Fornasarig, M | 1 |
| Grasso, GA | 1 |
| Battaglia, G | 1 |
| De Boni, M | 1 |
| Vianello, F | 1 |
| De Bona, M | 1 |
| Pasquino, M | 1 |
| Chiozzini, G | 1 |
| Saggioro, A | 2 |
| Xia, HX | 2 |
| Devault, K | 1 |
| Dallera, F | 1 |
| Gendarini, A | 1 |
| Scanzi, G | 1 |
| Massuda, H | 1 |
| Chinzon, D | 1 |
| Miszputen, S | 1 |
| Kendo, M | 1 |
| Silva, AE | 1 |
| Ferrari Júnior, AP | 1 |
| Castro, LP | 1 |
| Castro, FJ | 1 |
| Protzer, U | 1 |
| Holtermüller, KH | 1 |
| Gyenes, E | 1 |
| Mignon, M | 3 |
| Vallot, T | 2 |
| Arnold, R | 5 |
| Hennig, U | 2 |
| Fuchs, W | 1 |
| Justesen, T | 2 |
| Hansen, JM | 1 |
| Jensen, TG | 1 |
| Eriksen, J | 4 |
| Thomsen, OO | 1 |
| Scheibel, J | 1 |
| Bonnevie, O | 3 |
| Bremmelgaard, A | 1 |
| Vilien, M | 2 |
| Huber, R | 1 |
| Kohl, B | 1 |
| Sachs, G | 2 |
| Senn-Bilfinger, J | 1 |
| Simon, WA | 1 |
| Sturm, E | 1 |
| Rohner, HG | 2 |
| Celestin, LR | 1 |
| Theodossi, A | 1 |
| Palmer, KR | 1 |
| Reed, PI | 1 |
| Biasco, G | 2 |
| Cifani, F | 1 |
| DeFanis, C | 1 |
| Falcucci, M | 1 |
| Ferrini, G | 1 |
| Grossi, L | 2 |
| Iannetti, G | 1 |
| Larcinese, G | 1 |
| Lattanzio, R | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 1 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Khulusi, S | 1 |
| Badve, S | 1 |
| Patel, P | 1 |
| Lloyd, R | 1 |
| Marrero, JM | 1 |
| Finlayson, C | 1 |
| Mendall, MA | 1 |
| Northfield, TC | 1 |
| Diehl, HG | 1 |
| Avner, DL | 1 |
| Dorsch, ER | 1 |
| Jennings, DE | 2 |
| Greski-Rose, PA | 1 |
| Bell, GD | 4 |
| Bate, CM | 4 |
| Axon, AT | 2 |
| Tildesley, G | 2 |
| Kerr, GD | 3 |
| Green, JR | 2 |
| Emmas, CE | 1 |
| Taylor, MD | 2 |
| Lanas, A | 2 |
| Artal, A | 2 |
| Blás, JM | 2 |
| Arroyo, MT | 1 |
| Lopez-Zaborras, J | 1 |
| Sáinz, R | 2 |
| de Boer, WA | 2 |
| Driessen, WM | 1 |
| Poynard, T | 2 |
| Lemaire, M | 1 |
| Agostini, H | 1 |
| Lorenzetti, M | 1 |
| Marchetti, P | 1 |
| Volpe, L | 1 |
| Navalesi, R | 1 |
| Schütze, K | 1 |
| Hentschel, E | 2 |
| Vakil, N | 2 |
| Fennerty, MB | 1 |
| Treiber, G | 3 |
| Bertoni, G | 1 |
| Sassatelli, R | 1 |
| Nigrisoli, E | 1 |
| Tansini, P | 1 |
| Bianchi, G | 1 |
| Della Casa, G | 1 |
| Bagni, A | 1 |
| Bedogni, G | 1 |
| Davis, S | 1 |
| Idström, JP | 4 |
| Verdú, EF | 1 |
| Lau, JY | 2 |
| Sjöström, JE | 1 |
| Larsson, H | 1 |
| García, M | 1 |
| Barrao, ME | 1 |
| Moliner, FJ | 1 |
| López, J | 1 |
| Oksüzöğlu, G | 1 |
| Mur, M | 2 |
| Ceña, G | 2 |
| Martín, C | 1 |
| Monés, J | 2 |
| Cesana, B | 2 |
| Figueroa, G | 2 |
| Acuña, R | 2 |
| Troncoso, M | 2 |
| Portell, DP | 2 |
| Toledo, MS | 2 |
| Albornoz, V | 1 |
| Vigneaux, J | 1 |
| Tari, A | 1 |
| Hamada, M | 1 |
| Kamiyasu, T | 1 |
| Fukino, Y | 1 |
| Sumii, M | 1 |
| Haruma, K | 2 |
| Sumii, K | 2 |
| Inoue, M | 1 |
| Kajiyama, G | 3 |
| Zala, G | 1 |
| Schwery, S | 1 |
| Giezendanner, S | 1 |
| Flury, R | 2 |
| Wüst, J | 1 |
| Meyenberger, C | 1 |
| Wirth, HP | 2 |
| Pei, Y | 1 |
| Wang, B | 1 |
| Chen, S | 2 |
| Dresner, D | 1 |
| Coyle, W | 1 |
| Nemec, R | 1 |
| Peterson, R | 1 |
| Duntemann, T | 1 |
| Lawson, JM | 1 |
| Jönsson, B | 2 |
| Carlsson, J | 1 |
| Rudbäck, A | 1 |
| Zeijlon, L | 2 |
| Carrère, MO | 1 |
| Auquier, P | 1 |
| Sambuc, R | 1 |
| Pazzi, P | 2 |
| Carli, G | 1 |
| Gamberini, S | 2 |
| Scagliarini, R | 2 |
| Merighi, A | 1 |
| Parente, F | 3 |
| Colombo, E | 2 |
| Rosengren, H | 1 |
| Polson, RJ | 1 |
| Di Campli, E | 1 |
| Masulli, M | 1 |
| Di Bartolomeo, S | 1 |
| Allocati, N | 2 |
| Santander, C | 2 |
| Grávalos, RG | 1 |
| Gómez-Cedenilla, A | 1 |
| Cantero, J | 1 |
| Pajares, JM | 5 |
| Stermer, E | 1 |
| Levy, N | 1 |
| Ebina, K | 1 |
| Fujii, K | 1 |
| Chiba, H | 1 |
| Sito, E | 1 |
| Kwiecień, N | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 3 |
| Hahn, EG | 2 |
| Roesch, W | 1 |
| Parasakthi, N | 1 |
| Peh, SC | 3 |
| Anderson, PE | 2 |
| Tan, KK | 2 |
| Weldon, MJ | 1 |
| Broadbent, A | 1 |
| Chambers, S | 1 |
| Mistry, R | 1 |
| Ranganath, L | 1 |
| Gould, SR | 1 |
| Pommerien, W | 1 |
| Schultze, V | 1 |
| Braden, B | 1 |
| Lembcke, B | 1 |
| Wrangstadh, M | 5 |
| Londong, W | 4 |
| van Etten, RJ | 1 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 1 |
| Tytgat, GN | 4 |
| Navaratnam, P | 2 |
| Wong, NW | 2 |
| Chuah, SY | 1 |
| Rahman, NA | 1 |
| Lo, YL | 1 |
| Avsar, E | 1 |
| Kalayci, C | 1 |
| Lawrence, R | 1 |
| Kiziltas, S | 1 |
| Gültekin, O | 1 |
| Ulusoy, NB | 1 |
| Bulgakov, SA | 1 |
| Segami, T | 1 |
| Ito, M | 1 |
| Phull, PS | 1 |
| Griffiths, AE | 1 |
| Halliday, D | 1 |
| Jacyna, MR | 1 |
| Goenka, MK | 2 |
| Kochhar, R | 1 |
| Chakrabarti, A | 1 |
| Kumar, A | 1 |
| Gupta, O | 1 |
| Talwar, P | 1 |
| Mehta, SK | 1 |
| Das, K | 1 |
| Vaiphei, K | 1 |
| Nijhawan, R | 1 |
| Kocbhar, R | 1 |
| Shaw, S | 1 |
| Schenk, BE | 1 |
| Kuipers, EJ | 1 |
| Klinkenberg-Knol, EC | 1 |
| Meuwissen, SG | 1 |
| Lewis, SJ | 1 |
| Franco, S | 1 |
| Young, G | 1 |
| O'Keefe, SJ | 3 |
| Martin, JL | 1 |
| Richardson, PD | 2 |
| Genta, R | 1 |
| Evans, DG | 1 |
| Reddy, R | 1 |
| Clarridge, JE | 1 |
| Olson, CA | 3 |
| Edmonds, AL | 1 |
| Siepman, N | 3 |
| Dhar, A | 2 |
| Gupta, VK | 1 |
| Srinivasan, S | 1 |
| Fitton, A | 1 |
| Wiseman, L | 1 |
| Brummer, RJ | 1 |
| Stockbrügger, RW | 1 |
| Kato, M | 1 |
| Kudo, M | 1 |
| Sukegawa, M | 1 |
| Koshiyama, T | 1 |
| Nishikawa, K | 1 |
| Hokari, K | 1 |
| Spadaccini, A | 1 |
| De Fanis, C | 1 |
| Sciampa, G | 1 |
| Masciulli, V | 1 |
| Pantaleone, U | 1 |
| Di Virgilio, M | 1 |
| Magnarini, C | 1 |
| Pizzicannella, G | 1 |
| Pérez, T | 1 |
| Jiménez, I | 2 |
| Maruyama, M | 1 |
| Kawano, S | 1 |
| Murakami, M | 1 |
| Saita, H | 2 |
| Tsuji, S | 1 |
| Moreno, JA | 1 |
| Carpintero, P | 1 |
| Hermida, C | 1 |
| Lara, S | 1 |
| García Grávalos, R | 2 |
| Magaudda, L | 1 |
| Mondello, MR | 1 |
| Di Mauro, DD | 1 |
| Pallio, S | 1 |
| Bottari, M | 1 |
| Reynaert, H | 1 |
| Fernandes, E | 1 |
| Bourgain, C | 1 |
| Smekens, L | 1 |
| Rubin, CE | 1 |
| Aller, R | 1 |
| Moshkowitz, M | 1 |
| Konikoff, FM | 1 |
| Peled, Y | 1 |
| Brill, S | 1 |
| Hallak, A | 1 |
| Tiomny, E | 1 |
| Santo, M | 1 |
| Bujanover, Y | 1 |
| Gilat, T | 1 |
| Meining, A | 2 |
| Bästlein, E | 1 |
| Baba, S | 2 |
| Shortridge, VD | 1 |
| Stone, GG | 2 |
| Flamm, RK | 2 |
| Beyer, J | 2 |
| Versalovic, J | 1 |
| Graham, DW | 1 |
| Tanaka, SK | 2 |
| Pérez García, JI | 1 |
| Fric, P | 1 |
| Huslarová, A | 1 |
| Dítĕ, P | 2 |
| Jirásek, V | 1 |
| Roth, Z | 1 |
| Svoboda, J | 1 |
| Drazná, E | 1 |
| Dufek, V | 1 |
| Dvorák, M | 1 |
| Kunovská, M | 1 |
| Münzová, H | 1 |
| Pelech, T | 1 |
| Petrtýl, J | 1 |
| Zádorová, Z | 1 |
| Zavoral, M | 1 |
| Paar, D | 1 |
| Terjung, B | 1 |
| Sauerbruch, T | 1 |
| Vreeburg, EM | 2 |
| de Bruijne, HW | 1 |
| Snel, P | 3 |
| Bartelsman, JW | 1 |
| Rauws, EA | 2 |
| Caselli, M | 2 |
| Trevisani, L | 2 |
| Tursi, A | 1 |
| Sartori, S | 2 |
| Ruina, M | 2 |
| Luzzi, I | 1 |
| Gaudenzi, P | 1 |
| Alvisi, V | 2 |
| Ardizzone, S | 1 |
| La Corte, R | 1 |
| Bajocchi, G | 1 |
| Trotta, F | 1 |
| Dohil, R | 1 |
| Israel, DM | 1 |
| Hassall, E | 1 |
| Lerang, F | 1 |
| Moum, B | 1 |
| Haug, JB | 1 |
| Tolås, P | 1 |
| Breder, O | 1 |
| Aubert, E | 1 |
| Høie, O | 1 |
| Søberg, T | 1 |
| Flaaten, B | 1 |
| Farup, P | 1 |
| Berge, T | 1 |
| Weismüller, J | 1 |
| Lütke, A | 1 |
| d'Adamo, G | 1 |
| Spinelli, C | 1 |
| Forte, F | 1 |
| Gangeri, F | 1 |
| Kung, NN | 2 |
| Yuen, NW | 1 |
| Ng, PW | 1 |
| Wong, KC | 1 |
| Chung, EC | 1 |
| Lim, BH | 1 |
| Choi, CH | 1 |
| Li, TH | 1 |
| Ma, HC | 1 |
| Kwok, SP | 1 |
| Lee, YT | 2 |
| Chan, LY | 1 |
| Khuroo, MS | 1 |
| Yattoo, GN | 1 |
| Shah, AA | 1 |
| Sodi, JS | 1 |
| Klotz, U | 1 |
| Verdú, E | 2 |
| Schaffalitzky de Muckadell, OB | 1 |
| Havelund, T | 3 |
| Harling, H | 1 |
| Boesby, S | 1 |
| Fernström, P | 2 |
| Hasselgren, G | 5 |
| Lundell, L | 1 |
| Aadland, E | 1 |
| Efskind, P | 1 |
| Falk, A | 1 |
| Hyltander, A | 1 |
| Söderlund, C | 1 |
| Berstad, A | 1 |
| Mikus, D | 1 |
| Grabarević, Z | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Jagić, V | 1 |
| Turković, B | 1 |
| Rotkvić, I | 1 |
| Zoricić, I | 1 |
| Perić, J | 1 |
| Konjevoda, P | 1 |
| Perović, D | 1 |
| Jurina, L | 1 |
| Hanzevacki, M | 1 |
| Separović, J | 1 |
| Jadrijević, S | 1 |
| Jelovac, N | 1 |
| Miklić, P | 1 |
| Buljat, G | 1 |
| Marović, A | 1 |
| Seki, H | 1 |
| Leusing, C | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Shibata, T | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Abraira, V | 3 |
| Wang, K | 1 |
| Vcev, A | 7 |
| Vuković, D | 2 |
| Ivandić, A | 6 |
| Vceva, A | 7 |
| Dmitrović, B | 4 |
| Kovacić, D | 1 |
| Volaric, M | 1 |
| Paulini, D | 1 |
| Mićunović, N | 2 |
| Horvat, D | 1 |
| Mihaljević, S | 3 |
| Dekker, CP | 1 |
| Farley, A | 2 |
| Klör, HU | 2 |
| Jönsson, A | 1 |
| Kayser, S | 1 |
| Zbinden, R | 1 |
| Fried, M | 1 |
| Fleischmann, R | 1 |
| Demharter, R | 1 |
| Barnert, J | 1 |
| Füger, K | 1 |
| Wienbeck, M | 1 |
| Busch, R | 1 |
| Munkel, L | 1 |
| French, L | 1 |
| Rinaldi, V | 1 |
| Diana, F | 1 |
| Pugliano, F | 1 |
| Attili, AF | 1 |
| Pohle, T | 1 |
| Hilker, E | 1 |
| Domschke, W | 3 |
| Rudnicka, L | 1 |
| Bobrzyński, A | 2 |
| Stachura, J | 2 |
| Tan, WC | 1 |
| Hogan, J | 1 |
| Purkayastha, SK | 1 |
| Lombard, M | 1 |
| Krasner, N | 1 |
| Skála, I | 1 |
| Marecková, O | 1 |
| Vítko, S | 1 |
| Matl, I | 1 |
| Lácha, J | 1 |
| Kobler, E | 1 |
| Werth, B | 1 |
| Wüst, W | 1 |
| Reinhart, WH | 1 |
| Cardi, M | 1 |
| Muttillo, IA | 1 |
| Amadori, L | 1 |
| Barillari, P | 1 |
| Sammartino, P | 1 |
| Arnone, F | 1 |
| Signorelli, C | 1 |
| Bolognese, A | 1 |
| Shortridge, D | 1 |
| Ghoneim, AT | 1 |
| Uemura, N | 1 |
| Oomoto, Y | 1 |
| Mukai, T | 1 |
| Okamoto, S | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Taniyama, K | 1 |
| Sasaki, N | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Cottrill, MR | 1 |
| McKinnon, C | 1 |
| Mason, I | 1 |
| Chesters, SA | 1 |
| Slatcher, G | 1 |
| Copeman, MB | 1 |
| Turbitt, ML | 1 |
| Wurzer, H | 1 |
| Rodrigo, L | 2 |
| Stamler, D | 1 |
| Archambault, A | 1 |
| Rokkas, T | 2 |
| Skandalis, N | 3 |
| Fedorak, R | 1 |
| Mora, P | 1 |
| Megraud, F | 4 |
| Buckley, MJ | 1 |
| Hyde, DM | 1 |
| Keane, CT | 1 |
| O'Morain, CA | 3 |
| Harford, W | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Haber, M | 3 |
| Weissfeld, A | 2 |
| Rose, P | 3 |
| Jaup, BK | 1 |
| Dettmer, A | 1 |
| Rambow, A | 1 |
| von Fritsch, E | 1 |
| Veldhuyzen van Zanten, S | 2 |
| Spiller, R | 1 |
| Bradette, M | 2 |
| Chiba, N | 1 |
| Srinivasan, R | 1 |
| Minocha, A | 1 |
| O'Connor, HJ | 1 |
| Loane, J | 1 |
| Bindel, H | 1 |
| Bhutta, AS | 1 |
| Cunnane, K | 1 |
| Gedliczka, O | 1 |
| Konturek, S | 1 |
| Budzyński, A | 1 |
| Neil, GA | 2 |
| Suchower, LJ | 2 |
| Ronca, PD | 2 |
| Skoglund, ML | 2 |
| Pieramico, O | 1 |
| Zanetti, MV | 1 |
| Innerhofer, M | 1 |
| Malfertheiner, P | 2 |
| Papp, J | 1 |
| Döbrönte, Z | 1 |
| Juhász, L | 2 |
| Lonovics, J | 1 |
| Laszewicz, W | 1 |
| Dzieniszewski, J | 1 |
| Ciok, J | 1 |
| Marlicz, K | 1 |
| Bielecki, D | 1 |
| Popiela, T | 1 |
| Legutko, J | 1 |
| Knapik, Z | 1 |
| Poniewierka, E | 1 |
| Deltenre, M | 1 |
| Ilunga, KO | 1 |
| Silvers, D | 1 |
| Winters, J | 1 |
| Jhala, N | 1 |
| Esteve, M | 1 |
| Fernández-Bañares, F | 1 |
| Lite, J | 1 |
| Quintana, S | 1 |
| Salas, A | 1 |
| Harris, AW | 2 |
| Levi, S | 2 |
| Cooper, BT | 2 |
| Dixon, MF | 2 |
| Langworthy, H | 2 |
| Piper, D | 2 |
| Loo, VG | 1 |
| Fallone, CA | 1 |
| De Souza, E | 1 |
| Lavallée, J | 1 |
| Barkun, AN | 1 |
| Faucheux, JM | 1 |
| Tournebize, P | 1 |
| Viguier, A | 1 |
| Arne-Bes, MC | 1 |
| Larrue, V | 1 |
| Géraud, G | 1 |
| Tzivras, M | 2 |
| Souyioultzis, S | 2 |
| Kanellopoulou, E | 1 |
| Manika, Z | 2 |
| Davaris, P | 2 |
| Takac, B | 6 |
| Gardasanić, J | 1 |
| Horonitz, M | 1 |
| Karner, I | 2 |
| Dattilo, M | 1 |
| Suzuki, M | 3 |
| Mori, M | 2 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Karrasch, JA | 1 |
| Szczepañski, L | 1 |
| Walker, DG | 1 |
| Barkun, A | 1 |
| Tulassay, Z | 4 |
| Rácz, I | 1 |
| Howard, JM | 1 |
| van Rensburg, CJ | 2 |
| Boixeda de Miquel, D | 2 |
| Bordi, C | 3 |
| Pilato, FP | 2 |
| Damilano, I | 1 |
| Berquist, WE | 1 |
| Moreno, L | 2 |
| Suchower, L | 3 |
| Johnson, E | 3 |
| Ronca, P | 2 |
| Neil, G | 3 |
| Glaser, J | 1 |
| Hein, J | 1 |
| Daikeler, R | 1 |
| Weithofer, G | 1 |
| Vieth, M | 2 |
| Schmidt, M | 1 |
| Suzuki, J | 2 |
| Kobayasi, I | 2 |
| Fujita, T | 2 |
| Lanas Arbeloa, A | 1 |
| Serrano Aulló, MT | 1 |
| Carnicer, J | 1 |
| Konar, A | 1 |
| Das, AS | 1 |
| De, PK | 1 |
| Roy, A | 1 |
| Sonnenberg, A | 4 |
| Schwartz, JS | 2 |
| Cutler, AF | 1 |
| Bloom, BS | 1 |
| Koizumi, W | 1 |
| Tanabe, S | 1 |
| Hibi, K | 1 |
| Imaizumi, H | 1 |
| Ohida, M | 1 |
| Okabe, H | 1 |
| Saigenji, K | 1 |
| Okayasu, I | 1 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Sahba, B | 1 |
| Freston, J | 1 |
| Mehdi, A | 1 |
| Ajmi, S | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Humphries, TJ | 3 |
| Bassion, S | 1 |
| Delcò, F | 1 |
| El-Serag, HB | 1 |
| Liu, W | 1 |
| Lü, B | 1 |
| Xiao, S | 1 |
| Chen, Z | 1 |
| Takashima, M | 4 |
| Kajimura, M | 2 |
| Tucci, A | 1 |
| Poli, L | 1 |
| Paparo, GF | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 1 |
| Caletti, G | 1 |
| Katsorida, M | 1 |
| Woo, TW | 1 |
| Chang, MS | 1 |
| Chung, YK | 1 |
| Kim, KB | 1 |
| Sohn, SK | 1 |
| Kim, SG | 2 |
| Choi, WS | 1 |
| Macri, G | 1 |
| Milani, S | 1 |
| Surrenti, E | 2 |
| Passaleva, MT | 1 |
| Salvadori, G | 1 |
| Surrenti, C | 2 |
| Stimac, D | 5 |
| Kovac, D | 2 |
| Kolkman, JJ | 1 |
| Tan, TG | 1 |
| Oudkerk Pool, M | 1 |
| Van Kleef, WA | 1 |
| Geraedts, AA | 1 |
| Timmerman, RJ | 1 |
| Crobach, LF | 3 |
| Nicolai, JJ | 2 |
| Wolff, AA | 1 |
| Van Der Laan, J | 1 |
| Sanfélix Genovés, J | 1 |
| Pereiró Berenguer, I | 1 |
| Jimeno Bernard, R | 1 |
| García Tell, G | 1 |
| Navarro Pérez, J | 1 |
| Bonet Pla, A | 1 |
| Ballester Belenguer, J | 1 |
| Lambert, JR | 1 |
| Hanslo, D | 1 |
| Grundlings, HD | 1 |
| Girdwood, AH | 1 |
| Bal, C | 1 |
| Manzionna, G | 1 |
| Petrillo, M | 2 |
| Hwang, C | 1 |
| Cullen, D | 1 |
| Eisner, M | 1 |
| Kogut, DG | 1 |
| Thomson, JM | 1 |
| Catanzaro, R | 4 |
| Condorelli, G | 1 |
| Cipolla, R | 4 |
| Przytulski, K | 1 |
| Regula, J | 1 |
| Dziurkowska-Marek, A | 1 |
| Kohut, M | 1 |
| Hennig, E | 1 |
| Marek, T | 1 |
| Ostrowski, J | 1 |
| Nowak, A | 1 |
| Butruk, E | 1 |
| Blandizzi, C | 1 |
| Malizia, T | 1 |
| Gherardi, G | 1 |
| Costa, F | 1 |
| Marchi, S | 1 |
| Marveggio, C | 1 |
| Natale, G | 1 |
| Senesi, S | 1 |
| Bellini, M | 1 |
| Maltinti, G | 1 |
| Campa, M | 1 |
| Tacca, MD | 1 |
| Ellenrieder, V | 1 |
| Fensterer, H | 1 |
| Waurick, M | 1 |
| Adler, G | 1 |
| Glasbrenner, B | 1 |
| Cecchi, R | 1 |
| Torelli, E | 1 |
| Rizzo, C | 1 |
| Kiel, G | 1 |
| Osato, MS | 1 |
| Zhang, J | 3 |
| Figura, N | 1 |
| Cayla, R | 1 |
| Zerbib, F | 1 |
| Forestier, S | 1 |
| de Mascarel, A | 1 |
| Joubert-Collin, M | 2 |
| Huang, WH | 1 |
| Ho, AS | 1 |
| Shyu, RY | 1 |
| Lee, SC | 1 |
| Lee, MM | 1 |
| Hsu, CT | 2 |
| Nebiki, H | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
| Ando, K | 1 |
| Uchida, T | 1 |
| Harihara, S | 1 |
| Kuroki, T | 1 |
| Diaz de Rojas, F | 3 |
| Berenguer, J | 1 |
| Aran-Suau, R | 1 |
| Da Silveira, JC | 1 |
| Clerch, L | 1 |
| Garcia Aparicio, P | 1 |
| Caswell, C | 1 |
| Lee, JM | 1 |
| Bethke, TD | 1 |
| González Carro, P | 1 |
| Legaz Huidobro, ML | 1 |
| Pérez Roldán, F | 1 |
| Ruíz Carrillo, F | 1 |
| Pedraza Martín, C | 1 |
| Sáez Bravo, JM | 1 |
| Frantz, J | 1 |
| Connors, A | 1 |
| Langman, MJ | 3 |
| Kashifard, M | 1 |
| Malekzadeh, R | 2 |
| Siavoshi, F | 1 |
| Mikaeli, J | 1 |
| Barrera Linares, F | 1 |
| Gomollón García, F | 1 |
| Caballero Herráez, P | 1 |
| Valdepérez Torrubia, JJ | 1 |
| Ritsuno, H | 1 |
| Ohnuma, K | 1 |
| Ramos, F | 1 |
| García Arata, I | 1 |
| Kirdeikis, P | 2 |
| Lee, J | 1 |
| Röhss, K | 2 |
| Kitahora, T | 2 |
| Nagahashi, S | 2 |
| Zhang, T | 1 |
| Winter, T | 2 |
| Ogden, J | 1 |
| Bisso, G | 1 |
| Pivari, M | 1 |
| Fiorucci, S | 2 |
| Usai, P | 1 |
| Malesci, A | 1 |
| Stimac, T | 1 |
| Pezerović, D | 3 |
| Blazanović, A | 1 |
| Lee, CT | 1 |
| Kuo, BI | 1 |
| Cutler, A | 1 |
| Chua, AB | 1 |
| Ding, RP | 1 |
| Kandasami, P | 1 |
| Mazlam, MZ | 1 |
| Raj, SM | 1 |
| Nilsson, F | 1 |
| Walder, M | 1 |
| García-Romero, E | 1 |
| del Val, A | 1 |
| Garrigues, V | 1 |
| Cuquerella, J | 1 |
| Higón, MD | 1 |
| Barrachina, M | 2 |
| Pons, V | 1 |
| Bixquert, M | 1 |
| Dekkers, CP | 1 |
| Thjodleifsson, B | 1 |
| Bell, NE | 1 |
| Zanten, SJ | 1 |
| Leddin, D | 1 |
| Ching, CK | 1 |
| Ho, J | 3 |
| Yuen, ST | 1 |
| Lau, GK | 2 |
| Lai, CL | 3 |
| Liu, WZ | 1 |
| Shi, Y | 1 |
| Zhang, DZ | 2 |
| Xu, WW | 1 |
| Sintonen, H | 1 |
| Alander, V | 1 |
| Barradell, LB | 2 |
| McTavish, D | 3 |
| Stålhammar, NO | 1 |
| Craig, AM | 1 |
| Davey, P | 1 |
| Malek, M | 1 |
| Murray, F | 1 |
| Badia, X | 1 |
| Segú, JL | 1 |
| Ollé, A | 1 |
| Brosa, M | 1 |
| García Ponte, L | 1 |
| Takeuchi, K | 2 |
| Konaka, A | 1 |
| Nishijima, M | 1 |
| Yasuhiro, T | 1 |
| Lad, R | 1 |
| Armstrong, D | 2 |
| Goddard, AF | 1 |
| Lawes, S | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Pauly, MP | 1 |
| Levenson, SD | 1 |
| Nie, Y | 2 |
| Wu, H | 2 |
| Sha, W | 2 |
| Du, H | 1 |
| Dai, S | 2 |
| Li, Q | 1 |
| Crowe, J | 1 |
| Thompson, RP | 1 |
| Trewby, PN | 1 |
| Keeling, PN | 1 |
| Weir, D | 1 |
| Crouch, SL | 1 |
| Kovacs, TO | 1 |
| Campbell, D | 1 |
| Richter, J | 1 |
| Raskin, JB | 1 |
| Owen, RJ | 1 |
| Slater, ER | 1 |
| Gibson, J | 1 |
| Lorenz, E | 1 |
| Tompkins, DS | 1 |
| Kromer, W | 3 |
| Horbach, S | 1 |
| Lühmann, R | 3 |
| Lehmann, FS | 1 |
| Beglinger, C | 2 |
| Nuciforo, G | 2 |
| Dobrilla, G | 2 |
| Piazzi, L | 1 |
| Rodríguez Téllez, M | 1 |
| Valenzuela Barranco, M | 1 |
| Caballero Plasencia, A | 1 |
| Martín Ruiz, J | 1 |
| López-Andrade, A | 1 |
| Carmona Soria, I | 1 |
| Herrerías Gutiérrez, J | 1 |
| Axon, A | 2 |
| Stoppino, V | 1 |
| Germano, MP | 1 |
| Frigerio, P | 1 |
| De Paolis, PL | 1 |
| Faleo, D | 1 |
| Fischer, DR | 1 |
| Nussbaum, MS | 1 |
| Pritts, TA | 1 |
| Gilinsky, NH | 1 |
| Weesner, RE | 1 |
| Martin, SP | 1 |
| Giannella, RA | 1 |
| Benoit, R | 1 |
| Grobost, O | 1 |
| Chen, SY | 1 |
| Wang, JY | 1 |
| Chen, J | 1 |
| Zhang, XD | 1 |
| Zhang, SS | 1 |
| Hixson, R | 1 |
| Christmas, D | 1 |
| Miller, JL | 1 |
| Tennvall, GR | 1 |
| Norinder, A | 1 |
| Ohlin, B | 1 |
| Adeyemi, EO | 1 |
| Danial, MF | 1 |
| Helal, T | 1 |
| Benedict, S | 1 |
| Abdulle, AM | 1 |
| Tseng, GY | 1 |
| Hsieh, YH | 1 |
| Lee, FY | 1 |
| Mach, T | 1 |
| Zahradnik-Bilska, J | 1 |
| Dani, R | 1 |
| Queiroz, DM | 1 |
| Dias, MG | 1 |
| Franco, JM | 1 |
| Magalhães, LC | 1 |
| Mendes, GS | 1 |
| Moreira, LS | 1 |
| De Castro, LP | 1 |
| Toppa, NH | 1 |
| Rocha, GA | 1 |
| Cabral, MM | 1 |
| Salles, PG | 1 |
| Martino, G | 1 |
| Paoletti, M | 1 |
| D'Ambra, G | 1 |
| Liatsos, C | 1 |
| Karameris, A | 1 |
| Petridou, E | 1 |
| Lazaris, A | 1 |
| Antoniades, D | 1 |
| Kalafatis, E | 1 |
| Sou, Y | 1 |
| Takahashi, Y | 1 |
| Yoshinaga, T | 1 |
| Matsukawa, Y | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Lauritsen, K | 5 |
| Rutgersson, K | 1 |
| Galmiche, JP | 3 |
| Archambault, AP | 2 |
| Gudjónsson, H | 1 |
| Bailey, RJ | 2 |
| Frison, L | 1 |
| Havu, N | 1 |
| Thompson, AB | 1 |
| Ge, ZZ | 1 |
| Hu, YB | 1 |
| Mao, HV | 1 |
| Lak, BV | 1 |
| Long, T | 1 |
| Chung, NQ | 1 |
| Thang, DM | 1 |
| Hop, TV | 1 |
| Chien, NN | 1 |
| Hoan, PQ | 1 |
| Henley, KS | 1 |
| Perez-Perez, GI | 1 |
| Connor, BA | 1 |
| Stone, CD | 1 |
| Chey, WD | 1 |
| Ivanikov, IO | 1 |
| Khomeriki, NM | 1 |
| Kudriavtseva, LV | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Moreira Vicente, V | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Meneghelli, UG | 1 |
| de Paula Castro, L | 1 |
| Malafaia, O | 1 |
| Lyra, LG | 1 |
| Hu, FL | 2 |
| Qian, SC | 1 |
| Huang, NX | 1 |
| Manan, C | 1 |
| Lesmana, L | 1 |
| Carpio, RE | 1 |
| Perez, JY | 2 |
| Fock, KM | 4 |
| Kachintorn, U | 1 |
| Phornphutkul, K | 1 |
| Kullavanijaya, P | 1 |
| Chelvam, P | 3 |
| Lim, SG | 1 |
| Nielsen, I | 1 |
| Tassinari, D | 1 |
| Panzini, I | 1 |
| Abbasciano, V | 1 |
| Fölsch, UR | 1 |
| von Kleist, DH | 1 |
| Kirchner, T | 1 |
| Strobel, S | 1 |
| Kist, M | 1 |
| Ng, EK | 1 |
| Lam, YH | 1 |
| Chan, AC | 1 |
| Lee, DW | 1 |
| Law, BK | 1 |
| Lau, WY | 3 |
| Sugimoto, M | 1 |
| Luman, W | 1 |
| Ling, KL | 1 |
| Ng, HS | 2 |
| Gomollón, F | 3 |
| Santolaria, S | 1 |
| Ducóns, JA | 1 |
| Guirao, R | 1 |
| Vera, J | 1 |
| Montoro, M | 1 |
| She, Q | 1 |
| Jia, L | 1 |
| Yu, W | 1 |
| Spinzi, GC | 1 |
| Boni, F | 1 |
| Bortoli, A | 1 |
| Ballardini, G | 1 |
| Venturelli, R | 1 |
| Minoli, G | 1 |
| Shashidhar, H | 1 |
| Peters, J | 1 |
| Lin, CH | 1 |
| Rabah, R | 1 |
| Thomas, R | 1 |
| Tolia, V | 1 |
| Breiter, JR | 1 |
| Riff, D | 1 |
| Dorta, G | 1 |
| Nicolet, M | 1 |
| Vouillamoz, D | 1 |
| Margalith, D | 1 |
| Saraga, E | 1 |
| Bouzourene, H | 1 |
| Häcki, WH | 1 |
| Vernet Vernet, M | 1 |
| Roca Figueras, G | 1 |
| Jovell Fernández, E | 1 |
| Iglesias Rodríguez, M | 1 |
| Ureña Tapia, MM | 1 |
| Roca Fusalba, A | 1 |
| Carpio, D | 1 |
| Michopoulos, S | 1 |
| Tsibouris, P | 1 |
| Bouzakis, H | 1 |
| Balta, A | 1 |
| Vougadiotis, J | 1 |
| Broutet, N | 1 |
| Kralios, N | 1 |
| Katelaris, PH | 1 |
| Adamthwaite, D | 1 |
| Midolo, P | 1 |
| Davidson, G | 1 |
| Lambert, J | 1 |
| Vukobrat-Bijedić, Z | 1 |
| Lacević, N | 1 |
| Bratović, I | 1 |
| Gribajcević, M | 2 |
| Gogov, B | 1 |
| Radović, S | 1 |
| Shirai, N | 2 |
| Xiao, F | 2 |
| Ohashi, K | 2 |
| Ishizaki, T | 2 |
| Perie, F | 1 |
| Johnson, D | 1 |
| Perdomo, C | 2 |
| Barth, J | 2 |
| Jokubaitis, L | 1 |
| Hui, WM | 4 |
| Vanis, N | 1 |
| Salaka, U | 1 |
| Pasalić, G | 1 |
| Valdepérez, J | 1 |
| Garuz, R | 1 |
| Fuentes, J | 1 |
| Barrera, F | 1 |
| Malo, J | 1 |
| Tirado, M | 1 |
| Simón, MA | 1 |
| Frevel, M | 1 |
| Daake, H | 1 |
| Janisch, HD | 1 |
| Kellner, HU | 1 |
| Krezdorn, HG | 1 |
| Tanneberger, D | 1 |
| Wack, R | 1 |
| Imbesi, V | 2 |
| Montrone, F | 1 |
| Santagada, T | 1 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Leandro, G | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Pilotto, A | 1 |
| Ronzani, G | 1 |
| Tafner, G | 1 |
| Buzás György, M | 1 |
| Székely, E | 1 |
| Illyés, G | 1 |
| Széles, I | 1 |
| Spencer, CM | 1 |
| Faulds, D | 2 |
| Frank, F | 1 |
| Stricker, T | 1 |
| Stallmach, T | 1 |
| Braegger, CP | 1 |
| Van Rensburg, C | 1 |
| Chen, PC | 1 |
| Schneider, H | 1 |
| Simjee, AE | 1 |
| Hamid, SS | 1 |
| Seebaran, A | 1 |
| Destefano, M | 1 |
| Hoshihara, Y | 1 |
| Sakaki, N | 1 |
| Nakamura, T | 1 |
| Ogawa, N | 2 |
| Yao, T | 1 |
| Muto, Y | 1 |
| Nakazawa, S | 1 |
| Takemoto, T | 1 |
| Bytzer, P | 3 |
| Aalykke, C | 1 |
| Weywadt, L | 1 |
| Gjørup, T | 1 |
| Bekker, C | 1 |
| Kromann-Andersen, H | 1 |
| Kjaergaard, J | 2 |
| Rask-Madsen, J | 4 |
| Hansen, J | 3 |
| Vyberg, M | 1 |
| Teglbjaerg, PS | 2 |
| Jungnickel, PW | 1 |
| De Argila, CM | 1 |
| Treichel, HC | 1 |
| Stubberöd, A | 1 |
| Cockeram, A | 1 |
| Göthe, L | 1 |
| Sicilia, B | 1 |
| Sierra, E | 1 |
| Lago, A | 1 |
| Villar, M | 1 |
| García, S | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Testoni, PA | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Befrits, R | 1 |
| Odman, B | 1 |
| Sörngård, H | 1 |
| Lindberg, G | 2 |
| Roberts, P | 1 |
| Williamson, R | 1 |
| Fakheri, H | 1 |
| Khatibian, M | 1 |
| Fazel, A | 1 |
| Alizadeh, BZ | 1 |
| Sugimura, H | 1 |
| Khor, CJ | 1 |
| Ng, TM | 2 |
| Teo, EK | 1 |
| Sim, CS | 1 |
| Tan, AL | 1 |
| Ng, A | 1 |
| Law, NM | 1 |
| Lim, CC | 1 |
| Niecestro, R | 1 |
| Shahin, WA | 1 |
| Abdel-Baset, EZ | 1 |
| Nassar, AK | 1 |
| Atta, MM | 1 |
| Kabil, SM | 1 |
| Murray, JA | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 1 |
| Fung, FM | 2 |
| Chu, KM | 1 |
| Liu, XG | 1 |
| Yuen, MF | 2 |
| Bardou, M | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Trimboli, V | 1 |
| Tepes, B | 1 |
| Krizman, I | 1 |
| Gorensek, M | 1 |
| Gubina, M | 1 |
| Orel, I | 1 |
| Meyer, JM | 1 |
| Silliman, NP | 1 |
| Dixon, CA | 1 |
| Siepman, NY | 1 |
| Sugg, JE | 1 |
| Hopkins, RJ | 1 |
| Bateson, MC | 2 |
| Ell, C | 1 |
| Schoerner, C | 1 |
| Solbach, W | 1 |
| Ridl, W | 1 |
| Moser, W | 1 |
| Oncel, M | 1 |
| Kurt, N | 1 |
| Walsh, M | 1 |
| Plein, K | 1 |
| Madisch, A | 1 |
| Hotz, J | 2 |
| Cucino, C | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Lebedev, EG | 1 |
| Dicheva, DT | 1 |
| Ovsiannikova, EV | 1 |
| Antonenko, OM | 1 |
| Yang, KC | 1 |
| Wang, CS | 1 |
| Kuo, CF | 1 |
| Antonova, PV | 1 |
| Masoodi, I | 1 |
| Bechi, P | 1 |
| Bacci, S | 1 |
| Cianchi, F | 1 |
| Amorosi, A | 2 |
| Nesi, G | 1 |
| Dei, R | 1 |
| Romagnoli, P | 1 |
| Rakov, AL | 1 |
| Makarov, IuS | 1 |
| Gorbakov, VV | 1 |
| Mironenko, DA | 1 |
| Golochalova, TV | 1 |
| Herszényi, L | 1 |
| Ikeda, S | 1 |
| Tamamuro, T | 1 |
| Hamashima, C | 1 |
| Vichev, E | 1 |
| Krŭstev, N | 1 |
| Krŭstev, D | 1 |
| Baeva, N | 1 |
| Kiselova, A | 1 |
| Ianev, N | 1 |
| Loginov, AS | 1 |
| Reshetnyak, VI | 1 |
| Dudik, TV | 1 |
| Vostroknutova, GN | 1 |
| Il'chenko, AA | 1 |
| Kaprel'yants, AS | 1 |
| Barnett, JL | 1 |
| Robinson, M | 1 |
| Yee, YK | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Tong, TS | 1 |
| Hui, CK | 1 |
| Kryszewski, A | 1 |
| Kleczkowski, D | 1 |
| Rudzinski, J | 1 |
| Bartuzi, Z | 1 |
| Larkö, A | 1 |
| Mai, AL | 1 |
| Mai, KT | 1 |
| Udd, M | 1 |
| Miettinen, P | 1 |
| Palmu, A | 1 |
| Heikkinen, M | 1 |
| Janatuinen, E | 1 |
| Pasanen, P | 1 |
| Tarvainen, R | 1 |
| Kairaluoma, MV | 1 |
| Lohman, M | 1 |
| Mustonen, H | 1 |
| Julkunen, R | 1 |
| Starostin, BD | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Kurbel, S | 1 |
| Ostojić, R | 1 |
| Barbir, A | 1 |
| Hovat, D | 1 |
| Odeh, M | 1 |
| Lurie, M | 1 |
| Oliven, A | 1 |
| Tran, TT | 1 |
| Quandalle, P | 1 |
| Mutoh, H | 1 |
| Sugano, K | 1 |
| Shchetkin, DI | 1 |
| Choi, IJ | 2 |
| Choi, KW | 1 |
| Kim, JH | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Rew, JS | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Chung, IS | 1 |
| Chung, JM | 1 |
| Hong, WS | 1 |
| Miyazawa, M | 1 |
| Suzuki, K | 1 |
| Hungin, AP | 1 |
| Jones, R | 1 |
| Tytgat, G | 1 |
| Kim, JS | 1 |
| Park, MJ | 1 |
| Kim, BG | 1 |
| Beliaeva, GS | 1 |
| Bordin, DS | 1 |
| Ciancio, G | 1 |
| Nuti, M | 1 |
| Orsini, B | 1 |
| Iovi, F | 1 |
| Ortolani, M | 1 |
| Palomba, A | 1 |
| Ilani, SM | 1 |
| Bown, RL | 1 |
| Akhmadkhodzhaev, AM | 1 |
| Gościmski, A | 1 |
| Matras, J | 1 |
| Wallner, G | 1 |
| Kulidzhanov, AIu | 1 |
| Usik, SF | 1 |
| Kheĭlyk, AI | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Adachi, K | 1 |
| Kawauchi, H | 1 |
| Kinoshita, Y | 1 |
| Norris, CM | 1 |
| McManus, PV | 1 |
| Petty, D | 1 |
| Kay, EA | 1 |
| Bliesath, H | 1 |
| Hartmann, M | 1 |
| Schneider, A | 2 |
| Wurst, W | 1 |
| Karasawa, H | 1 |
| McQuaid, KR | 1 |
| Isenberg, JI | 1 |
| Perroni, GB | 1 |
| De Matteis, G | 1 |
| Pellizzeri, F | 1 |
| Cassone, A | 1 |
| Malara, F | 1 |
| Perng, DS | 1 |
| Jan, CM | 1 |
| Chen, LT | 1 |
| Kaloustian, E | 1 |
| Veyssier, P | 1 |
| Ponce García, J | 1 |
| Tjivras, M | 1 |
| Kapsalas, D | 1 |
| Kyriaki, D | 1 |
| Alevizou, V | 1 |
| Fertakis, A | 1 |
| Cheng, A | 1 |
| Leung, JW | 1 |
| Shibuya, H | 1 |
| Hayashi, Y | 1 |
| Tseng, SW | 1 |
| Ohi, R | 1 |
| Zak, J | 2 |
| Le Roux, E | 1 |
| Lastovica, A | 1 |
| Quatrini, M | 1 |
| Cassetta, MR | 1 |
| Berlin, I | 1 |
| Molinier, P | 1 |
| Duchier, A | 1 |
| Cournot, A | 1 |
| Durrel, J | 1 |
| Dellatolas, F | 1 |
| Duchier, J | 1 |
| Sangaletti, O | 1 |
| Kumar, TR | 1 |
| Naidu, MU | 1 |
| Shobha, JC | 1 |
| Reddy, DN | 1 |
| Subhash, S | 1 |
| Chaubal, C | 1 |
| Prasad, R | 1 |
| Babu, S | 1 |
| Khalil, H | 1 |
| Leucht, U | 1 |
| Sherman, P | 1 |
| Shames, B | 1 |
| Loo, V | 1 |
| Matlow, A | 1 |
| Drumm, B | 1 |
| Penner, J | 1 |
| Powell, KU | 1 |
| Burridge, SM | 1 |
| Spencer, G | 1 |
| Bolton, G | 1 |
| Purser, K | 1 |
| Brooks, S | 1 |
| Prosser, S | 1 |
| Harrison, G | 2 |
| Gant, PW | 2 |
| Westin, JA | 1 |
| Fisher, D | 1 |
| Marriage, B | 1 |
| McColl, KE | 3 |
| Nujumi, AM | 1 |
| Dorrian, CA | 1 |
| Macdonald, AM | 1 |
| Fullarton, GM | 1 |
| Harwood, J | 1 |
| Chiverton, SG | 2 |
| Kleinert, R | 2 |
| Grymbowski, T | 1 |
| Schwarz, JA | 1 |
| Feliciano, DV | 1 |
| Lajoie, C | 1 |
| Colon-Pagan, J | 2 |
| Morse, RS | 2 |
| Johnson, TL | 2 |
| Walsh, JH | 1 |
| McCullough, AJ | 1 |
| Marks, JW | 1 |
| Sklar, M | 2 |
| Stone, RC | 2 |
| Cagliola, AJ | 2 |
| D'Adda, T | 2 |
| Szalay, F | 1 |
| Acharya, M | 1 |
| Hellström, PM | 1 |
| Langenberg, W | 1 |
| Bosma, A | 1 |
| Dankert, J | 1 |
| Tsuneoka, K | 1 |
| Hinchliffe, RF | 2 |
| Thompson, M | 1 |
| Morris, P | 1 |
| Daly, MJ | 1 |
| Carroll, NJ | 1 |
| Gouilloud-Celle, S | 1 |
| Koop, H | 4 |
| Gompertz, RH | 1 |
| Man, WK | 2 |
| Li, SK | 1 |
| Spencer, J | 3 |
| Michalowski, AS | 1 |
| Buckley, MM | 1 |
| Heel, RC | 1 |
| Lysy, J | 1 |
| Karmeli, F | 1 |
| Wengrower, D | 1 |
| Inserra, G | 1 |
| Monello, S | 1 |
| Sofia, M | 1 |
| Rizzo, G | 1 |
| Ayoubi Khajekini, M | 1 |
| Blasi, A | 2 |
| Cariani, G | 2 |
| Vandelli, A | 2 |
| Santini, D | 2 |
| Caselli, A | 1 |
| Fontana, G | 2 |
| Daw, MA | 1 |
| Deegan, P | 1 |
| Leen, E | 1 |
| Stumpf, M | 2 |
| Eissele, R | 1 |
| Lamberts, R | 2 |
| Stöckmann, F | 1 |
| Creutzfeldt, W | 3 |
| Di Girolamo, A | 1 |
| Dainelli, B | 1 |
| Akimoto, Y | 1 |
| Yamasaki, S | 1 |
| Kuwahara, K | 1 |
| Waldum, HL | 1 |
| Petersen, H | 1 |
| Pisciotta, G | 1 |
| Johnston, DA | 1 |
| Young, GO | 1 |
| Tigler-Wybrandi, NA | 1 |
| Bridger, S | 1 |
| Olausson, M | 3 |
| Sollano, JD | 1 |
| Espiritu, AC | 1 |
| Alvarez, SZ | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Barth, H | 1 |
| Hengels, KJ | 2 |
| Rohde, H | 1 |
| Weil, J | 1 |
| Powell, K | 1 |
| Morden, A | 1 |
| Jones, PH | 1 |
| Trowell, JE | 1 |
| Alfonso, V | 1 |
| Alonso, C | 1 |
| Simon, TJ | 1 |
| Bradstreet, DC | 1 |
| Danilewitz, MD | 1 |
| Garisch, JA | 1 |
| Belaïche, J | 1 |
| Zeitoun, P | 1 |
| Thiéfin, G | 1 |
| Duchateau, A | 1 |
| Diébold, MD | 1 |
| Díaz Rubio, M | 1 |
| Sainz Samitier, R | 1 |
| Malagelada, JR | 1 |
| Rodrigo, JM | 1 |
| Ruiz Ferrán, J | 1 |
| Bamberg, P | 1 |
| Segura, J | 1 |
| Kager, L | 1 |
| Nilsson, LH | 1 |
| Seensalu, R | 1 |
| Backman, L | 1 |
| Granström, L | 1 |
| Kollberg, B | 1 |
| Sidenvall, L | 1 |
| Moberg, S | 1 |
| Sörstad, J | 1 |
| Aversa, GP | 1 |
| Marinos, Y | 1 |
| Honson, K | 1 |
| Muramatsu, M | 1 |
| Isobe, Y | 1 |
| Arai, I | 1 |
| Hirose-Kijima, H | 1 |
| Usuki-Ito, C | 1 |
| Nagai, H | 1 |
| Aihara, H | 1 |
| Otomo, S | 1 |
| Mela, G | 1 |
| Sumberaz, A | 1 |
| Gönne, S | 2 |
| Riedel, R | 1 |
| Postius, S | 1 |
| Santucci, L | 1 |
| Farroni, F | 1 |
| Morelli, A | 1 |
| Andersen, BN | 2 |
| Laursen, LS | 2 |
| Rehfeld, JF | 1 |
| Piper, DW | 1 |
| Maton, PN | 1 |
| Holt, S | 1 |
| Wong, PY | 1 |
| Lane, MR | 1 |
| Glise, H | 1 |
| Martinson, J | 1 |
| Solhaug, JH | 1 |
| Engström, G | 1 |
| Hallerbäck, B | 1 |
| Robutti, F | 1 |
| Lok, AS | 2 |
| Ng, MM | 2 |
| Branicki, FJ | 2 |
| Valenzuela, JE | 1 |
| Berlin, RG | 1 |
| Snape, WJ | 1 |
| Petrozza, J | 1 |
| Van Deventer, GM | 1 |
| Cagliola, A | 1 |
| Ching, MS | 1 |
| Mihaly, GW | 1 |
| Angus, PW | 2 |
| Morgan, DJ | 1 |
| Devenish-Meares, S | 1 |
| Smallwood, RA | 3 |
| Valori, RM | 1 |
| Cockel, R | 1 |
| Keshavarzian, A | 1 |
| Haydek, JM | 1 |
| Zepeda, DO | 1 |
| Stinneford, JG | 1 |
| Fields, JZ | 1 |
| Mulder, CJ | 2 |
| Schipper, DL | 1 |
| Chang, J | 1 |
| McCullough, A | 1 |
| Sontag, SJ | 1 |
| Roufail, WM | 1 |
| Bishop, RH | 1 |
| Gitlin, N | 1 |
| Berman, RS | 1 |
| McFarland, RJ | 1 |
| O'Donoghue, DP | 1 |
| Dronfield, MW | 1 |
| Keeling, PW | 1 |
| Burke, GJ | 1 |
| Dickinson, RJ | 1 |
| Shreeve, DR | 1 |
| Peers, EM | 2 |
| Thompson, JN | 2 |
| Poon, GP | 1 |
| Wilairatana, S | 2 |
| Kurathong, S | 2 |
| Atthapaisalsarudee, C | 1 |
| Saowaros, V | 2 |
| Leethochawalit, M | 1 |
| Leong, YP | 1 |
| Leela, MP | 1 |
| Yin, TP | 1 |
| Ahmad, H | 1 |
| Jalleh, R | 1 |
| Lee, HB | 1 |
| Mahendran, T | 1 |
| Jørgensen, T | 1 |
| Crowe, JP | 1 |
| Wilkinson, SP | 1 |
| Willoughby, CP | 1 |
| Bendtsen, F | 2 |
| Ovesen, L | 1 |
| Rosenkilde-Gram, B | 1 |
| Arnold, JD | 1 |
| Tijtgat, GN | 1 |
| Cluysenaer, OJ | 1 |
| Meyer, WW | 1 |
| Hazenberg, BP | 1 |
| Vogten, AJ | 1 |
| Gerrits, C | 1 |
| Stuifbergen, WH | 1 |
| Mainguet, P | 1 |
| Delmée, M | 1 |
| Debongnie, JC | 1 |
| Koop, I | 1 |
| Klein, M | 1 |
| Miglioli, M | 1 |
| di Febo, G | 1 |
| Meijer, JL | 1 |
| Wong, EC | 1 |
| Mai, CR | 1 |
| Ke, MY | 1 |
| Isal, JP | 2 |
| Farup, PG | 2 |
| Rosseland, AR | 1 |
| Halvorsen, L | 2 |
| Andersen, OK | 1 |
| Bernklev, T | 2 |
| de Bruijne, JW | 1 |
| Bium, AL | 1 |
| Okada, M | 1 |
| Niida, H | 1 |
| Stern, WR | 1 |
| Jones, DB | 3 |
| Daneshmend, TK | 1 |
| Pounder, R | 1 |
| Bertaccini, G | 1 |
| Cisternino, M | 1 |
| Coruzzi, G | 1 |
| Francavilla, A | 2 |
| Gallazzi, M | 1 |
| Ingrosso, M | 1 |
| Labò, G | 2 |
| Rinetti, M | 3 |
| Sivelli, R | 1 |
| Tomassetti, P | 2 |
| Lanzon-Miller, S | 1 |
| Hamilton, MR | 1 |
| Ball, S | 1 |
| Chronos, NA | 1 |
| Raymond, F | 1 |
| McLauchlan, G | 1 |
| Crean, GP | 1 |
| Dahlgren, S | 1 |
| Domellöf, L | 1 |
| Hradsky, M | 1 |
| Norryd, C | 1 |
| Brunkwall, J | 1 |
| Svensson, G | 1 |
| Svensson, JO | 1 |
| Karlsson, J | 1 |
| Knutson, U | 1 |
| Gasslander, T | 1 |
| Berglindh, T | 1 |
| McArthur, KE | 1 |
| Jensen, RT | 1 |
| Gardner, JD | 1 |
| Hewson, EG | 1 |
| Shulkes, A | 1 |
| Brook, CW | 1 |
| Sewell, RB | 1 |
| Israsena, S | 1 |
| Kladchareon, N | 1 |
| Kukreja, A | 1 |
| Atthapaisal, C | 1 |
| Lekayanont, S | 1 |
| Churnratanakul, S | 1 |
| Udayachalerm, W | 1 |
| Wright, JP | 1 |
| Newton, KA | 1 |
| Marotta, F | 1 |
| Cheli, R | 1 |
| Vezzaldini, P | 1 |
| Abbiati, R | 1 |
| Gradnik, R | 1 |
| Ebrard, F | 1 |
| Pare, P | 1 |
| Navert, H | 1 |
| Williams, CN | 1 |
| Freeman, HJ | 1 |
| Baker, SJ | 1 |
| Marcon, NE | 1 |
| Sutherland, L | 1 |
| Hüttemann, W | 3 |
| duBosque, G | 1 |
| Hebbeln, H | 1 |
| Martens, W | 1 |
| Horstkotte, W | 1 |
| Karvonen, AL | 1 |
| Keyriläinen, O | 1 |
| Uusitalo, A | 1 |
| Salaspuro, M | 1 |
| Tarpila, S | 1 |
| Andrén, K | 1 |
| Helander, HF | 2 |
| Vezzadini, P | 1 |
| Jonsson, E | 2 |
| Bose, K | 1 |
| Daly, M | 1 |
| Friedman, G | 1 |
| Bankel, M | 1 |
| Gotthard, R | 1 |
| Lundquist, G | 1 |
| Poulsen, SS | 1 |
| Raaberg, L | 1 |
| Therkelsen, K | 1 |
| Skov Olsen, P | 1 |
| Kirkegaard, P | 1 |
| Moore, M | 1 |
| Derodra, JK | 1 |
| Berger, J | 2 |
| Kelbaek, H | 1 |
| Jensen, KG | 1 |
| Linde, J | 1 |
| Højlund, M | 1 |
| Andersen, HH | 1 |
| Bergsåker-Aspöy, J | 1 |
| Gillberg, R | 1 |
| Kilander, A | 1 |
| Offergaard, S | 1 |
| Nielsen, AM | 1 |
| Stenderup, J | 1 |
| Wandall, JH | 1 |
| Prichard, PJ | 1 |
| Rubinstein, D | 1 |
| Dudley, FJ | 1 |
| Louis, WJ | 1 |
| Spiro, HM | 1 |
| Barr, JA | 1 |
| Collier, N | 1 |
| Bush, A | 1 |
| Cope, L | 1 |
| Gribble, RJ | 1 |
| Reynolds, JR | 2 |
| Hardcastle, JD | 1 |
| Clark, AG | 1 |
| Smart, HL | 2 |
| Kitchingman, G | 1 |
| Somerville, KW | 1 |
| Payton, CD | 1 |
| Meredith, PA | 1 |
| Hughes, DM | 1 |
| Macdougall, AI | 1 |
| Reid, JL | 1 |
| Forrest, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study[NCT03980496] | Phase 4 | 50 participants (Actual) | Interventional | 2010-09-09 | Completed | ||
| Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China[NCT00953381] | Phase 2 | 235 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China[NCT00952978] | Phase 3 | 496 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing[NCT00778193] | Phase 4 | 125 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs[NCT00443963] | Phase 4 | 0 participants (Actual) | Interventional | 2006-12-31 | Withdrawn (stopped due to The study was not approved by the Human Studies Subcommittee.) | ||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study[NCT02674802] | 3,500 participants (Anticipated) | Observational | 2015-12-31 | Recruiting | |||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
107 reviews available for omeprazole and Curling Ulcer
| Article | Year |
|---|---|
Fitz-Hugh-Curtis syndrome in a man positive for Chlamydia trachomatis.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlamydia Infections; Chlamydia trachomati | 2018 |
[Endoscopic hemostasis in the treatment of the gastroduodenal ulcer bleeding].
Topics: Administration, Intravenous; Comparative Effectiveness Research; Duodenal Ulcer; Hemostasis, Endosco | 2013 |
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infect | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 2013 |
The clinical importance of proton pump inhibitor pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost Savings; Duodenal U | 2002 |
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D | 2003 |
[What treatments can reduce the digestive complications of NSAIDs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Gastrointestinal Diseases; Histamine H2 Ant | 2003 |
[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Female; | 2004 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 2005 |
Cost-effectiveness of a 'score and scope' strategy for the management of dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cost-Benefit Analysis; Decision Trees; Diagn | 2005 |
[Recent topics on important drugs for H. pylori eradication: Omeprazole].
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Therapy, Combin | 2005 |
Medical management of peptic ulcer.
Topics: Aluminum; Antacids; Benzimidazoles; Bismuth; Carbenoxolone; Cimetidine; Duodenal Ulcer; Humans; Omep | 1984 |
Pharmacologic options for the control of peptic ulcer disease.
Topics: Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Carbenoxolone; Cimetidine; Duodenal Ulcer; His | 1984 |
[Zollinger-Ellison syndrome].
Topics: Benzimidazoles; Calcium; Cimetidine; Diarrhea; Duodenal Ulcer; Female; Fluorouracil; Gastrectomy; Ga | 1984 |
What should be done when initial endoscopic therapy for bleeding peptic ulcer fails?
Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Hemostasis, Endoscopic; Humans | 1995 |
Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
Topics: Adult; Cimetidine; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Female; Humans; Male; M | 1995 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adj | 1995 |
Epidemiology and prevention of non-steroidal anti-inflammatory drug effects in the gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Humans; Misoprostol; Omeprazole; Prevalence | 1995 |
Optimizing acid suppression for treatment of acid-related diseases.
Topics: Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole; | 1995 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; | 1994 |
[New antisecretory drugs in the treatment of ulcer].
Topics: Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Parasympatholytics; Stomach Ulcer | 1994 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
Topics: Costs and Cost Analysis; Depression, Chemical; Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux | 1994 |
Refractory peptic lesions. Therapeutic strategies for ulcers and reflux esophagitis that resist standard regimens.
Topics: Anti-Ulcer Agents; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Drug Therapy, Com | 1993 |
Gastric acid secretion and intragastric acidity: measurement in health and disease.
Topics: Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Helico | 1993 |
Acid pump blockers: what are their current therapeutic roles?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Gastroesophageal Reflux; | 1993 |
Clinical efficacy of pantoprazole compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1994 |
A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Metho | 1994 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1994 |
[Omeprazole. Its pharmacology and therapeutic efficacy].
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison Syndrome | 1993 |
Is there any acid peptic disease that is refractory to proton pump inhibitors?
Topics: Clinical Trials as Topic; Drug Resistance; Duodenal Ulcer; Gastric Acid; Gastroesophageal Reflux; Hu | 1993 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal U | 1993 |
Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Humans; | 1995 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidin | 1995 |
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Cost-effectiveness of H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Helicobacter | 1996 |
[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].
Topics: Animals; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Rats; Re | 1995 |
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1996 |
Prevention of NSAID-gastropathy.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer | 1996 |
Therapy of NSAIDs-induced gastropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Histamine H2 Antagonists | 1996 |
[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study].
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Injections, Intravenous; | 1997 |
[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials a | 1998 |
Pantoprazole--a third proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme I | 1997 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Helicobacter pylori eradication as a surrogate marker for the reduction of duodenal ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biomarkers; Drug Therapy, Combination; Duodenal Ulcer; Female | 1998 |
Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?
Topics: Anti-Ulcer Agents; Barrett Esophagus; Duodenal Ulcer; Gastroesophageal Reflux; Helicobacter Infectio | 1998 |
[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1999 |
Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Topics: Cost-Benefit Analysis; Duodenal Ulcer; Economics, Pharmaceutical; Esophagitis, Peptic; Health Care C | 1993 |
Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Juic | 1999 |
Gastrointestinal effects of nonsteroidal anti-inflammatory therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Cyclooxygenase | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
[Present position in the prevention and therapy of NSAID-induced ulcers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer | 1999 |
[Black esophagus related to acute esophageal necrosis: a new case].
Topics: Acute Disease; Anti-Ulcer Agents; Combined Modality Therapy; Duodenal Ulcer; Esophagoscopy; Esophagu | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
[Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis; | 1999 |
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Topics: Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome | 2000 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duoden | 2000 |
Esomeprazole.
Topics: Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazol | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical | 2001 |
[Experience in the use of losek (omeprazole) in gastroenterology].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Double | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
[Duodenal ulcer].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; | 2002 |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.
Topics: Adult; Anti-Ulcer Agents; Child; Duodenal Ulcer; Germany; Helicobacter Infections; Helicobacter pylo | 2002 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Review article: esomeprazole in the treatment of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibito | 2002 |
Medical therapy of peptic ulcer disease.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Diet; Duodenal Ulcer; Histamine H2 Antag | 1992 |
[The medical therapy of peptic ulcer. The state of the art].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Stoma | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
[Omeprazole and maintenance treatment: new concepts for traditional therapies?].
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole | 1992 |
Do perforated duodenal ulcers need an acid-decreasing surgical procedure now that omeprazole is available?
Topics: Duodenal Ulcer; Humans; Omentum; Omeprazole; Peptic Ulcer Perforation; Pylorus; Recurrence; Vagotomy | 1992 |
[High demands on drug administration and pharmacological principles applied in ulcer diseases].
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Hista | 1991 |
Medical treatment of peptic ulcer disease.
Topics: Antacids; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Peptic Ulcer; Prostaglandins | 1991 |
'Difficult' duodenal ulcer patients: clinical and therapeutic problems.
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omep | 1991 |
[Intragastric pH modifications induced by antisecretory treatments].
Topics: Duodenal Ulcer; Esophagitis; Gastric Acidity Determination; Gastroesophageal Reflux; Histamine H2 An | 1991 |
[New developments in drug therapy: omeprazole].
Topics: Cimetidine; Duodenal Ulcer; Humans; Omeprazole; Ranitidine; Smoking; Stomach Ulcer | 1991 |
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Gastrointestinal Diseases; Histamine H2 Antagonists; H | 1991 |
[Effects of gastric acid secretion inhibition on intrinsic factor secretion and cobalamin absorption].
Topics: Absorption; Cimetidine; Duodenal Ulcer; Gastrectomy; Gastric Acid; Gastritis, Atrophic; Humans; Intr | 1991 |
[Effects of antisecretory therapy on serum gastrin and argyrophil cells of the fundus mucosa].
Topics: Cimetidine; Duodenal Ulcer; Esophagitis; Gastric Mucosa; Gastrins; Humans; Omeprazole; Ranitidine; V | 1991 |
Omeprazole.
Topics: Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison S | 1991 |
Omeprazole. Overview and opinion.
Topics: Duodenal Ulcer; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Omeprazole; Stomach Ulce | 1991 |
[Ulcer disease--drug treatment and its limitations].
Topics: Campylobacter Infections; Duodenal Ulcer; Humans; Long-Term Care; Omeprazole; Organometallic Compoun | 1990 |
Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials.
Topics: Duodenal Ulcer; Humans; Meta-Analysis as Topic; Omeprazole; Ranitidine | 1990 |
Clinical experience with omeprazole: assessment of efficacy and safety.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli | 1989 |
Omeprazole in the treatment of duodenal ulcer.
Topics: Adenosine Triphosphatases; Cimetidine; Clinical Trials as Topic; Duodenal Ulcer; H(+)-K(+)-Exchangin | 1989 |
The clinical utility and safety of omeprazole.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; | 1989 |
Omeprazole in the management of refractory duodenal ulcer.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Histamine H2 Antagonists; Hu | 1989 |
Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
Topics: Drug Administration Schedule; Duodenal Ulcer; Gastric Acid; Histamine H2 Antagonists; Humans; Omepra | 1989 |
Clinical utility and safety of omeprazole.
Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zolli | 1989 |
Relationship between inhibition of acid secretion and healing of peptic ulcers.
Topics: Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Wound Healing | 1989 |
Efficacy of the H+/K+-adenosine triphosphatase inhibitor omeprazole in peptic ulcer.
Topics: Cimetidine; Duodenal Ulcer; Humans; Omeprazole; Ranitidine; Stomach Ulcer; Therapeutic Equivalency | 1989 |
Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis.
Topics: Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer | 1989 |
H+/K+-adenosine triphosphatase inhibitors. A new approach to the treatment of acid-peptic diseases.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer | 1989 |
[Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Aspi | 1986 |
[Inhibition of H+/K+-ATPase in the parietal cell with omeprazole: a new principle of gastric acid inhibition].
Topics: Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; | 1985 |
Emerging strategies in ulcer therapy: pumps and receptors.
Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Pariet | 1985 |
Omeprazole.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto | 1988 |
Assessment of two new therapies for peptic ulcer disease: omeprazole and the prostaglandin analogues.
Topics: Alprostadil; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Enprostil; Gastric Juice; Gastrins; Humans; | 1988 |
Omeprazole.
Topics: Achlorhydria; Animals; Duodenal Ulcer; Humans; Omeprazole; Rats; Zollinger-Ellison Syndrome | 1987 |
455 trials available for omeprazole and Curling Ulcer
| Article | Year |
|---|---|
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; | 2022 |
Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers.
Topics: Child; Duodenal Ulcer; Female; Humans; Interleukin-10; Interleukin-17; Leukocytes, Mononuclear; Male | 2018 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Cla | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; He | 2018 |
[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Adult; Amoxicillin; Anti-Bacterial Agents | 2012 |
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Dou | 2016 |
Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Adm | 2016 |
Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 2009 |
Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Dru | 2009 |
Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities.
Topics: Aged; Aged, 80 and over; Comorbidity; Confidence Intervals; Dose-Response Relationship, Drug; Drug A | 2009 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
[Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].
Topics: Adult; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; Esomeprazole; Female; Gastric Aci | 2009 |
[Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2010 |
A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2011 |
Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, | 2010 |
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; C | 2011 |
Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2011 |
Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbo | 2012 |
Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastric | 2011 |
Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therap | 2002 |
[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal | 2002 |
[Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 2002 |
Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug T | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Metho | 2002 |
Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 2002 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clar | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Acid-base blood balance in patients with ulcer under treatment by the gastric secretion inhibitors and antacids].
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aluminum Compounds; Antacids; Duodenal Ulcer; Famotidine; | 2002 |
Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Me | 2003 |
Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Capsules; | 2003 |
[Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Fe | 2003 |
Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2003 |
Helicobacter pylori stimulates inducible nitric oxide synthase in diverse topographical patterns in various gastroduodenal disorders.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; E | 2003 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clavulanic Acids; Double-Blin | 2003 |
[The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbo | 2003 |
[Results of an open multicenter study of the efficiency of one-week anti-helicobacter therapy using omeprazole, clarithromycin, and amoxicillin in patients with duodenal peptic ulcer].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 2003 |
[Comparative analysis of the effectiveness of two Helicobacter pylori eradication plans based on omeprazole, clarithromycin and amoxicillin in patients with duodenal peptic ulcer: results of a randomized double-blind, controlled study].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doub | 2003 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; H | 2004 |
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Gastric acid and salivary bicarbonate. Is there a relationship in duodenal ulcer patients?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bicarbonates; Drug Therapy, Combinatio | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Co | 2005 |
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; | 2005 |
A comparison of oral omeprazole and intravenous cimetidine in reducing complications of duodenal peptic ulcer.
Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Blood Transfusion; Cimetidine; Duodenal Ulcer; | 2006 |
[Melatonin in treatment of duodenal ulcer].
Topics: Adolescent; Adult; Anti-Ulcer Agents; Antioxidants; Duodenal Ulcer; Female; Humans; Male; Melatonin; | 2006 |
[The effectiveness of SCENAR therapy in complex treatment of duodenal ulcer, and the mechanisms of its action].
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Electric Stimulation Therapy; Female; Follow-U | 2006 |
Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2006 |
Furazolidone-based triple therapy for H pylori gastritis in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2006 |
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Bl | 2007 |
Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2006 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
[Gastrin-17 level in the omeprazole treatment of duodenal ulcer].
Topics: Adult; Anti-Ulcer Agents; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule | 2005 |
[Age and eradication treatment of duodenal ulcer].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Combinations; | 2007 |
One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; | 2007 |
Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; | 2007 |
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Dy | 2008 |
Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.
Topics: Alanine Transaminase; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; | 1983 |
Omeprazole: no evidence for frequent hepatic reactions.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duodenal Ul | 1984 |
[Inhibition of the proton pump with omeprazole. A new principle of ulcer therapy?].
Topics: Animals; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Gastric Acid | 1983 |
[Treatment of duodenal ulcer outbreak with omeprazole. Results of a multicenter non-controlled study].
Topics: Adult; Aged; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Female; Gastroscopy; Humans; | 1984 |
Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Female; Gastric | 1984 |
Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study.
Topics: Adult; Aged; Alcohol Drinking; Anti-Ulcer Agents; Benzimidazoles; Depression, Chemical; Duodenal Ulc | 1984 |
Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Dose-Response Relationship, Drug; Duodenal Ulc | 1984 |
Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Dose-Response Relationship, Drug; Duoden | 1984 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; | 1995 |
Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study.
Topics: Adult; Aged; Anti-Ulcer Agents; Confidence Intervals; Drug Therapy, Combination; Duodenal Ulcer; End | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Ulcer A | 1995 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Jui | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Anti | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Dr | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; | 1995 |
[Long-term cyclic and periodic omeprazole in the prevention of recurrences of duodenal ulcer].
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; | 1995 |
Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Colony Count, Microbial; Drug Therapy, Combination; Duo | 1995 |
Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study.
Topics: Drug Administration Schedule; Duodenal Ulcer; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin.
Topics: Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow | 1995 |
[Comparison between ranitidine, famotidine, and omeprazole in the treatment of bleeding duodenal ulcer].
Topics: Duodenal Ulcer; Famotidine; Humans; Omeprazole; Peptic Ulcer Hemorrhage; Ranitidine | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Hel | 1995 |
Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duode | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1995 |
Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1995 |
Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Fo | 1995 |
Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.
Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Hel | 1995 |
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1994 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
[Prognostic factors of the speed of cicatrization in duodenal ulcer. Controlled trial of omeprazole versus ranitidine].
Topics: Adult; Aged; Aged, 80 and over; Cicatrix; Duodenal Ulcer; Endoscopy, Digestive System; Female; Human | 1995 |
Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansop | 1995 |
A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Aged; Anti-Ulcer Agents; | 1995 |
In vivo effect of omeprazole on HLA-DR expression and the monocyte-macrophage function in patients with duodenal ulcer disease.
Topics: Adult; Chemotaxis, Leukocyte; Duodenal Ulcer; Female; HLA-DR Antigens; Humans; Immunity, Cellular; M | 1994 |
Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Carb | 1994 |
Histologic patterns of omeprazole and nizatidine-healed duodenal ulcers:accuracy of endoscopic diagnosis.
Topics: Adult; Biopsy; Duodenal Ulcer; Duodenoscopy; Humans; Intestinal Mucosa; Middle Aged; Nizatidine; Ome | 1994 |
Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals.
Topics: Adolescent; Adult; Aged; Amoxicillin; Drug Administration Schedule; Duodenal Ulcer; Eating; Female; | 1994 |
Long term treatment with omeprazole 20 mg three days a week or 10 mg daily in the prevention of duodenal ulcer relapse.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duodenal | 1994 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric | 1994 |
Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease.
Topics: Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Helicobacter Infections; Heli | 1995 |
Histological maturity of healed duodenal ulcer and ulcer recurrence after treatment with omeprazole or cimetidine.
Topics: Adolescent; Adult; Aged; Cimetidine; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; | 1994 |
Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; Drug Ther | 1995 |
Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Clinical Trials as Topic; Drug Therapy, Combination; | 1994 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease.
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer.
Topics: Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Acid | 1995 |
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.
Topics: Adult; Aged; Antacids; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer | 1994 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori | 1994 |
Serum gastrin levels following administration of omeprazole alone or in combination with pirenzepine.
Topics: Drug Therapy, Combination; Duodenal Ulcer; Gastrins; Humans; Omeprazole; Peptic Ulcer; Pirenzepine; | 1994 |
A multicenter, double-blind, randomized controlled study of omeprazole versus ranitidine in the treatment of duodenal ulcer in Israel.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Isra | 1994 |
[The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole].
Topics: Chi-Square Distribution; Duodenal Ulcer; Female; Humans; Infusions, Intravenous; Male; Middle Aged; | 1994 |
Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer.
Topics: Administration, Oral; Drug Administration Schedule; Duodenal Ulcer; Female; Gastric Acid; Humans; Ma | 1994 |
Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1994 |
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1994 |
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients.
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastrit | 1994 |
Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Anti-Ulcer Agents; Double-Blind Metho | 1994 |
A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gast | 1994 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Double-B | 1994 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; | 1993 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1993 |
Alternate-day therapy with omeprazole for duodenal ulcer.
Topics: Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole | 1993 |
Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Drug Administration | 1994 |
Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.
Topics: Dose-Response Relationship, Drug; Duodenal Ulcer; Female; Gastric Acid; Humans; Hydrogen-Ion Concent | 1994 |
One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studi | 1994 |
Antisecretory effect of three premeal doses of cimetidine 400 mg versus a single morning dose of omeprazole 20 mg: pathophysiological implications for duodenal ulcer treatment.
Topics: Adult; Aged; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Eating; Female; Gastric Acid; | 1993 |
Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duode | 1993 |
Orally administered omeprazole versus injection therapy in the prevention of rebleeding from peptic ulcer with visible vessel. A multicenter randomized study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Duodenal Ulcer; Epi | 1993 |
[Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Double-Blin | 1993 |
Omeprazole vs ranitidine in the healing of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Male; Middle | 1993 |
Treatment of duodenal ulcer with omeprazole or ranitidine in a Brazilian population: a multicenter double-blind, parallel group study.
Topics: Adult; Brazil; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Ma | 1993 |
Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination | 1993 |
Acute treatment of duodenal ulcer: experience with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Administration Schedule; Duodenal U | 1993 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; M | 1993 |
Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Duodenal Ulcer; En | 1995 |
Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin.
Topics: Adult; Aged; Clarithromycin; Duodenal Ulcer; Follow-Up Studies; Helicobacter pylori; Humans; Male; M | 1995 |
Short- and long-term omeprazole for the treatment and prevention of duodenal ulcer, and effect on Helicobacter pylori.
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Male; Midd | 1995 |
[Ulcer healing through the elimination of Helicobacter pylori: is a week of therapy enough?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug The | 1996 |
Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Du | 1996 |
A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Ulcer Agents; Double-Blin | 1995 |
Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; An | 1995 |
Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acidity Determination; Humans; Hydrogen-Io | 1995 |
Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Duodenal Ulcer; Dy | 1996 |
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; | 1996 |
Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribut | 1996 |
[Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Gastric | 1996 |
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; | 1996 |
Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acid; Gas | 1996 |
[A clinical trial of lansoprazole in the treatment of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; H(+ | 1995 |
Efficacy of ciprofloxacin in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Ciprofloxacin; Double-Blin | 1996 |
Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Co | 1996 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Prolonged treatment with omeprazole does not improve the eradication rate of Helicobacter pylori infection--a short report [corrected].
Topics: Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenoscopy; Female; Fo | 1995 |
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, C | 1996 |
Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; | 1996 |
The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients.
Topics: Adult; Circadian Rhythm; Cross-Over Studies; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Acid | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Duod | 1996 |
One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, C | 1995 |
Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole.
Topics: Adult; Anti-Ulcer Agents; Candidiasis; Cimetidine; Duodenal Diseases; Duodenal Ulcer; Famotidine; Fe | 1996 |
Helicobacter pylori eradication--evaluation of triple therapy containing omeprazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 1996 |
Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors | 1996 |
Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Intestinal Absorption; Male; Middle Aged; | 1996 |
Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole.
Topics: Adult; Anti-Ulcer Agents; Defecation; Duodenal Ulcer; Duodenum; Enzyme Inhibitors; Female; Gastroint | 1996 |
Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastroscopy; Helic | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Chi-Square Distributi | 1996 |
[Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duoden | 1996 |
Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Dr | 1996 |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bacterial Typing | 1997 |
[Treatment of duodenal ulcer with pantoprazole. A multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 1997 |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combina | 1997 |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Adm | 1997 |
A comparison of omeprazole and placebo for bleeding peptic ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; Fe | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study.
Topics: Aged; Anti-Ulcer Agents; Blood Transfusion; Double-Blind Method; Duodenal Ulcer; Female; Hemostasis, | 1997 |
Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study.
Topics: Aged; Anti-Ulcer Agents; Blood Transfusion; Double-Blind Method; Duodenal Ulcer; Female; Hemostasis, | 1997 |
Does profound acid inhibition improve haemostasis in peptic ulcer bleeding?
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Hemostasis, Endoscopic; Humans; Infusions, Intraveno | 1997 |
Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Hydrogen-Ion Conc | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
Another therapeutic schedule in eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti | 1997 |
Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Fema | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, | 1997 |
Treatment of bleeding peptic ulcers with omeprazole.
Topics: Anti-Ulcer Agents; Blood Transfusion; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Follow-Up S | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
Prophylaxis of acute gastroduodenal bleeding after renal transplantation.
Topics: Acute Disease; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastrointestinal Hemorrhage; | 1997 |
[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study].
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Female; Humans; Injections, Intravenous; | 1997 |
PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; D | 1997 |
Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter I | 1997 |
Two omeprazole-based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal | 1997 |
Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Canada; Clarithromycin; Double-Blind Method; Drug Resista | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1996 |
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; D | 1996 |
One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gas | 1997 |
Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Female; Helicobacte | 1997 |
Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duod | 1997 |
[Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Duo | 1997 |
Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation).
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Administration Schedule; Drug Synergis | 1997 |
Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Biopsy; Double-Blind Method | 1997 |
Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpr | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomona | 1997 |
[Omeprazole and azithromycin with and without metronidazole in the eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Duodenal U | 1997 |
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose- | 1997 |
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-B | 1998 |
Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dose-Response Relationship | 1997 |
[new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1998 |
Accuracy of CLOtest after Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulc | 1998 |
Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1998 |
A prospective randomized study of amoxycillin and omeprazole with and without metronidazole in the eradication treatment of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Fasting; Female; | 1997 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
[Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Drug | 1996 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study.
Topics: Adult; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; | 1998 |
Omeprazole, azithromycin and either amoxycillin or metronidazole in eradication of Helicobacter pylori in duodenal ulcer patients.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; | 1998 |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Metho | 1997 |
[Helicobacter pylori: 6-day triple therapy in duodenal ulcer].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; He | 1998 |
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duode | 1998 |
US double-blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Doubl | 1998 |
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1998 |
Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinica | 1998 |
Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clinical Protocols; Drug Therapy, Combination; Duode | 1998 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1998 |
New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infecti | 1998 |
Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
Topics: Adult; Aged; Alanine; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1998 |
Omeprazole and ranitidine in long-term treatment of duodenal ulcer: a double-blind comparison of length of time in remission.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; D | 1998 |
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr | 1998 |
Omeprazole in the treatment of ulcers induced by NSAIDs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1998 |
Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combi | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole.
Topics: Adult; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Acid; Helicobacter Infections; Helicobacte | 1998 |
Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Br | 1998 |
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; | 1998 |
Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Doubl | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1998 |
Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clavulanic Acid; Drug Th | 1998 |
Helicobacter pylori clearance and serum gastrin and pepsinogen I concentrations in omeprazole treatment of duodenal ulcer patients.
Topics: Adult; Age Factors; Aged; Duodenal Ulcer; Female; Gastrins; Helicobacter pylori; Humans; Male; Middl | 1999 |
[Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 1999 |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-B | 1999 |
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Decision Trees; Direct Service Costs; Drug Evaluati | 1990 |
The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Trees; Duodenal Ulcer; Hel | 1995 |
The effect of antibiotic therapy on bleeding from duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, | 1999 |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspeps | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Costs; Drug Therapy, | 1999 |
High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers.
Topics: Adult; Aged; Amoxicillin; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duo | 1999 |
"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicob | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1999 |
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Me | 1999 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug R | 1999 |
Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1999 |
Use of omeprazole in the management of giant duodenal ulcer: results of a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Female; Gastroscopy; Heli | 1999 |
Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; China; Cimetidine; Cost-Be | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1999 |
The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Contraindications; Dr | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ul | 1999 |
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, C | 1999 |
Pantoprazole suppresses Helicobacter pylori without affecting cure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Thera | 1999 |
Omeprazole and ranitidine in the prevention of relapse in patients with duodenal ulcer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Enzyme Inhibitors; | 1999 |
Does eradication of Helicobacter pylori alone heal duodenal ulcers?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobac | 2000 |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Duoden | 2000 |
[Losek therapy of duodenal ulcer in contamination with different strains of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme In | 1999 |
Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2000 |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asia, Southeastern; | 2000 |
Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury.
Topics: Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Duodenal | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; D | 2000 |
[The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Metho | 2000 |
One week triple therapy for Helicobacter pylori associated duodenal ulcer disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichom | 1999 |
Effect of intragastric pH on control of peptic ulcer bleeding.
Topics: Adolescent; Adult; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Female; Gastric Aci | 2000 |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop | 2000 |
Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2000 |
The effects of omeprazole on healing and appearance of small gastric and duodenal lesions during dosing with diclofenac in healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cross-Over Studies; Diclofenac; D | 2000 |
One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; | 2000 |
Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug T | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
[Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benef | 2000 |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; C | 2000 |
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 2000 |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2000 |
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine | 2000 |
Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Gast | 2000 |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal U | 2000 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, C | 2000 |
Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; D | 2000 |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithr | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2000 |
Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease.
Topics: Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Female; Helicobacter Infections; Helicoba | 2001 |
Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Heli | 2001 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Antacids; An | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithr | 2001 |
The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori.
Topics: Adolescent; Aged; Aged, 80 and over; Amoxicillin; Dose-Response Relationship, Drug; Double-Blind Met | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Ag | 2000 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 1999 |
Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer.
Topics: Anti-Ulcer Agents; Chi-Square Distribution; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Ga | 2001 |
[Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Adm | 2001 |
Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study.
Topics: Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Ome | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2001 |
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2001 |
[Treatment of perforated gastroduodenal ulcer by simple suture followed by Helicobacter pylori eradication].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2002 |
[Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer].
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulc | 2002 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2002 |
[Various mechanisms of cytoprotective effect of omeprazole and low intensity laser radiation on the gastroduodenal mucosa in the treatment of patients with duodenal ulcer].
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cytoprotection; Duodenal Ulcer; Duodenum; Gastric Juice; Gastr | 2002 |
Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2002 |
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans; | 2002 |
[Treatment of patients with ulcer associated with Helicobacter pylori (experience with a triple therapy regimen].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2002 |
[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Apoptosis; Benzimidazoles; Duodenal Ulce | 2002 |
Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal | 1992 |
Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 1992 |
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ul | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter | 1992 |
Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Metronidazole; Omep | 1992 |
Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Metho | 1992 |
Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Double-Blind Method; Drug | 1992 |
Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Humans; Hydrogen-Ion Con | 1992 |
Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Midd | 1992 |
Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Benzimi | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Dr | 1992 |
Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.
Topics: Double-Blind Method; Duodenal Ulcer; Gastric Acid; Gastrins; Humans; Male; Omeprazole | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden | 1992 |
Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Ag | 1992 |
Omeprazole versus ranitidine in the treatment of resistant duodenal ulcer.
Topics: Duodenal Ulcer; Humans; Omeprazole; Ranitidine | 1992 |
Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
Topics: Cimetidine; Double-Blind Method; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Male; Mid | 1991 |
Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dinoprostone; Duodenal Ulcer; Eicosanoids; Female; Gastr | 1992 |
Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Endoscopy; Female; Helicobacter Infection | 1991 |
Enhanced clearing of Helicobacter pylori after omeprazole plus roxithromycin treatment.
Topics: Drug Combinations; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; | 1991 |
Effect of intravenous omeprazole on twenty-four-hour intragastric pH in patients with a history of peptic ulcer. Comparison of two four-dosage regimens.
Topics: Double-Blind Method; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-I | 1991 |
Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox.
Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Drug Combinations; Duodenal Ulcer; Endoscopy, Gastrointes | 1991 |
An open trial on short-term omeprazole therapy for gastric and duodenal ulcers.
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Duodenal Ulcer; Duodenoscopy; Female; Gastroscopy; | 1991 |
Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 1991 |
Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication.
Topics: Adult; Aged; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mid | 1991 |
A comparison of omeprazole and ranitidine for duodenal ulcer in South African patients. A multiracial study.
Topics: Adult; Aged; Black People; Discriminant Analysis; Double-Blind Method; Drug Administration Schedule; | 1991 |
[Comparative multicentric study of omeprazole versus ranitidine in the treatment of duodenal ulcer].
Topics: Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Prognosis; Ranitidine; S | 1991 |
The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients.
Topics: Duodenal Ulcer; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multivariate Analys | 1991 |
Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Gastrins; H | 1991 |
Omeprazole.
Topics: Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison S | 1991 |
Omeprazole 20 mg daily for duodenal ulcer: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Duodenal Ulcer; Female; Follow-Up Stud | 1991 |
Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research.
Topics: Absenteeism; Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antacids; Drug Administrati | 1991 |
Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients.
Topics: Adult; Drug Evaluation; Duodenal Ulcer; Enterochromaffin Cells; Gastric Mucosa; Humans; Male; Micros | 1991 |
Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori.
Topics: Adult; Chronic Disease; Double-Blind Method; Duodenal Ulcer; Female; Gastritis; Helicobacter Infecti | 1991 |
U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.
Topics: Double-Blind Method; Duodenal Ulcer; Female; Gastrins; Humans; Male; Middle Aged; Omeprazole; Raniti | 1991 |
Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. Cooperative study group.
Topics: Aged; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Multicenter Studies as | 1990 |
Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial.
Topics: Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Randomized C | 1990 |
Omeprazole versus placebo in duodenal ulcer healing. The United States experience.
Topics: Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic | 1990 |
Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Male | 1990 |
Clinical experience with omeprazole: assessment of efficacy and safety.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli | 1989 |
Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Female; Humans; Male; Omeprazole; Ranitidi | 1989 |
Omeprazole or cimetidine once daily for the treatment of duodenal ulcers?
Topics: Adult; Cimetidine; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazol | 1989 |
Omeprazole compared with ranitidine once daily in the treatment of duodenal ulcer.
Topics: Adult; Aged; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Ran | 1989 |
Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Mal | 1989 |
Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Cimetidine; Double-Blind Method; Duodenal Ulcer; | 1989 |
Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Follow-Up Studies; Gastric Acid; Gast | 1989 |
Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief.
Topics: Adult; Aged; Antacids; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omepr | 1989 |
Omeprazole in the treatment of duodenal ulcer.
Topics: Adenosine Triphosphatases; Cimetidine; Clinical Trials as Topic; Duodenal Ulcer; H(+)-K(+)-Exchangin | 1989 |
The clinical utility and safety of omeprazole.
Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; | 1989 |
Omeprazole in the management of refractory duodenal ulcer.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Histamine H2 Antagonists; Hu | 1989 |
Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
Topics: Adult; Aged; Drug Evaluation; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Male; Middle | 1989 |
Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers.
Topics: Adult; Cimetidine; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Duodenal Ulce | 1989 |
Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission?
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Duodenal Ulcer; Female; Humans; Male; Middle Aged | 1989 |
[Omeprazole in the therapy of acid-induced diseases].
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Eso | 1987 |
[Therapeutic achlorhydria: for which diseases, when and for how long?].
Topics: Achlorhydria; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Hi | 1988 |
[The Italian pilot experience with omeprazole. Preliminary pharmacologic and clinical results].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Duodenal Ulcer; Female; Gastric Acid; Humans | 1987 |
Effect of low-dose omeprazole on gastric acid secretion in duodenal ulcer patients.
Topics: Adult; Double-Blind Method; Duodenal Ulcer; Female; Gastric Acid; Humans; Male; Middle Aged; Omepraz | 1988 |
The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cimetidine; Duodenal Ulcer; Female; Humans; Male; Middle | 1988 |
Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulc | 1986 |
Omeprazole.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto | 1988 |
[Stomach tolerance of nonsteroidal antirheumatic drugs: comparative endoscopic study].
Topics: Adult; Alprostadil; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspiri | 1987 |
Omeprazole in the treatment of duodenal ulcer: the first study in Thai patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Duodenal Ulcer; Female; Humans | 1988 |
Omeprazole and ranitidine in duodenal ulcer healing.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Omeprazo | 1988 |
Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Duodenoscopy; Female; Humans; | 1987 |
[Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage. A French multicenter, controlled therapeutic trial].
Topics: Adult; Aged; Cimetidine; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Female; Huma | 1987 |
Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief.
Topics: Adult; Aged; Antacids; Cimetidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 1988 |
20 versus 30 mg omeprazole once daily: effect on healing rates in 115 duodenal ulcer patients.
Topics: Adult; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Female; Humans; Male; Middle Aged; | 1986 |
Effects of omeprazole in duodenal ulcer patients.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Female; Gastric | 1986 |
Effect and tolerability of omeprazole in the treatment of duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; Duodenal Ulcer; Duodenitis; Female; Humans | 1986 |
A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studie | 1986 |
The effect of 20 Mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acid concentration in duodenal ulcer patients.
Topics: Adult; Bile Acids and Salts; Circadian Rhythm; Clinical Trials as Topic; Duodenal Ulcer; Female; Gas | 1987 |
Effects of low dose omeprazole on gastric secretion and plasma gastrin in patients with healed duodenal ulcer.
Topics: Adult; Circadian Rhythm; Double-Blind Method; Duodenal Ulcer; Fasting; Gastric Acid; Gastric Mucosa; | 1986 |
[Short-term therapy of duodenal ulcer with omeprazole and ranitidine. Results of a German multicenter study].
Topics: Adolescent; Adult; Aged; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulc | 1985 |
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Clinical Trials as Topic; Double-Blind M | 1985 |
The rate of healing of duodenal ulcers during omeprazole treatment.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; Female; Ga | 1985 |
Omeprazole heals duodenal, but not gastric ulcers more rapidly than ranitidine. Results of two German multicentre trials.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer | 1985 |
Reduction of gastric acid secretion by 10 mg and 30 mg omeprazole once daily.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duode | 1985 |
Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Duode | 1985 |
24-hour intragastric pH: continuous monitoring or nasogastric aspiration?
Topics: Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acidity Determination; Humans; Intubation | 1986 |
Intravenous omeprazole rapidly raises intragastric pH.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Duodenal Ulcer; Gastric Acid | 1985 |
325 other studies available for omeprazole and Curling Ulcer
| Article | Year |
|---|---|
Perforation of a duodenal ulcer into a non-parasitic liver cyst: a rare case of a penetrate hole blockaded with conservative medical management.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cefoperazone; Cysts; Drug Therapy, Combination; Duodenal U | 2014 |
[State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers; Clarithromycin | 2013 |
Omeprazole-associated rhabdomyolysis.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Male; Omeprazole; Proton Pump Inhibitors; Rhabdomy | 2014 |
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor.
Topics: Duodenal Neoplasms; Duodenal Ulcer; Gastrinoma; Humans; Magnesium; Male; Middle Aged; Omeprazole; Pe | 2014 |
Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; China; Cost-Benefit Analysis; Decision Trees; Drug Costs; D | 2016 |
Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Azithromycin; Brazil; Drug Administration Schedule; Dru | 2008 |
[Eradication therapy and processes of proliferation and apoptosis in the stomach of patients with duodenal ulcer].
Topics: Adult; Aged; Anti-Ulcer Agents; Apoptosis; Cell Proliferation; Drug Therapy, Combination; Duodenal U | 2009 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
[Effect of eradication therapy on nitrogen oxide activity in the gastric juice of patients with chronic gastritis and ulcer disease].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Comb | 2009 |
Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cost-Benefit Analysis; Duod | 2010 |
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cl | 2010 |
[Dynamics of regeneration of epitheliocytes from gastric mucosa at different modes of antirelapse treatment of ulcer disease].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Thera | 2010 |
Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area.
Topics: Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resis | 2010 |
Anti-ulcer constituents of Annona squamosa twigs.
Topics: Animals; Annona; Anti-Ulcer Agents; Aporphines; Aspirin; Benzylisoquinolines; Berberine Alkaloids; C | 2011 |
Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome.
Topics: Abdominal Pain; Anti-Ulcer Agents; Child; Combined Modality Therapy; Diarrhea; Duodenal Ulcer; Follo | 2011 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
[Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication].
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenogastric Reflux | 2011 |
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Topics: Abdominal Pain; Biopsy, Needle; Blood Chemical Analysis; Celiac Disease; Child; Deficiency Diseases; | 2011 |
To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bangladesh; Drug Therapy, | 2011 |
Gastroprotective effects of extracts and guttiferone A isolated from Garcinia achachairu Rusby (Clusiaceae) against experimentally induced gastric lesions in mice.
Topics: Animals; Anti-Ulcer Agents; Benzophenones; Disease Models, Animal; Dose-Response Relationship, Drug; | 2012 |
Endoscopic and endoscopic ultrasound (EUS) features of annular pancreas: duodenal ulceration and a dilated bile duct.
Topics: Aged; Anti-Ulcer Agents; Bile Duct Diseases; Bile Ducts; Colonic Pseudo-Obstruction; Dilatation, Pat | 2012 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cohort Studies; Duodenal Ul | 2002 |
Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Disease Susceptibility; Duo | 2002 |
[Effect of pantoprazole on non-variceal bleeding].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2000 |
[Long-term curative effects of suture plus proximal gastric vagotomy or triad-therapy for duodenal ulcer with acute perforation].
Topics: Acute Disease; Adolescent; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Fema | 2002 |
[Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 2002 |
[Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Gastric Juice; Gastr | 2002 |
[Omeprazole. Antiulcer and gastric anti-secretory agent: one of the most prescribed drugs in France].
Topics: Anti-Ulcer Agents; Drug Monitoring; Drug Prescriptions; Drug Utilization; Duodenal Ulcer; France; Hu | 2002 |
[Pharma clinics medication of the month. Esomeprazole].
Topics: Cost Control; Drug Costs; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; | 2002 |
Anti-Helicobacter pylori therapy in India: differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene.
Topics: Adult; Alleles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacteria | 2003 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
[The state of immune system and effects of current therapy and immunomodulators].
Topics: Adjuvants, Immunologic; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2003 |
[Clinical efficacy of combined anti-Helicobacter treatment of patients with duodenal ulcer].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal | 2003 |
[Therapeutic tactics for treating patient with duodenal ulcer complicated my hemorrhage].
Topics: Drug Therapy, Combination; Duodenal Ulcer; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Hu | 2003 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om | 1997 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
[Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Benzimidazoles; Cost of Illne | 2003 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; | 2003 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digest | 2003 |
[Pharmacotherapy in complex treatment of ulcerous stenosis].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Cimetidine; Drug Therapy, Combinati | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Summaries for patients. Effects of antibiotic treatment for Helicobacter pylori on normal bowel bacteria.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy.
Topics: Animals; Anti-Ulcer Agents; Atropine; Cysteamine; Duodenal Ulcer; Female; Gastrectomy; Omeprazole; P | 2003 |
Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2003 |
Massive gastrointestinal bleeding in infants with ascariasis.
Topics: Animals; Anthelmintics; Ascariasis; Ascaris lumbricoides; Blood Transfusion; Child, Preschool; Combi | 2003 |
Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.
Topics: Adult; Aged; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Bile Acids and Salts; Cytokines; Dru | 2003 |
[Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug | 2003 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
[Efficacy of controloc in the treatment of acid-dependent diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 2003 |
Effect of antibacterial therapy and salivary secretion on the efficacy of Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2004 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal U | 2004 |
Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Develop | 2004 |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Asian People; Clarithromycin; Drug Resistan | 2005 |
Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cysteamine; Duodenal Ulcer; Gas | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Desmodium gangeticum: a potent anti-ulcer agent.
Topics: Alcohols; Animals; Anti-Ulcer Agents; Aspirin; Cold Temperature; Duodenal Ulcer; Ethanol; Fabaceae; | 2005 |
Hepatic penetration of a single large duodenal ulcer.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Fatal Outcome; Humans; Liver Diseases; M | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
[What does the H. pylori eradication bring?].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Drug | 2005 |
Cholecystoduodenal fistula secondary to penetrating duodenal ulcer: a case of conservative management.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ul | 2006 |
Omeprazole maintenance therapy prevents recurrent ulcer bleeding after surgery for duodenal ulcer.
Topics: Aged; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Juice; Humans; Hydrogen-Ion Concentration; Male; Mi | 2006 |
Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
[Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease].
Topics: Adult; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Famotidine; | 2006 |
Late-onset life threatening hemorrhage of omeprazole-resistant duodenal ulcer managed by interventional radiology: report of a case.
Topics: Aged; Angiography; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug | 2006 |
[Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; D | 2006 |
Chest pain during triple therapy for duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chest Pain; Clarithromycin; | 2007 |
[Antihelicobacter effects of melatonin].
Topics: Adult; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter | 2007 |
[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Cla | 2007 |
[Duodenal ulcer and helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Duodenoscopy; | 2007 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans | 2008 |
Gastrointestinal bleeding in a toddler secondary to chronic renal failure and hyper-gastrinemia.
Topics: Anemia, Hypochromic; Anti-Ulcer Agents; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer; | 2008 |
[Stress ulcer prophylaxis in septic patients. Evidence-based overview].
Topics: Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Evidence-Based Medicine; Gastric Acid; Gastrointestin | 2008 |
Omeprazole and liver function tests.
Topics: Benzimidazoles; Duodenal Ulcer; Humans; Liver; Liver Function Tests; Omeprazole | 1983 |
[Changes in therapy of duodenal ulcers. The European Gastro-Club 1983 discusses new pathophysiologic and epidemiologic data referring to drug and surgical therapy].
Topics: Amino Acids; Benzimidazoles; Carbenoxolone; Cimetidine; Duodenal Ulcer; Gastric Acid; Histamine; His | 1983 |
Duodenal ulcers that will not heal.
Topics: Anti-Ulcer Agents; Benzimidazoles; Bismuth; Cimetidine; Drug Resistance; Duodenal Ulcer; Humans; Ome | 1984 |
Effect of daily oral omeprazole on 24 hour intragastric acidity.
Topics: Administration, Oral; Adult; Aged; Benzimidazoles; Drug Administration Schedule; Duodenal Ulcer; Gas | 1983 |
Action of omeprazole (a benzimidazole derivative) on secretory responses to sham feeding and pentagastrin and upon serum gastrin and pancreatic polypeptide in duodenal ulcer patients.
Topics: Adult; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Eating; Gastric Acid; Gastr | 1984 |
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Ga | 1984 |
The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease.
Topics: Adult; Benzimidazoles; Blood Pressure; Duodenal Ulcer; Gastric Emptying; Humans; Male; Middle Aged; | 1984 |
Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats.
Topics: Animals; Aspirin; Benzimidazoles; Chemical Phenomena; Chemistry; Duodenal Ulcer; Epirizole; Gastric | 1984 |
[Acid secretion inhibition with new mechanisms of action: substituted benzimidazole].
Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Chemical Phenomena; Chemistry; Dogs; Duodenal Ulcer; Gas | 1984 |
[Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1995 |
Lansoprazole--a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; | 1995 |
Second proton-pump inhibitor marketed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal | 1995 |
Beta-endorphin in silent duodenal ulcer.
Topics: Adult; beta-Endorphin; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Nociceptors; Omeprazole; P | 1995 |
Lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Cos | 1995 |
Healing and relapse rates of duodenal ulcer with omeprazole vs ranitidine.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Ranitidine; | 1995 |
Omeprazole and the metabolism of caffeine.
Topics: Caffeine; Duodenal Ulcer; Humans; Omeprazole; Research Design; Statistics as Topic; Stomach Ulcer | 1995 |
Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence.
Topics: Adult; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazol | 1995 |
[Course of histological lesions of the gastric mucosa after eradication of H. pylori in patients with duodenal ulcer. Initial study and 6-month follow-up].
Topics: Adult; Aged; Anti-Bacterial Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Female; Follo | 1995 |
[Urticaria caused by omeprazole].
Topics: Aged; Duodenal Ulcer; Humans; Male; Omeprazole; Peptic Ulcer Hemorrhage; Urticaria | 1994 |
Interaction between Helicobacter pylori and human gastric epithelial cells in culture: effect of antiulcer drugs.
Topics: Anti-Ulcer Agents; Bacterial Adhesion; Carcinoma; Cells, Cultured; Cimetidine; Duodenal Ulcer; Epith | 1994 |
Acute gout associated with omeprazole.
Topics: Acute Disease; Adult; Duodenal Ulcer; Gout; Humans; Male; Middle Aged; Omeprazole | 1995 |
Association between medically induced achlorhydria of the stomach and a severe postoperative infection? A report of two cases.
Topics: Achlorhydria; Adult; Aged; Bacteria, Anaerobic; Bacterial Infections; Duodenal Ulcer; Gastrectomy; H | 1994 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
[Maintenance therapy with antiulcer drugs: review of 71 cases].
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Carbonates; Cross-Over Studies; Duodenal Ulcer; Fam | 1995 |
Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.
Topics: Acute Disease; Adolescent; Adult; Aged; Breath Tests; Chronic Disease; Duodenal Ulcer; Esophagitis, | 1995 |
[Possibilities of the use of present-day antisecretory preparation omeprazole].
Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Benzilates; Benzocaine; Choline; Cimetidine; Drug Combina | 1994 |
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Topics: Animals; Anti-Ulcer Agents; Benzodiazepines; Duodenal Ulcer; Epirizole; Ethanol; Famotidine; Gastric | 1994 |
Omeprazole--a more potent suppressor of gastric acid secretion: is it better?
Topics: Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Ranitidine | 1994 |
The effects of omeprazole on the ultrastructure of gastric parietal cells.
Topics: Child; Child, Preschool; Cimetidine; Duodenal Ulcer; Esophagitis, Peptic; Female; Humans; Infant, Ne | 1994 |
Seven-year follow-up of patients with duodenal ulcer disease.
Topics: Duodenal Ulcer; Follow-Up Studies; Histamine H2 Antagonists; Humans; Omeprazole; Prognosis; Survival | 1994 |
Prevention of duodenal ulcer relapse by long-term treatment with omeprazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Humans; Middle Aged; Multicenter Studies | 1994 |
Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
Topics: Cost-Benefit Analysis; Drug Costs; Duodenal Ulcer; Humans; Omeprazole; Probability; Prognosis; Ranit | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
Omeprazole and enteric infection.
Topics: Duodenal Ulcer; Gram-Negative Bacterial Infections; Humans; Intestinal Diseases; Omeprazole | 1994 |
Hepatitis following treatments with famotidine and then cimetidine.
Topics: Chemical and Drug Induced Liver Injury; Cimetidine; Duodenal Ulcer; Famotidine; Fatty Liver; Female; | 1994 |
Eradication of Helicobacter pylori with clarithromycin and omeprazole.
Topics: Adult; Aged; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobact | 1994 |
Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics.
Topics: Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infe | 1993 |
Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
Topics: Acetates; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Epirizole; Ethano | 1993 |
Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A.
Topics: Adult; Aged; Clinical Enzyme Tests; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastritis, Hypertro | 1993 |
[Nonsteroidal antiinflammatory drugs and duodenal ulceration].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Humans; Misoprostol; Omeprazole; Stomach Ul | 1993 |
[Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse].
Topics: Adolescent; Adult; Aged; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; M | 1993 |
Does interaction between omeprazole and cyclosporin exist?
Topics: Cyclosporine; Drug Interactions; Duodenal Ulcer; Humans; Kidney Transplantation; Male; Middle Aged; | 1993 |
[The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis].
Topics: Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middl | 1993 |
Effect of short- and long-term treatment with omeprazole on cell cycle distribution in the gastric mucosa. Results of a flow cytometric study.
Topics: Adult; Cell Cycle; Duodenal Ulcer; Female; Flow Cytometry; Gastric Mucosa; Gastrins; Humans; Male; M | 1993 |
[Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Drug Administration Schedule; Duodenal Ulcer; | 1993 |
Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections | 1993 |
Omeprazole: is it the answer of peptic ulcer disease?
Topics: Adenosine Triphosphatases; Drug Administration Schedule; Duodenal Ulcer; Humans; Omeprazole; Peptic | 1993 |
Omeprazole dosing: AM vs. PM: does sunset make a difference?
Topics: Drug Administration Schedule; Duodenal Ulcer; Gastric Acidity Determination; Gastrins; Gastroesophag | 1993 |
[Peptic ulcer and Helicobacter pylori. Comments on the authors' cases].
Topics: Adult; Aged; Anti-Ulcer Agents; Colloids; Drug Evaluation; Duodenal Ulcer; Female; Helicobacter Infe | 1993 |
pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.
Topics: Amoxicillin; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hyd | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; | 1993 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
[One week triple therapy for eradication of Helicobacter pylori infection: simple and effective].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Adm | 1995 |
Resolution of gastric outlet obstruction after eradication of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; G | 1995 |
Deterioration of renal function in a nephropathic diabetic patient during omeprazole plus amoxicillin therapy for Helicobacter pylori-associated duodenal ulcer.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Diabetic Nephropathies; Duodenal Ulcer; Female; Helicobacter I | 1995 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Helicobacter pylori and gastroduodenal secretory function.
Topics: Anti-Ulcer Agents; Bicarbonates; Duodenal Ulcer; Duodenum; Gastric Acid; Gastric Mucosa; Helicobacte | 1996 |
Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzamides; Clarithromycin; Drug Interactions | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; | 1996 |
Should omeprazole be used for the treatment and prevention of duodenal ulcer as a monotherapeutic agent?
Topics: Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Hu | 1996 |
[Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1996 |
[Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 1996 |
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Costs and Cost Analysis; D | 1996 |
Italian omeprazole triple therapy--a 1-week regimen.
Topics: Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter | 1996 |
[Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori].
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Cost-Benefit Analysis; Duodenal Ulcer; Helicobacter In | 1995 |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1996 |
The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Drug Therapy, | 1996 |
Inhibition of Helicobacter pylori by garlic extract (Allium sativum).
Topics: Anti-Bacterial Agents; Duodenal Ulcer; Enzyme Inhibitors; Garlic; Gastritis; Helicobacter Infections | 1996 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter | 1996 |
[Prospective study of erradication of Helicobacter pylori in patients with duodenal ulcer: analysis of antral and gastric body biopsies].
Topics: Duodenal Ulcer; Helicobacter pylori; Humans; Omeprazole; Prospective Studies; Stomach | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combi | 1996 |
Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity.
Topics: Anti-Ulcer Agents; Case-Control Studies; Child; Dose-Response Relationship, Drug; Duodenal Ulcer; En | 1996 |
Simultaneous evaluation of gastric and duodenal ulcers-healing activities of anti-ulcer agents in rats.
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Atropine; Chronic Disease; Cimetidine; Duodenal Ulcer; Hist | 1996 |
Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole.
Topics: Anti-Ulcer Agents; Biopsy; Colony Count, Microbial; Duodenal Ulcer; Helicobacter Infections; Helicob | 1996 |
Re: short-term treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1996 |
The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Down-Regulation; Duodenal Ulcer; Enzyme Inhibitors; Helicob | 1996 |
Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer.
Topics: Acute Disease; Adult; Aged; Anti-Ulcer Agents; Bacteria; Drug Administration Schedule; Drug Therapy, | 1996 |
[Is there a correlation between the values of breath tests and the response to the treatment for the eradication of Helicobacter pylori?].
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Duodenal Ulcer; Female; Helicobacter Infections; Helic | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
[Morphological variations of the human gastric mucosa after omeprazole treatment: a scanning electron microscopic study].
Topics: Adult; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Esophagitis, Peptic; Gastric Mucosa; Humans; Micro | 1996 |
Proton-pump inhibition and gastric giardiasis: a causal or casual association?
Topics: Aged; Amoxicillin; Animals; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mu | 1995 |
Helicobacter pylori, gastric ulcer, and duodenal ulcer.
Topics: Age of Onset; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omepr | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; | 1997 |
[Breath test in the diagnosis of Helicobacter pylori infection: concordance with histological methods and correlation with anatomopathological lesions of the gastric mucosa].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Drug T | 1996 |
Life-threatening interaction between clarithromycin and disopyramide.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disopyramide | 1997 |
Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 1997 |
Effective 2-wk therapy for Helicobacter pylori disease in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Evaluation; Drug T | 1997 |
Omeprazole-induced acute interstitial nephritis.
Topics: Acute Disease; Aged; Anti-Ulcer Agents; Biopsy; Blood Urea Nitrogen; Creatinine; Duodenal Ulcer; Fem | 1997 |
Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Inflammatory Agents, Non-Ste | 1997 |
Acid secretion, response to omeprazole, and Helicobacter pylori status.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Human | 1997 |
Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: Adult; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Female; Follow-Up Studies; Gastric Acidity Determi | 1997 |
Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies.
Topics: Animals; Anti-Ulcer Agents; Atropine; Bromocriptine; Cimetidine; Cysteamine; Duodenal Ulcer; Female; | 1997 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Drug | 1997 |
Unhealed duodenal ulcers despite Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Ad | 1997 |
Duodenal stenosis may not regress after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Constriction, Pathologic; Drug Therapy, Combination; Duodenal Ulcer; | 1997 |
Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobact | 1997 |
Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; | 1997 |
Short-term eradication therapy for Helicobacter pylori does not reduce the incidence of gastric metaplasia in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1997 |
[Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; D | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Tr | 1996 |
Cure of Helicobacter pylori: a hidden curse?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Esop | 1997 |
Time of Helicobacter pylori eradication assessment following treatment.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Helicobacter Infections; Helico | 1997 |
Helicobacter pylori eradication in duodenal ulcer disease is cost-beneficial: a Belgian model.
Topics: Anti-Ulcer Agents; Belgium; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy; Duode | 1997 |
In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.
Topics: Ampicillin; Anti-Bacterial Agents; Clarithromycin; Duodenal Ulcer; Helicobacter pylori; Humans; Metr | 1997 |
Neuromyopathy secondary to omeprazole treatment.
Topics: Duodenal Ulcer; Humans; Male; Middle Aged; Nervous System Diseases; Omeprazole | 1998 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
[Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1997 |
New, improved Helicobacter pylori eradication therapy in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Therapy, Combinati | 1998 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Campylobacter Infections; Clarithromycin; Drug Resistan | 1998 |
[Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-U | 1998 |
Natural history of severe duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Female; | 1998 |
Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis.
Topics: Cost of Illness; Decision Support Techniques; Drug Therapy; Duodenal Ulcer; Enzyme Inhibitors; Esoph | 1998 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enterocolitis, Pseudom | 1998 |
Effects of YJA20379-4 on gastric secretion, Helicobacter pylori growth and various gastric and duodenal lesions in rats.
Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Dithiothreitol; Duodenal Ulcer; Female; Gastric Acid; Ga | 1998 |
Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis.
Topics: Adult; Aged; Azithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Female; Gastric Muc | 1998 |
Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Follow-Up Stu | 1998 |
Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Blotting, Western | 1998 |
[Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
[Eradicating treatment against Helicobacter pylori].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1998 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; | 1998 |
Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromyci | 1999 |
Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Costs and Cost Analysis; Decision Support Tec | 1996 |
Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Duodenal Ulcer; Helicobacter pylori; Humans; Markov Chains | 1997 |
Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Bi | 1999 |
Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Base Sequence; Clarithromycin; DNA Primers; Drug Therapy, | 1999 |
Treatment of Helicobacter pylori: where are we now? What are the key questions?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter | 1999 |
Ulcer activity but not duodenal stenosis regresses after eradication of Helicobacter pylori.
Topics: Adult; Anti-Ulcer Agents; Duodenal Diseases; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies | 1999 |
Use of omeprazole in life-threatening metabolic alkalosis.
Topics: Alkalosis; Carcinoid Tumor; Duodenal Neoplasms; Duodenal Ulcer; Fatal Outcome; Humans; Male; Middle | 1999 |
Rabeprazole is latest entrant in proton-pump-inhibitor class.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy?
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusion; Confidence Intervals; Duodenal | 1999 |
Rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1999 |
Proliferating cell nuclear antigen (PCNA) immunostaining in Helicobacter pylori infection: impact of eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biomarkers, Tumor; Drug Therapy, Combinatio | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diverticulum; Drug Ther | 2000 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
[Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug | 2000 |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2000 |
[The role of omeprazole in the eradication of Helicobacter pylori in patients with duodenal ulcers].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 2000 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agent | 1999 |
Helicobacter pylori infection in recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; C | 2000 |
[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulc | 2000 |
Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population.
Topics: Adolescent; Adult; Age Distribution; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Ch | 2000 |
Eradication of Helicobacter pylori from the stomach and duodenum of patients with duodenal ulcers.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Enzyme-Linked Immunosorbent Assay; | 2001 |
The effectiveness of one-week triple eradication therapy for perforated duodenal ulcer patients treated with simple closure.
Topics: Adult; Amoxicillin; Clarithromycin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dru | 2001 |
Short-term changes in Helicobacter pylori gastritis and bulbitis during and after 2 weeks of treatment with omeprazole and amoxicillin in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Endoscopy, | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
[Results of child observation during 3 years after the eradication treatment].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Duodenal Ulc | 2001 |
Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications.
Topics: Adult; Aged; Cell Count; Duodenal Ulcer; Female; Gastric Acid; Gastric Mucosa; Gastrin-Secreting Cel | 2001 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
[Gastroduodenitis and ulcers--statistical study for 1998].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bulgaria; Clarithromycin; Drug Ther | 2000 |
Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bismuth; DNA Fingerprinting; Duodenal Ulcer; Female; | 2001 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2001 |
Fine-needle aspiration biopsy of an intra-abdominal inflammatory mass secondary to a penetrating duodenal ulcer mimicking neoplasm.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Diagnosis, Dif | 2001 |
Cutaneous leucocytoclastic vasculitis associated with omeprazole.
Topics: Aged; Anti-Ulcer Agents; Drug Hypersensitivity; Duodenal Ulcer; Female; Humans; Omeprazole; Vasculit | 2002 |
[Circadian monitoring of intragastric pH in evaluation of efficiency of antisecretory therapy of duodenal ulcer].
Topics: Adult; Anti-Ulcer Agents; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acidity Determination; H | 2002 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; E | 2002 |
Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; | 2002 |
[The gastric mucigenous function in the treatment of patients with ulcer with various antisecretory preparations].
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Famotidine; Female; Gastric Acidity Det | 2002 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |
A drug usage review of omeprazole.
Topics: Dose-Response Relationship, Drug; Drug Therapy; Drug Utilization; Duodenal Ulcer; England; Esophagit | 1992 |
[Endoscopic stage classification of peptic ulcer and characterization of the healing process by proton pump inhibitors].
Topics: Adenosine Triphosphatases; Duodenal Ulcer; Duodenoscopy; Gastroscopy; H(+)-K(+)-Exchanging ATPase; H | 1992 |
Optimizing the information obtained from continuous 24-hour gastric pH monitoring.
Topics: Circadian Rhythm; Data Interpretation, Statistical; Duodenal Ulcer; Gastric Acidity Determination; H | 1992 |
Comparison of omeprazole and nizatidine in the treatment of duodenal ulcers.
Topics: Adult; Aged; Duodenal Ulcer; Female; Gastrins; Humans; Male; Middle Aged; Nizatidine; Omeprazole | 1992 |
[Severe hyponatremia: possible role of omeprazole].
Topics: Aged; Duodenal Ulcer; Esophagitis; Humans; Hyponatremia; Male; Omeprazole; Stomach Diseases | 1992 |
Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori?
Topics: Adult; Aged; Duodenal Ulcer; Fasting; Female; Gastrins; Helicobacter Infections; Helicobacter pylori | 1992 |
Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer.
Topics: Child; Child, Preschool; Duodenal Ulcer; Gastric Acidity Determination; Humans; Hydrogen-Ion Concent | 1992 |
Omeprazole therapy for Helicobacter pylori infection.
Topics: Adolescent; Adult; Child; DNA Fingerprinting; Duodenal Ulcer; Female; Gastritis; Helicobacter Infect | 1992 |
Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.
Topics: Administration, Oral; Adult; Biological Availability; Circadian Rhythm; Drug Administration Schedule | 1992 |
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Benzimidazoles; Duodenal Ulcer; | 1992 |
Criteria for use of omeprazole in adult inpatients and outpatients.
Topics: Adult; Barrett Esophagus; Duodenal Ulcer; Education, Pharmacy, Continuing; Esophagitis, Peptic; Huma | 1992 |
Long-term omeprazole monotherapy is ineffective against Helicobacter pylori infection.
Topics: Adult; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omep | 1992 |
Lack of eradication of Helicobacter pylori after omeprazole.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Helicobacter Infecti | 1991 |
[Peptic ulcer and drug therapy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Campylobacter; Campylobacter Infections; Duodenal Ulcer; Ga | 1991 |
H2 antagonist and omeprazole nonresponders.
Topics: Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole | 1991 |
Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model.
Topics: Adenosine Triphosphatases; Animals; Duodenal Ulcer; Female; Gastric Acid; H(+)-K(+)-Exchanging ATPas | 1991 |
Omeprazole in short-term treatment of Helicobacter pylori positive duodenal ulcer.
Topics: Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ome | 1991 |
Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis.
Topics: Adult; Aged; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle | 1991 |
Antral Helicobacter pylori-like organisms in different states of gastric acid secretion.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastric Acid; Gastritis; Helic | 1991 |
Effects of a new benzimidazole derivative, NC-1300-O-3, on gastric secretion and gastroduodenal lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1991 |
24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients.
Topics: Duodenal Ulcer; Gastric Acid; Gastrins; Humans; Omeprazole; Vagotomy, Proximal Gastric | 1991 |
Omeprazole therapy modifies the gastric localization of Helicobacter pylori.
Topics: Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pyloric Antrum | 1991 |
Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.
Topics: Aged; Aging; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Acid; Gastrins; Humans; Male; | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
[Helicobacter pylori and duodenal ulcer treated with omeprazole].
Topics: Adult; Aged; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pil | 1991 |
Comparative tolerability profile of omeprazole in clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Cimet | 1991 |
Lack of activity of omeprazole against Helicobacter pylori.
Topics: Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1991 |
Omeprazole.
Topics: Duodenal Ulcer; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Stomach Ulcer | 1991 |
Effects of the new H2-receptor antagonist 3-amino-4-[4- [4- (1-piperidinomethyl)-2-pyridyloxy]-cis-2-butenylamino]-3-cyclobutene-1, 2- dione hydrochloride on gastric acid secretion and ulceration.
Topics: Animals; Anti-Ulcer Agents; Cold Temperature; Cysteamine; Duodenal Ulcer; Gastric Acid; Histamine; H | 1990 |
Omeprazole in H2 blocker non-responders.
Topics: Drug Resistance; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole | 1990 |
Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1990 |
Omeprazole may kill Helicobacter pylori.
Topics: Duodenal Ulcer; Helicobacter pylori; Humans; Omeprazole | 1991 |
Gynecomastia during omeprazole therapy.
Topics: Duodenal Ulcer; Gynecomastia; Humans; Male; Middle Aged; Omeprazole | 1991 |
Omeprazole and acid peptic disease.
Topics: Animals; Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Om | 1991 |
Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Duodenal Ulcer; Female; Half-Life; Human | 1991 |
Omeprazole in gastric and duodenal ulcers.
Topics: Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Prognosis; Stomach Ulcer | 1991 |
Omeprazole for duodenal ulceration in Crohn's disease.
Topics: Adult; Crohn Disease; Duodenal Ulcer; Female; Humans; Male; Omeprazole | 1990 |
Gastroduodenal ulcers in rats induced by 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): requirement for gastric acid secretion and the role of prostaglandins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alprostadil; Animals; Atropine; Duodenal Ulcer; Female | 1990 |
[Current perspectives in ulcer disease].
Topics: Anti-Bacterial Agents; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Huma | 1990 |
24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients.
Topics: Adult; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Humans; Male; Middle Aged; | 1990 |
Ulcer healing: does omeprazole efficacy depend on daytime or 24-hour acid inhibition?
Topics: Drug Administration Schedule; Duodenal Ulcer; Gastric Acid; Humans; Omeprazole; Wound Healing | 1990 |
Acid suppression.
Topics: Duodenal Ulcer; Gastric Acid; Humans; Omeprazole | 1990 |
Acid suppression.
Topics: Depression, Chemical; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Humans; Omeprazol | 1990 |
Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.
Topics: Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omeprazole; Pepsinogens; Radioimmuno | 1990 |
Duodenal ulcer resistant to usual omeprazole dose.
Topics: Drug Resistance; Duodenal Ulcer; Gastric Acid; Humans; Male; Middle Aged; Omeprazole; Recurrence | 1990 |
Histamine and duodenal ulcer: effect of omeprazole on gastric histamine in patients with duodenal ulcer.
Topics: Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Gastric Juice; Gastric Mucosa; Hist | 1986 |
Effect of omeprazole on intragastric and duodenal bulb acidity in duodenal ulcer patients.
Topics: Adult; Aged; Duodenal Ulcer; Duodenum; Electrodes; Female; Gastric Acid; Gastric Acidity Determinati | 1989 |
Duodenal ulcers that are difficult to treat.
Topics: Duodenal Ulcer; Humans; Omeprazole | 1989 |
Omeprazole, campylobacter pylori, and duodenal ulcer.
Topics: Campylobacter; Campylobacter Infections; Drug Administration Schedule; Duodenal Ulcer; Humans; Omepr | 1989 |
Irradiation-induced duodenal ulcer disease refractory to ranitidine: healing by omeprazole.
Topics: Aged; Carcinoma, Renal Cell; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Kidney Neopla | 1989 |
Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer.
Topics: Campylobacter; Campylobacter Infections; Duodenal Ulcer; Gastritis; Humans; Omeprazole | 1989 |
Omeprazole v ranitidine.
Topics: Duodenal Ulcer; Humans; Omeprazole; Ranitidine | 1989 |
[Omeprazole in peptic ulceration: acid inhibition and endoscopic healing].
Topics: Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Humans; Omeprazole; Stomach Ulcer | 1989 |
Healing process of duodenal ulcers induced by indomethacin plus histamine in rats.
Topics: Animals; Cimetidine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Gastric Acid; Histamine; Hydr | 1989 |
Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. March 15 and 16, 1989 (omeprazole and domperidone).
Topics: Animals; Diabetes Complications; Domperidone; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omepr | 1989 |
The drug treatment of duodenal ulcer: physiological considerations in the choice of therapy.
Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Carbenoxolone; Dinoprostone; Duodena | 1986 |
Resistant duodenal ulcer: when, why and what to do?
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Male; Omepraz | 1988 |
Duodenal ulcers that are difficult to heal.
Topics: Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Histamine H2 Antagonists; Humans; Omeprazole; Ranitid | 1988 |
Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.
Topics: Adult; Circadian Rhythm; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Gastrins; Huma | 1987 |
Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
Topics: Adenosine Triphosphatases; Digestive System Diseases; Duodenal Ulcer; Esophagitis, Peptic; Gastric A | 1986 |
Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients.
Topics: Adult; Drug Administration Schedule; Duodenal Ulcer; Fasting; Gastric Acid; Gastrins; Humans; Male; | 1988 |
An acid-independent antiulcer effect of M1 antimuscarinics in the rat.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Cysteamine; Duodenal Ulcer; Female; Gastric Acid; Omeprazole | 1988 |
[AG1749: a study of its inhibition of gastric pH after morning or evening dosage].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Depression, Chemical; Drug Administration Schedule; | 1988 |
Effect of intermittent weekend therapy with omeprazole on basal and postprandial serum gastrin concentrations in patients with duodenal ulcer.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Female; Gastrins; Humans; Male; Middle Ag | 1988 |
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
Topics: Adult; Aged; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastrins; Humans; Male; Middle Aged; Omepr | 1988 |
Treatment of duodenal ulcer disease. Clinical results with omeprazole.
Topics: Alanine Transaminase; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal | 1986 |
Twenty-four hour intragastric acidity during treatment with oral omeprazole.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Fa | 1986 |
Effect of antisecretory agents and vagotomy on healing of "chronic" cysteamine-induced duodenal ulcers in rats.
Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Brunner Glands; Chronic Disease; Cimetidine; Cysteamine; | 1986 |
Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients.
Topics: Adult; Aged; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Female; Gastric Acid; | 1986 |
Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Topics: Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule; Duodenal Ulcer; Famotidine; Gastric Aci | 1986 |
Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome.
Topics: Adult; Biopsy; Duodenal Ulcer; Female; Gastric Mucosa; Humans; Male; Middle Aged; Omeprazole; Pariet | 1986 |
Duodenal ulcer disease.
Topics: Anti-Ulcer Agents; Benzimidazoles; Campylobacter Infections; Cimetidine; Duodenal Ulcer; Duodenoscop | 1985 |
Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Duodenogastric Reflux; Electrolytes; Feedi | 1985 |
[Is it justifiable to perform noncontrolled therapeutic trials in duodenal ulcer? Apropos of omeprazole].
Topics: Anti-Ulcer Agents; Benzimidazoles; Drug Evaluation; Duodenal Ulcer; Ethics, Medical; Humans; Omepraz | 1985 |
Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Humans; Kidney Failure, Chro | 1985 |